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ýv Abstract 
The  effects  of  Mirazie  (MZD),  an  extract  of  myrrh,  on  Schistosoma  mansoni  were 
investigated  and  compared  to  those  of  praziquantel  (PZQ).  The  effects  of  both  drugs  on 
the  soluble  proteome  and  the  immune  responses  to  schistosome  infections  were  also 
investigated.  In  vitro  studies  showed  that  MZD  was  more  effective  than  PZQ  against  the 
schistosomula  stage.  However,  its  effects  against  adult  worms  were  less  than  those  of 
PZQ.  Lengthy  exposures  to  high  concentrations  of  MZD  were  required  for  the  drug  to 
be  effective.  In  vivo  studies  showed  that  MZD  had  no  anti-schistosomal  activity  against 
S.  mansoni  in  mice. 
In  vitro  exposure  of  adult  worms  to  either  PZQ  or  MZD  caused  significant  changes  in 
the  expression  of  some  proteins.  Interestingly,  some  vaccine  candidates  including 
paramyosin  and  actin  were  among  the  proteins  that  showed  differential  expression. 
Treament  of  human  S.  haematobium  infection  with  PZQ  favoured  the  development  of 
protective  immune  responses  that  render  the  individuals  resistant  to  reinfection.  Sera 
from  putatively  resistant  individuals  showed  distinct  recognition  patterens  of  soluble 
worm  antigen,  after  exposure  to  reinfection,  compared  to  sera  from  susceptible 
individuals.  Interestingly,  many  putative  vaccine  candidate  antigens  were  recognised  by 
antibody  isotypes  that  are  found  in  individuals  with  some  degree  of  resistance  to 
infection. 
In  conclusion,  although  the  in  vitro  studies  revealed  some  promising  effects  of  MZD, 
the  results  of  the  in  vivo  studies  do  not  support  the  use  of  this  drug  in  the  treatment  of 
schistosome  infections. 
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General  Introduction 1.1  Introduction 
Schistosomiasis  is  a  chronic  parasitic  disease  caused  by  a  blood  dwelling  trematode 
(fluke)  of  the  genus  Schistosoma  It  is  a  major  parasitic  disease  in  the  tropics  and 
subtropics,  with  more  than  200  million  people  in  76  countries  estimated  to  be  infected 
and  about  600  million  people  at  risk  of  infection  (Savioli  et  aL,  1997). 
Schistosomiasis  is  strongly  linked  with  human  behaviour,  as  humans  are  both  the 
victims  of  the  disease  and  in  most  epidemiological  settings  the  major  source  for  the 
spread  of  the  infection.  Infection  occurs  on  human  contact  with  infected  water 
containing  the  cercariae.  Within  minutes  to  hours  of  contact  of  the  cercariae  with  the 
skin  of  a  susceptible  host,  they  penetrate  the  skin,  shed  their  tails  and  complete  their 
transformation  into  highly  motile  schistosomula.  The  schistosomula  migrate  into  the 
micro-circulation  and  are  carried  to  the  heart,  then  to  the  lungs  and  after  another  10  days 
or  so,  they  reach  the  small  veins  of  the  portal  circulation  in  the  liver.  There,  they  mature 
and  the  mature  male  and  female  worms  pair.  The  female  worms  start  to  lay  eggs  4-6 
weeks  after  the  initial  penetration  of  the  cercariae  through  the  skin  (Strickland  and 
Abdel-Wahab,  1991).  There  is  strong  evidence  that  coupling  with  male  worms  is 
essential  for  the  development,  sexual  maturation  and  subsequent  egg  production  by 
female  worms.  However,  the  stimulus  for  their  development  and  maturation  is  not  yet 
determined  (Ribeiro-Paes  and  Rodrigues,  1997). 
The  pathology  and  clinical  symptoms  of  schistosomiasis  are  mainly  related  to  the 
immunological  reactions  stimulated  by  the  deposition  of  eggs  which  pass  from  the 
blood  into  the  tissues  of  the  host.  Soluble  egg  antigens  originating  from  the  developing 
miracidium  in  the  egg  diffuse  out  through  ultra-microscopic  pores  in  the  egg  shell  and 
17 initiate  the  granulomatous  reaction,  a  manifestation  of  a  delayed  hypersensitivity 
response  mediated  by  T-cells  (Warren,  1972). 
The  control  of  human  schistosomiasis  is  principally  dependent  upon  the  use  of 
chemotherapy.  The  major  objectives  of  chemotherapy  are  to  eradicate  or  control  human 
infection  thus  alleviating  the  symptoms  of  the  disease  by  preventing  finther  deposition 
of  eggs  and  reducing  the  number  of  eggs  passed  by  patients  into  the  environment.  The 
reduction  of  contamination  of  the  environment  with  eggs  could  result  in  reduced 
miracidium-snail  contact  and  thus  lead  to  lower  levels  of  transmission  (El  Garem, 
1998).  However,  few  clear  examples  of  such  reductions  can  be  found  in  the  literature 
(Ouma  et  aL,  1985).  Fortunately,  non-toxic,  oral,  schistosomicidal  drugs  are  available  to 
treat  the  infection.  The  drug  of  choice  is  praziquantel  (Fallon  et  al.,  1992).  Reinfection 
after  treatment  and  the  possible  appearance  of  resistant  strains  ensures  schistosomiasis 
remains  a  major  public  health  problem  (Ismail  et  al.,  1996).  In  the  last  few  years  two 
enew'  drugs  including  artemesinin  derivatives  and  Mirazido,  reported  to  have  the 
potential  for  treating  human  schistosomiasis  have  been  investigated. 
1.2  Parasite 
1.2.1  Historical  notes 
The  ancient  Egyptians  recorded  human  infection  with  schistosomes  in  the  papyrus  of 
Kuhn  with  symbolic  depiction  of  endemic  haernaturia  around  1900  years  BC.  In  1910, 
Ruffer  described  ova  in  the  kidneys  of  Egyptian  mummies  who  lived  around  1250-1090 
years  BC  (El  Garem,  1998). 
In  Egypt,  Theodore  Bilharz  described  the  worm  that  caused  Egyptian  endemic 
haematuria  in  1851.  He  named  the  parasite  Dislomum  haematobium.  In  1858,  Weinland 
18 proposed  the  name  Schistosoma.  At  that  time  it  was  thought  that  one  species  was 
responsible  for  both  the  intestinal  and  vesicular  forms  of  schistosomiasis.  In  1905  Sir 
Patrick  Manson  postulated  that  intestinal  and  vesicular  schistosomiasis  are  distinct 
diseases,  caused  by  distinct  species  of  worms.  The  complete  life  cycle  of  the  parasite 
and  the  role  of  the  snail  intermediate  host  were  defined  in  1913  by  Miyairi  and 
confirmed  experimentally  by  Leiper  (a  graduate  of  the  University  of  Glasgow)  in  1915 
(Smith  and  Roberts,  1989;  Strickland  and  Ramirez,  2000). 
1.2.2  Details  of  the  life  cycle  of  schistosomes 
Adult  worms  mate  in  the  small  vasculature,  of  the  liver  and  migrate  against  the  venous 
blood  flow  to  the  venous  plexus.  The  female  progresses  further  alone  to  the  narrowest 
parts  of  the  veins  and  lays  her  eggs.  The  favoured  eventual  location  of  the  adult  worm 
and  consequently  of  egg  deposition  varies  according  to  species;  S.  haemalobium  is 
concentrated  in  the  blood  vessels  around  the  bladder  and  S.  mansoni  in  the  inferior 
mesenteric  vessels  of  the  large  intestine  (Strickland  and  Ramirez,  2000). 
In  order  for  the  parasites'  life  cycle  to  be  completed,  eggs  must  pass  from  their  site  of 
deposition  in  the  vasculature  through  the  tissues  and  into  the  lumen  of  the  intestine  or 
the  bladder.  This  is  achieved  in  part  by  virtue  of  their  spines  and  the  secretion  of 
histiolytic  enzymes.  In  mice,  about  50%  of  the  deposited  ova  succeed  in  reaching  the 
external  environment  via  urine  and  stools  of  the  host  while  the  remaining  eggs  are 
retained  in  the  tissues.  If  eggs  reach  fresh  water,  they  hatch  and  motile,  relatively  short- 
lived  miracidia  emerge  and  swim  ceaselessly  in  water  where  they  may encounter  their 
next  and  intermediate  snail  host  (El  Garem,  1998). 
In  the  vicinity  of  a  snail  host,  miracidia  are  stimulated  to  swim  more  rapidly  and  change 
direction  much  more  frequently,  thus  increasing  their  chances  of  encountering  the  snail. 
19 During  penetration  of  the  snail,  the  miracidium  sheds  its  epithelium  and  begins 
development  into  a  mother  sporocyst,  normally  near  the  point  of  entrance.  After  about  2 
weeks,  the  mother  sporocyst  produces  daughter  sporocysts,  which  migrate  to  other 
organs  within  the  snail.  The  mother  sporocyst  continues  producing  daughter  sporocysts 
for  up  to  6  to  7  weeks  (Smith  and  Roberts,  1989). 
Cercariae  metamorphose  from  sporocysts  and  start  to  emerge  from  the  snail  into  the 
water  about  4  weeks  after  snail  infection  with  miracidia.  The  cercariae  can  survive  up  to 
3  days  under  controlled  laboratory  conditions  although  their  infectivity  begins  to 
diminish  by  8-12  hours.  Once  cercariae  come  in  contact  with  the  skin  of  a  suitable  host, 
they  penetrate  the  skin  and  trmsform  into  schistosomula.  Schistosomula  enter  the 
vascular  system  directly  (less  commonly,  indirectly  through  the  lymphatics).  They 
migrate  through  the  right  heart  to  the  lungs,  and  then  via  the  left  heart  and  the  systemic 
circulation  to  the  splanchnic  vasculature  of  the  hepatic  portal  system,  eventually 
reaching  the  sinuses  of  the  liver  to  mature  in  about  4  to  6  weeks  to  complete  the  cycle 
(Sturrock,  2001). 
1.23  Morphology 
Morphology  of  cercariae  and  schistosomula 
Schistosome  cercariae  are  furcocercus  with  a  head  (the  immature  body  of  the  adult 
worm)  175  to  240pm  long  by  55  to  100pm  wide  and  a  locomotory  organ  or  tail  175  to 
250tim  long  by  35  to  50Am  wide.  The  head  has  an  anterior  organ,  often  called  the  oral 
sucker,  and  a  prominent,  muscular  ventral  sucker  or  acetabulum.  (see  figure  1.1d)  The 
body  is  bounded  by  a  syncytial  tegument  with  an  external  lipid  bilayers  which,  in 
20 electron  micrographs,  appears  trilaminate  and  covered  with  an  external  amorphous  and 
carbohydrate  rich  "glycocalyx"  (Smith  and  Roberts,  1989;  Sturrock,  2001). 
During  cercarial  penetration  the  tail  is  shed  and  the  body,  now  called  a  schistosomulum, 
enters  the  skin  of  the  definitive  host  (see  figure  IA  e).  The  conversion  from  the  cercariae 
to  schistosomula  is  a  crucial  and  potentially  vulnerable  point  of  the  life  cycle.  This 
transformation  process  involves  many  structural  and  physiological  changes,  the  most 
important  of  which  is  the  loss  of  the  outer  water-proof  glycocalyx  and  its  replacement 
with  an  outer  lipid  bilayer,  providing  the  organism  with  a  heptalaminate  membrane. 
Furthermore,  acquisition  of  host  antigens  and  other  manifestations  of  immunological 
survival  mechanisms  become  evident  at  this  point  (Basch,  1991). 
Morphology  of  adult  worms 
Adult  worms  are  from  12  to  26mm.  in  length  and  from  0.3  to  0.6mm  in  width.  'Me  adult 
male  worm  is  shorter  and  thicker  than  the  longer,  slender  female.  The  male  has  a 
longitudinal  body  cleft,  the  gynaccophoric  canal  or  schist  (hence  their  names),  in  which 
the  female  lies  during  most  of  her  life.  Both  sexes  have  weakly  developed  oral  suckers 
perforated  by  the  mouth.  The  ventral  sucker,  situated  antero-ventrally,  is  more  strongly 
developed  in  male  worms  than  female  worms  (see  figure  1.1g).  The  entire  body  is 
covered  with  a  tegument  which  is  a  continous  syncytium  bounded  with  an  external 
heptalaminate  membrane. 
Beneath  the  tegument,  there  are  circular  and  longitudinal  muscles  coordinated  by  a 
network  of  neural  fibres  to  permit  contractions  and  other  movements.  Ile  alimentary 
canal  passes  from  the  oral  cavity  into  an  oesophagus,  dividing  immediately  anterior  to 
the  ventral  sucker  into  two  lateral  gut  caeca  that  reunite  behind  the  gonads  to  form  a 
single,  blind  posterior  gut  caecum.  There  is  no  anus  and  the  contents  of  the  gut  are 
21 periodically  regurgitated  through  the  mouth.  The  vomitus  contains  both  parasite 
digestive  enzymes  and  the  products  of  digestion,  largely  breakdown  products  of 
erythrocytes. 
The  reproductive  organs  of  schistosomes  are  unremarkable  in  that  male  reproductive 
system  consist  of  several  testes  (6  to  9  in  S.  mansoni),  a  number  of  vasa  deferentia 
joining  to  form  a  vesiculd  seminalis,  an  ejaculatory  duct,  and  a  genital  pore  situated 
posterior  to  the  vetral  sucker.  The  female  reproductive  system  is  composed  of  an 
elongated  ovary,  an  oviduct,  vitelline  glands,  shell  glands,  and  an  ootype  in  the  central 
canal  that  passes  forward  to  the  uterus.  The  straight  or  slightly  tortuous  tubule-shaped 
uterus  leads  to  the  genital  pore  just  behind  the  ventral  sucker. 
The  excretory  system  is  composed  of  fine  tubules  which  link  the  protonephridial  flame 
cells  embedded  in  the  mesenchymatous  cells  to  the  posterior  excretory  bladder, 
allowing  excretion  of  excess  water  and  soluble  metabolic  waste  products  (Strickland 
and  Ramirez,  2000;  Sturrock,  2001). 
Morphology  of  the  eggs 
The  eggs  of  all  schistosome  that  have  so  far  been  described  are  non-operculate.  They 
are  either  ovoid  or  spherical  and  range  in  size  from  60  to  400pm  in  length.  They  are 
immature  when  laid  but  mature  rapidly  during  their  6-10  days'  passage  to  the  exterior 
(see  figure  1.1a).  The  mature  egg  contains  a  single  miracidium,  a  ciliated  larval  stage. 
The  shell,  which  is  either  clear  or  yellow  in  colour,  is  composed  of  sclerotin-tanned 
protein  and  is  perforated  by  numerous  micropores  through  which  can  pass  enzymes 
produced  by  the  enclosed  miracidium.  The  egg  of  &  mansoni  is  oval  in  shape  with 
prominent  lateral  spine.  It  measures  115  to  175pm  in  length  and  45  to  70[im  in  width 
(Strickland  and  Ramirez,  2000;  Sturrock,  2001). 
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Figure  1.1  Life  cycle  of  S.  mansoni. 
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(a)  Eggs  of  S  mansoni,  (b)  miracidium,  (c)  Intra-molluscan  stages,  (d)  Cercaria,  (e) 
schistosomulum,  (f)  maturing  worms  in  the  mesenteric  blood  vessels,  (g)  Adult  worm 
pairs  and  (h)  eggs  surrounded  by  granuloma. 
(Courtesy  of  The  Wellcome  Trust.  International  Health  Image  Collection.  ) 
23 1.3  Clinical  picture  of  schistosomiasis  mansoni 
The  first  evidence  of  infection  may  be  a  transient  itching  and  a  mild  skin  rash  that 
develops  immediately  after  water  contact.  This  occurs  at  the  sites  of  cercarial 
penetration.  Depending  on  several  factors,  acute  or  chronic  schistosomiasis  may 
develop. 
1.3.1  Acute  schistosomiasis 
Acute  schistosomiasis,  often  called  Katayama  fever,  occurs  4  to  6  weeks  following 
initial  exposure  to  infection.  It  is  a  feature  of  infection  in  travellers  and  visitors  to 
endemic  areas  and  is  less  commonly  found  in  the  indigenous  peoples  of  endemic  areas. 
Katayama  fever  usually  starts  at  the  time  adult  worms  begin  to  mature  and  with  the 
onset  of  egg  deposition.  It  is  presented  as  a  systemic  allergic  illness  characterised  by 
fever,  chills,  weakness,  weight  loss,  cough,  arthralgias,  marked  eosinophilia  and  often, 
abdominal  pain  and  bloody  diarrhoea  (Neva  and  Brown,  1994). 
1.3.2  Chronic  schistosomiasis 
The  pathogenesis  of  chronic  schistosoniiasis  is  almost  exclusively  explained  by  the 
hosts'  granulornatous  response  to  schistosome  eggs  deposited  in  tissues.  Deposition  of 
eggs  in  the  intestinal  wall  results  in  granulomatous  lesions  which  may  result  in  intestinal 
polyposes,  haemorrhages,  enteropathies,  fibrosis  and  strictures.  The  liver  is  another 
favoured  site  for  the  trapping  of  S.  manson!  eggs  during  infection.  The  chronic 
granulomatous  response  produces  a  peri-sinusoidal  inflammation  and  fibrosis  called 
SYMMers'  clay  pipe-stem  fibrosis.  The  pathogenesis  of  severe  schistosomiasis  results 
from  the  slow,  cumulative  blockage  of  portal  flow  that  results  in  portal  hypertension, 
24 porto-systernic  collateral  circulation,  oesophageal  varices  and  upper  gastrointestinal 
bleeding  which  is  the  most  common  morbid  consequence  of  hepatic  schistosomiasis  and 
is  responsible  for  the  ma  ority  of  deaths  due  to  schistosomiasis.  Interestingly,  the  liver  i 
functions  remain  normal  until  the  very  late  stages  of  the  disease.  Eggs  can  embolise  in 
other  places  including  the  central  nervous  system  resulting  in  granuloma  formations  at 
such  sites  (Neva  and  Brown,  1994;  Strickland  and  Ramirez,  2000;  King,  2001). 
1.4  Diagnosis  of  S.  munsoni 
In  order  to  diagnose  schistosome  infection,  to  determine  the  strain  of  schistosomes  and 
to  determine  the  severity  of  infection,  several  methods  have  been  developed  and 
exploited. 
1.4.1  Parasitological  diagnosis 
Detection  of  ova  and  their  morphological  identification  is  the  traditional  method  of 
diagnosis.  It  is  a  cheap,  direct  and  specific  means  of  diagnosis  but  there  is  a  possibility 
of  missing  light  infections  that  are  characterised  by  low  egg  output.  The  most  widely 
used  protocols  are  those  based  on  the  Kato-Katz  thick  faecal  smear  (Kato  and  Miura, 
1954;  Katz  et  al.,  1972).  Other  methods  including  stool  concentration  techniques  and 
rectal  snip  examination  are  also  used.  For  instance,  a  separation  technique  based  upon 
the  greater  density  of  viable  schistosome  eggs  relative  to  faecal  material  has  been 
described  and  has  been  found  to  be  more  sensitive  in  detecting  light  infections  than  the 
Kato-Katz  thick  smear  method  (Eberl  et  aL,  2002). 
25 1.4.2  Detection  of  parasite  antigens 
The  presence  of  detectable  quantities  of  parasite-derived  antigens  in  the  circulation  and 
excreta  of  infected  hosts  has  prompted  considerable  research  on  their  potential  for 
immunodiagnosis  of  schistosomiasis.  Several  circulating  antigens  have  been  employed 
including  circulating  anodic  antigen  (CAA)  and  circulating  cathodic  antigen  (CCA), 
named  according  to  their  migratory  behaviour  in  immuno-electrophoresis.  A  variety  of 
assay  methods  have  been  used  to  detect  these  antigens.  Parasite  antigen  detection 
methods  have  the  advantage  of  being  schistosome  specific.  However,  they  can  miss 
light  infections  and,  because  of  the  shared  carbohydrate  epitopes  between  schistosome 
species,  they  cannot  be  used  for  differentiation  between  schistosome  species  (Doenhoff 
et  aL,  2004). 
1.43  Detection  of  antibodies 
This  method  is  based  on  the  detection  of  anti-schistosomal  antibodies  produced  by  the 
host  in  response  to  exposure  to  infection.  Both  humans  and  animals  normally  respond  to 
a  range  of  different  parasite  antigens.  Several  crude  and  purified  antigens  from  different 
life  cycle  stages  have  been  used  in  antibody  detection  assays.  The  most  widely  used 
assay  method  is  the  enzyme-linked  immunosorbent  assay  (ELISA).  This  method  is 
normally  less  specific  than  the  antigen  detection  method,  it  is  of  limited  value  in 
monitoring  the  curative  effects  of  chemotherapy  and  it  is  not  correlated  with  the 
intensity  of  infection.  However,  the  use  of  purified  antigens  in  such  assays  has  greatly 
improved  these  factors  (Hamilton  et  aL,  1998;  Doenhoff  et  al.,  2004).  For  instance,  the 
use  of  the  CEF6  fraction  of  soluble  egg  antigens,  which  consists  of  two  antigens  (a 
30kDa  (o-I  and  a  36-41kDa  cc-1),  has  been  tested  for  the  diagnosis  of  schistosomiasis 
26 with  sensitivity  and  specificity  values  of  91%  and  90%,  respectively  (Mott  and  Dixon, 
1982). 
1.4.4  Detection  of  parasite  DNA 
In  the  last  few  years,  a  polymerase  chain  reaction  has  been  developed  for  the  diagnosis 
of  human  S.  mansoni  infections.  It  exploits  a  highly  repeated  schistosome  DNA 
sequence  that  can  be  detected  in  the  sera  and  faeces  of  infected  individuals.  The  method 
is  very  specific  and  very  sensitive.  It  is  normally  used  effectively  in  situations  when 
there  is  good  laboratory  infi-astructure  (Pontes  et  aL,  2002). 
1.5  Liver  granuloma  in  S.  mansoni  infection 
After  egg  deposition,  soluble  egg  antigens  (SEA)  are  released  from  the  developing 
miracidium.  These  antigens  induce  host  sensitisation  and  recruitment  of  lymphocytes, 
eosinophils,  macrophages,  giant  cells  and  fibroblasts  which  constitute  the  host 
granulomatous  response  (Boros  and  Warren,  1970).  The  granulomatous  response  serves 
to  wall-off  the  eggs  and  prevent  the  release  of  potentially  toxic  molecules  and  help  to 
destroy  the  ova  (Doenhoff  et  aL,  1986).  Iffie  mechanism  of  granuloma  formation  is  T 
lymphocyte-dependent  (Harrison  and  Doenhoff,  1983)  and  the  CD4'  T  helper  subset  is 
key  (Mathew  and  Boros,  1986). 
While  the  schistosome  granuloma  formation  and  development  is  largely  dependent  on 
Th2-immune  response,  the  role  of  Thl-immune  response  cannot  be  neglected  especially 
in  the  early  phases  of  granuloma  formation.  With  the  beginning  of  egg  deposition  and 
early  phases  of  granuloma  formation  in  murine  schistosomiasis,  at  weeks  5  to  6,  high 
levels  of  IFN-y  and  low  levels  of  IL-4  and  IL-5  have  been  reported  implicating  a  role  of 
Th  I  -immune  response.  As  deposition  of  eggs  in  tissues  continues,  the  immune  response 
27 is  shifted  toward  a  Th2-type  immune  response  and  by  8  weeks  after  infection,  when 
granuloma  attain  their  maximal  sizes,  high  levels  of  IL-4,  IL-5  and  minimal  levels  of 
IFN-y  are  detected.  These  results  indicate  that  the  egg-induced  granuloma  is  mainly  a 
Th2-type  immune  response  (Pearce  et  al.,  1991;  Lukacs  and  Boros,  1992).  The  role  of 
the  Th2  response  in  granuloma  formation  was  confirmed  with  the  work  carried  out  by 
Kaplan  and  colleagues  (1998).  They  used  (signal  transducer  and  activator  of 
transcription  4)  STAT74-  and  STAT6-deficient  mice,  which  lack  Tbl  and  Th2  type 
responses,  respectively.  Lymphocytes  from  both  naive  and  infected  STAT6-deficient 
mice  produced  minimal  levels  of  7112  cell  cytokines  but  showed  enhanced  production  of 
IFN-y  following  schistosome  egg  injection.  This  shift  away  from  a  Th2  cell-mediated 
immune  response  was  coupled  with  the  development  of  pulmonary  and  hepatic 
granulomas  that  were  greatly  decreased  in  size  compared  with  those  in  control 
littermates.  Hepatic  granulomas  in  STAT6-deficient  mice  were  composed 
predominantly  of  mononuclear  cells  with  only  a  sparse  appearance  of  eosinophils.  The 
smaller  size  of  the  hepatic  granulomas  was  accompanied  by  decreased  amounts  of  liver 
hydroxyproline  indicating  reduced  collagen  deposition.  In  contrast,  lymphocytes  from 
infected  STAT4-deficient  mice  produced  Th2  cell  cytokines  in  amounts  comparable  to 
those  produced  by  control  littermates,  but  low  levels  of  IFN-y.  The  granuloma  size  and 
amount  of  collagen  deposition  in  the  liver  were  equivalent  to  those  seen  in  control 
littermates.  These  studies  demonstrate  that  M  cells  are  required  for  the  full 
development  of  the  granulomas  and  fibrosis  (Kaplan  et  al.,  1998). 
While  much  is  known  about  the  roles  of  cytokines  in  granuloma  formation,  new 
information  is  being  generated.  For  instance,  repeated  injections  of  rIL-2  or  rIL4  in 
chronically  infected  mice  restored  the  down-regulated  liver  granulomas  to  their  peak 
size  (Mathew  et  al.,  1990;  Yamashita  and  Boros,  1992).  Injections  of  anti-IL-2 
(Cheever  et  al.,  1992)  and  anti-IL4  monoclonal  antibodies  (Yamashita  and  Boros, 
28 1992)  suppressed  the  granulomas  in  acute  murine  infection.  These  results  together 
confirm  the  inflammatory  role  of  IL-2  and  IL-4  in  schistosomiasis. 
Using  IL-4,  IL-13  and  IL-VIL-13-deficient  mice  infected  with  S.  mansoni,  Fallon  and 
colleagues  demonstrated  that  IL-13-deficient  mice  showed  significantly  enhanced 
survival  following  infection,  which  correlated  with  reduced  hepatic  fibrosis.  In  contrast, 
increased  mortality  was  manifest  in  IL4-deficient  and  IL4/13-deficient  mice,  and  this 
correlated  with  hepatocyte  damage  and  intestinal  pathology.  Ibis  hepatic  damage  was 
caused  as  a  result  of  a  skewed  Thl  type  response.  They  concluded  that  IL-13  is 
detrimental  to  survival  following  infection,  whereas  IL-4  is  beneficial  (Fallon  et  al., 
2000a;  Fallon  et  al.,  2000b).  Furthermore,  IL-13  stimulated  collagen  production  in 
fibroblasts,  and  procollagen  I  and  procollagen  III  mRNA  expressions  were  decreased  in 
mice  treated  with  an  IL-13  inhibitor,  soluble  IL-13  R  alpha  2-17c  fusion  protein.  The 
reduction  in  fibrosis  observed  in  IL-4-deficient  mice  was  much  less  pronounced  than 
that  in  soluble  IL-13  R  alpha  2-Fc  treated  mice.  Ilese  results  confirm  that  IL-13  is  the 
dominant  Th2-type  cytokine  regulating  fibrosis  (Chiaramonte  et  al.,  1999). 
Furthermore,  administration  of  recombinant  tumour  necrosis  factor-alpha  (rTNF-oc)  to 
chronically  infected  mice  enhanced  liver  granuloma  size  and  injection  of  anti-  TNF-a  to 
acutely  infected  animals  suppressed  their  granulomas  (Joseph  and  Boros,  1993).  In 
human  S  mansoni  infection,  TNF-cc  was  associated  with  aggravation  of  hepatic 
periportal  fibrosis  while  IFN-y  and  IL-  10  was  associated  with  protection  against  fibrosis 
(Henri  et  al.,  2002;  Booth  et  al.,  2004). 
Recombinant  interleukin  (IL)-12  administered  together  with  schistosome  eggs  partly 
prevented  pulmonary  granuloma  formation  on  subsequent  intravenous  challenge  with 
eggs,  partly  inhibited  hepatic  granuloma  formation  and  dramatically  reduced  the  tissue 
29 fibrosis  in  murine  S.  mansoni  infection.  The  effect  of  IL-12  was  attributed  to  increased 
production  of  IFN-y.  These  results  revitalised  the  concept  of  the  development  of  a 
vaccine  preventing  pathology  rather  than  infection  (Wynn  et  al.,  1994;  Wynn  et  al., 
1995;  Sher  et  al.,  1996;  Qadir  et  al.,  2001). 
Interleukin-10  seems  to  be  the  most  important  down-regulatory  cytokine  for  granuloma 
formation  and  fibrosis.  Repeated  injections  of  anti-IL-10  mAb  and  studies  of  IL-4,  IL- 
10,  IL-12  in  single  and  double  knockout  mice  showed  that  IL-10  is  an  important 
endogenous  down-regulator  of  Tb2-type  as  well  as  Thl-type  cytokine  synthesis, 
preventing  over  expression  of  either  of  these  immune  response  types.  It  was  also  shown 
that  IL-  10  regulates  not  only  the  intensity  of  hepatic  inflammation,  but  also  granuloma 
organization  and  cohesiveness  (Wynn  et  al.,  1997;  Boros  and  )NUtfield,  1998;  Sadler  et 
al.,  2003).  In  vitro,  IL-  10  was  shown  to  be  an  important  cytokine  regulating  the  in  vitro 
granulornatous  reactivity  of  PBMC  from  intestinal  S.  manson!  patients  (Falcao  et  al., 
1998).  In  murine  S  mansoni  infection,  IL-10  is  generated  by  both  the  innate  and 
adaptive  immune  response,  with  both  sources  regulating  the  development  of  type-2 
immunity,  immune-mediated  pathology,  and  survival  of  the  infected  host.  Most  of  the 
I  CD4  +T  cell-produced  IL-10  was  confined  to  a  subset  of  T  cells  expressing  CD25 
(Hesse  et  al.,  2004). 
The  role  of  transforming  growth  factor-beta  (TGF-P)  in  S.  mansoni  granuloma 
formation  and  fibrosis  is  controversial.  On  the  one  hand,  treatment  of  cultured  hepatic 
cells  with  TGF-p  I  increased  the  level  of  type  I  procol  lagen  mRNA  and  increased  levels 
of  TGF-P  I  gene  expression  that  precedes  the  increase  in  collagen  synthesis  was 
demonstrated  (Czaja  et  aL,  1989).  On  the  other  hand,  SEA-induced  TGF-P  correlated 
with  diminished  hepatic  granuloma  size  during  S  mansoni  infection  in  the  baboons, 
implying  its  participation  in  down-modulation  of  granuloma  (Mola  et  aL,  1999). 
30 Furthermore,  diminished  immuno-pathology  in  S.  mansoni  infection  following 
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intra- 
nasal  administration  of  cholera  toxin  B  subunit  conjugated  to  an  immunodominant 
peptide  (amino  acid  234-246)  of  Sm-P40  of  S.  niansoni  eggs  correlated  with  enhanced 
TGF-P  production  (Hernandez  et  al.,  2002).  A  similar  immuno-modulating  effect  of 
TGF-P  in  S.  japonicum  hepatic  fibrosis  was  reported  (Zhu  et  aL,  2000). 
Other  molecules  and  chemokines  may  play  a  role  in  formation  or  modulation  of  hepatic 
granulomas.  The  co-stimulatory  B7  molecule,  on  the  surface  of  antigen-presenting  cells, 
may  bind  to  CD28  receptor  on  T  cells  and  enhance  their  proliferation  (Greenfield  et  al., 
1998).  Intercellular  adhesion  molecule  I  (ICAM-1),  lymphocyte  function-associated 
antigen  I  (LFA-1),  very  late  antigen  4  (VLA-4)  and  VLA-6  may  play  a  role  in  initiation 
and  maintenance  of  hepatic  granulomas  (Jacob  et  al.,  1997).  Furthermore,  mice  infected 
with  S.  mansoni  and  deficient  in  the  IgE  gene  developed  smaller  granulomas  than  the 
wild  animals  implicating  a  role  for  IgE  in  granuloma  formation  (King  et  al.,  1997).  On 
the  other  hand,  gene  knock  out  experiments  indicated  a  role  for  B  lymphocytes  and  Fcc- 
R-bearing  cells  in  down  regulation  of  granulomas  and  fibrosis  (Jankovic  et  al.,  1997; 
Jankovic  et  al.,  1998). 
Of  course  the  effects  of  single  or  combination  of  cytokines  on  the  formation  of  the 
granulomas  are  relatively  easy  to  investigate  but  it  must  be  remembered  that  during 
granuloma  formation  in  humans  and  animals,  an  array  of  different  cytokines  operate  at 
different  levels  and  at  different  times. 
31 1.6  Immunity  to  schistosomiasis 
1.6.1  Evidence  of  acquired  immunity  in  humans  to  schistosomiasis 
The  strongest  circumstantial  evidence  for  immunity  to  schistosomiasis  in  humans  is  the 
pattern  of  infection  intensity  in  human  populations  in  relation  to  their  age.  The  age- 
intensity  curve  assumes  a  convex  shape  with  older  individuals  being  less  heavily 
infected  than  young  children.  This  pattern  has  been  described  in  areas  endemic  with  S. 
haematobium  (Wilkins  et  al.,  1984;  King  et  al.,  198  8)  and  &  mansoni  (Gryseels,  199  1). 
The  peak  intensity  of  infection  was  shifted  from  approximately  15  years  of  age,  for 
areas  of  low  transmission,  to  10  years  of  age  for  areas  of  high  transmission  of  & 
haematobium  infection  in  Zimbabwe  suggesting  a  role  for  acquired  immunity  that  is 
dependent  on  a  cumulative  experience  of  infection  (Woolhouse  et  aL,  1991).  Similarly, 
a  negative  correlation  between  the  mean  intensity  of  infection  and  the  age  of  the  peak  of 
intensity  has  been  described  in  S.  manson!  infection  in  Kenya  (Fulford  et  aL,  1992)  and 
in  Senegal  (Marguerite  et  al.,  1999).  In  this  context,  chemotherapy  accelerated  the 
development  of  the  acquired  immune  responses  to  S.  haematobium  infection  (Mutapi  et 
al.,  1998)  and  this  has  been  speculated  to  be  a  result  of  increasing  the  exposure  and 
release  of  previously  concealed  antigens  of  the  damaged  or  dead  parasites  (Woolhouse 
and  Hagan,  1999). 
In  order  to  dissect  the  age-related  immunity  to  schistosomiasis  and  to  overcome  the 
problems  encountered  with  human  population  studies,  Butterworth  and  colleagues 
established  the  treatment-reinfection  approach  to  studying  S.  mansoni  in  humans.  They 
treated  children  with  praziquantel  to  remove  the  existing  worms  and  re-examined  the 
children  for  infection  12  months  after  chemotherapy.  The  mean  age  of  the  resistant 
group,  with  no  or  few  eggs  in  their  stools,  was  two  years  greater  than  the  susceptible 
32 group,  with  high  egg  output  in  the  stools.  These  results  were  interpreted  as  evidence  that 
the  resistance  was  acquired  and  age-dependent  (Butterworth  et  al.,  1984;  Butterworth  et 
al.,  1985). 
A  similar  approach  was  used  for  the  study  of  human  S.  haematobium  infection  in  the 
Gambia.  Reinfection  was  found  to  depend  on  exposure  and  other  factors  (Hagan  et  al., 
1985).  In  a  second  study  by  the  same  group,  the  trend  for  reinfection  to  decrease  with 
increasing  age,  after  an  allowance  for  variation  in  exposure,  was  highly  significant. 
These  observations  suggested  that  subjects  in  this  area  slowly  acquired  an  increasing 
degree  of  immunity  to  the  acquisition  of  S.  haematobium  infection  (Hagan  et  al.,  1987; 
Wilkins  et  al.,  1987).  Recently,  more  detailed  experiments  have  confirmed  the  role  of 
acquired  immunity  in  human  schistosomiasis  haematobium  (Hagan  et  al.,  1991;  Mutapi 
et  al.,  2003)  and  schistosomiasis  mansoni  (Demeure  et  al.,  1993;  Abebe  et  al.,  2001). 
1.6.2  Evidence  of  humoral  immunity: 
Due  to  ethical  considerations  it  is  impossible  to  Conduct  exposure  experiments  to 
examine  the  immune  responses  against  schistosomes  infection  in  humans.  As  an 
alternative,  several  experimental  animals  as  well  as  animal  reservoir  hosts  have  been 
exploited  to  study  the  immune  response  to  schistosome  infection.  In  mice,  while  S. 
mansoni  irradiated  cercariae  protected  B-cell  deficient  mice  against  re-infection  with  S. 
mansoni,  the  protection  achieved  was  not  as  great  as  that  achieved  in  the  wild-type  mice 
vaccinated  with  the  same  regime,  implicating  a  role  for  B-cells  in  immunity  to  S 
mansoni  infection.  The  level  of  protection  was  restored  when  B-cell  deficient  mice 
received  sera  from  singly  vaccinated  wild-type  mice.  Furthermore,  multiple 
vaccinations  of  mice  deficient  in  IFN-y  increased  the  levels  of  protection  compared  to 
those  obtained  with  a  single  vaccination.  The  increased  protection  was  attributed  to  an 
33 increase  in  the  antibody  levels  (Jankovic  et  al.,  1999b).  Multiple  vaccination  of  wild- 
type  mice  was  associated  with  Th2  reactivity  in  the  form  of  an  increase  in  IL-4,  IL-5 
and  IgGl  antibodies  (Caulada-Benedetti  et  al.,  1991).  Moreover,  sera  from  multiply 
vaccinated  mice  conferred  protection  when  transferred  to  naYve  mice  confirming  the 
role  of  humoral  immunity  in  protection  against  schistosomiasis  in  mice  (Wynn  et  al., 
1996). 
In  rats,  that  are  essentially  non-permissive  hosts,  primary  infection  with  S  manson! 
induced  a  strong,  immunologically  mediated  resistance  to  re-infection,  with  IgE  directly 
implicated  in  this  phenomenon  (Capron  and  Capron,  1994).  Treatment  of  rats  with  anti- 
IgE  antibodies  partially  inhibited  the  expression  of  this  protective  immunity,  supporting 
the  role  of  IgE  in  protection  against  schistosomiasis  in  rats  (Cetre  et  aL,  2000).  In 
relation  to  this,  serum  from  rats  multiply  immunised.  with  radiation-attenuated  cercariae 
conferred  passive  protection  to  naive  animals  when  it  was  given  at  time  the  challenge 
parasites  were  migrating  through  the  lungs  (Ford  et  aL,  1987). 
In  baboons,  a  single  infection  with  1000  S.  manson!  cercariae  and  multiple  infections 
with  100  cercariae  per  week  for  10  weeks  induced  59%  and  80%  protection  to  challenge 
infection,  respectively.  The  animals  in  this  experiment  were  cured  with  praziquantel 
prior  to  challenge  with  1000  cercariae.  The  only  immune  correlate  of  protection  was  the 
levels  of  soluble  adult  worm  antigen  (SWAP)-specific  IgE  in  senim  at  the  time  of 
challenge  infection  and/or  6  weeks  later  (Nyindo  et  aL,  1999).  Furthermore,  three  and 
five  vaccinations  of  vervet  monkeys  with  radiation-attenuated  S  mansoni  cercariae 
resulted  in  48%  and  39%  protection,  respectively.  The  specific  IgG  levels  peaked  after 
three  vaccinations  and  there  was  a  clear  correlation  between  the  antibody  levels  at  the 
time  of  challenge  and  the  protection  observed  in  individual  vervcts  (Yole  et  aL,  1996). 
34 In  human  populations,  the  first  trial  to  correlate  the  reinfection  levels  after  treatment 
with  humoral  responses  was  carried  out  by  Butterworth  and  colleagues.  They  treated 
129  Kenyan  school  children  infected  with  S  mansoni  and  measured  the  reinfection 
levels  and  the  parasite  specific  IgG  and  IgM.  They  found  a  negative  correlation  between 
reinfection  intensities  and  both  IgM  anti-schistosomulurn  antibodies  and  IgM  and  IgG 
anti-egg  antibodies.  They  concluded  that  these  antibodies  act  as  blocking  antibodies  that 
interfere  with  an  effective  immune  response  (Butterworth  et  al.,  1987). 
The  first  clear  correlation  between  antibodies  and  resistance  came  from  the  work  of 
Hagan  and  colleagues  on  S  haematobium  in  endemic  areas  in  the  Gambia.  A  40% 
sample  of  the  age  spectrum  of  the  study  village  were  included  in  this  study  and  the 
prevalence  of  re-infection  after  treatment  was  found  to  be  higher  in  children  than  in 
adults  although  some  had  the  same  level  of  exposure.  IgG  subclasses  and  IgE  specific  to 
adult  worm  and  egg  antigens  were  measured.  It  was  found  that  IgE  was  highly 
correlated  with  resistance  to  re-infection  and  IgG4  was  correlated  with  susceptibility  to 
re-infection  (Hagan  et  aL,  1991).  Similarly,  correlation  between  anti-adult  worm  IgE 
(Dunne  et  al.,  1992)  and  anti-larval  IgE  (Rihet  et  aL,  1991)  and  resistance  to  re- 
infection  after  treatment  was  reported  in  human  S.  mansoni  infection. 
In  another  treatment  re-infection  study  of  S.  mansoni,  IgE  showed  positive  and  IgG4, 
and  IgG2  showed  negative  association  with  resistance  to  re-infection  after 
chemotherapy.  The  opposite  effects  of  IgE  and  IgG4  were  undissociable  in  the  analysis, 
indicating  that  these  isotypes  probably  antagonise  each  other  in  protection  (Demeure  et 
al.,  1993).  This  antagonism  was  further  supported  by  the  work  of  Caldas  and  colleagues 
(2000).  They  reported  an  increase  in  IgE  anti-SWAP  and  anti-schistosomular  tegument 
(STEG)  responses  and  a  decrease  in  IgG4  anti-SEA  and  anti-STEG  responses  after 
treatment  in  the  resistant  group  (Caldas  et  al,  2000). 
35 In  a  Zimbabwean  study,  anti-SEA  IgE  and  anti-SWAP  IgA  negatively  correlated  with 
levels  and  intensity  of  S.  haematobium  infection.  On  the  other  hand,  intensity  of 
infection  correlated  positively  with  total  IgG,  IgG4  and  IgM  responses  to  SEA  and  with 
IgG4  and  IgM  responses  to  SWAP.  These  findings  supported  the  concept  of  IgG4  and 
IgM  as  blocking  antibodies.  Interestingly,  similar  recognition  patterns  by  IgE  and  IgG4 
of  the  schistosomulum  antigens  was  detected  in  immunoblotting  suggesting  a  sort  of 
competition  between  these  antibodies  for  the  same  antigens  (Ndhlovu  et  al.,  1996).  A 
similar  positive  correlation  between  IgE  and  IgA  and  protective  immunity  against  S. 
haematobium  was  reported  in  Egyptian  individuals  (Khalil  et  al.,  1999). 
In  S.  japonicum,  a  positive  correlation  between  anti-SWAP  and  anti-SEA  IgG4 
antibodies  and  susceptibility  to  reinfection  and  a  negative  correlation  between  anti- 
SWAP  and  anti-SEA  IgE  antibodies  and  intensity  of  reinfection  were  reported  in  a 
Chinese  population  (Li  et  al.,  2001). 
In  summary,  the  immunoepidemiological  studies  of  human  populations  showed 
significant  correlation  between  resistance  to  re-infection  with  schistosomes  and  some 
antibodies.  Of  particular  interest  are  IgE,  which  correlated  positively  with  resistance  and 
IgG4,  which  correlated  negatively  with  resistance  to  re-infection. 
1.7  Treatment  of  human  schistosomiasis 
At  present,  praziquantel,  oxamniquine  and  metrifonate  appear  on  the  World  Health 
Organisation's  list  of  essential  drugs:  metrifonate  is  employed  for  the  treatment  and 
control  of  infection  with  S.  haematobium,  oxamniquine  for  S.  mansoni  and  praziquantel 
for  all  schistosome  species  infecting  humans,  including  9  japonicum  (Cioli  et  at, 
1995). 
36 1.7.1  Metrifonate 
Metrifonate  is  an  organophosphorous  compound.  It  is  unstable  in  aqueous  solutions  and 
it  spontaneously  and  non-enzymatically  transforms  into  various  compounds,  of  which 
the  most  interesting  is  dichlorvos  which  is  the  active  molecule  (Nordgen  et  aL,  1980). 
By  inhibition  of  schistosome  acetylcholinesterase,  metrifonate  (or  its  breakdown 
product,  dichlorvos)  causes  accumulation  of  acetylcholine  and  flaccid  paralysis  of 
worms.  The  paralyzed  schistosomes  lose  their  hold  on  the  inner  wall  of  blood  vessels 
and  are  swept  away  in  the  bloodstream.  As  S.  haematobium  are  located  mostly  in  the 
veins  of  the  vesical  plexus,  they  are  shifted  to  the  lungs  via  the  vena  cava  where  they 
remain  trapped  and  eventually  die  (Cioli  et  aL,  1995). 
The  generally  accepted  therapeutic  regimen  in  h  an  S.  haematobium  i  ections  UM  nfi 
consists  of  3  oral  administrations  of  7.5-10mg  kg"  at  intervals  of  14  days  (Davis  and 
Bailey,  1969).  Cure  rates  have  been  reported  to  average  between  40-60%  after  one  dose, 
50-80%  after  two  doses,  and  over  90%  after  three  doses  (Snellen,  198  1). 
Metrifonate  is  a  well-tolemted  drug  with  low  incidence  of  mild  and  tmnsient  side  effects 
thought  to  be  a  consequence  of  cholinergic  stimulation.  Ilese  side  effects  include; 
fatigue,  muscular  weakness,  tremor,  sweating,  salivation,  fainting,  abdominal  colic, 
diarrhoea,  nausea,  vomiting  and  bronchospasm  (Davis,  1993). 
1.7.2  Oxamniquine 
Oxamniquine  is  considered  as  an  oxidative  metabolite  of  the  parent  compounds; 
lucanthone  and  UK-3883.  It  is  effective  against  S.  mansoni  and  ineffective  against  S. 
haematobium  and  S.  japonicum.  It  shows  more  activity  against  male  worms  than  female 
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most  likely  through  the  irreversible  inhibition  of  nucleic  acid  synthesis  in  sensitive 
schistosomes  (Cioli  et  aL,  1995).  Furthermore,  hycanthone  and  oxamniquine  have  anti- 
cholinergic  effects  that  by  blocking  the  acetylcholine  receptors,  will  remove  the 
inhibiting  effect  of  acetylcholine.  The  resulting  disturbance  of  motility  disrupts 
peristalsis  and  feeding  mechanisms  to  the  point  of  causing  a  delayed  death  by  starvation 
(Hillman  et  aL,  1978). 
The  usual  therapeutic  dose  is  a  single  oral  dose  of  15-20mg  kg-1,  although  a  higher  dose 
of  up  to  60mg  kg"  divided  over  2-3  days  may  be  needed  in  Egypt,  South  Africa  and 
Zimbabwe  (World  Health  Organisation,  1990).  With  the  appropriate  therapeutic  dose, 
cure  rates  of  over  80%  and  often  over  90%  have  been  reported.  The  drug  has  been  used 
safely  in  all  stages  of  the  disease.  Some  late-stage  and  complicated  forms  have  shown 
clinical  improvement.  Oxamniquine  is  well  tolerated  with  side  effects  limited  to  a  mild 
and  transient  dizziness,  headache  and  occasional  drowsiness.  Transient  neuropsychiatric 
disturbances  have  been  recorded  in  a  very  small  number  of  patients  (Foster,  1987; 
Davis,  1993). 
1.73  Praziquantel 
Praziquantel,  a  pyrazino-isoquinoline  derivative,  is  the  drug  of  choice  for  the  treatment 
of  schistosomiasis  because  it  has  a  high  efficacy  against  all  schistosome  species  and 
against  cestodes;  lacks  serious  short-term  and  long-term  side  effects;  is  administered  as 
a  single  oral  dose  and  is  cheap  (Cioli  et  al.,  1995;  Kabatereine  et  al.,  2003). 
The  most  important  effects  of  praziquantel  on  schistosomes  are  tegumental  damage  in 
the  fonn  of  vacuolisation  at  the  base  of  tegumental  syncytium  and  blebbings  at  the 
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1978)  and  metabolic  changes  (Andrews,  1985). 
Damage  to  the  surface  of  the  parasite  could  prime  hosts  immune  responses  by  exposing 
antigens  previously  concealed  from  the  hosts  immune  system  (Harnett  and  Kusel,  1986; 
Brindley  et  al.,  1989;  Woolhouse  and  Hagan,  1999).  This  is  indirectly  supported  by  the 
previous  finding  that  the  effects  of  praziquantel  are  dependent  upon  the  hosts  immune 
responses  (Sabah  et  al.,  1985;  Brindley  and  Sher,  1987).  In  this  context,  treatment  with 
praziquantel  has  been  shown  to  change  the  antibody  isotype  profile  of  treated  children. 
The  effect  was  dramatic,  a  single  treatment  with  praziquantel  had  the  capacity  to 
transform  the  response  of  susceptible  children  to  that  of  adults  considered  to  be  immune 
against  infection  (Mutapi  et  aL,  1998;  Mutapi  et  al.,  2003). 
Ile  exact  mode  of  action  of  praziquantel  is  not  known,  however,  its  effects  can  be 
interpreted  as  a  direct  or  indirect  consequence  of  Ca2+  redistribution  among  various 
worm  tissues  and  the  environment  (Day  et  al.,  1992).  In  support  of  this,  calcium 
channels  have  been  described  in  schistosomes  and  they  have  been  shown  to  be  crucial 
for  praziquantel  action  (Kohn  et  al.,  200  1  b;  Kohn  et  al.,  2003). 
The  standard  recommended  dose  of  praziquantel  is  a  single  oral  dose  of  40mg  kg"  body 
weight  for  S.  mansoni,  S.  haemalobium,  and  S.  intercalatum.  In  S  japonicum  infections, 
a  total  dose  of  60mg  kg"  is  recommended,  split  in  two  or  three  doses  in  a  single  day.  S 
mekongi  may  require  two  treatments  at  60mg  kg"  (Davis,  1993).  Praziquantel  is  a  safe 
drug  with  minimal  side  effects  related  to  the  gastrointestinal  tract  in  the  form  of 
abdominal  pain,  nausea,  vomiting,  anorexia  and  diarrhoea.  Other  side  effects  including 
headache,  dizziness,  drowsiness,  pruritus  and  fatigue  may  occur  (Davis,  1993). 
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S.  mansoni,  80-90%  for  S.  japonicum,  89%  for  S.  intercalatum  and  60-80%  for  double 
infections  with  S.  mansoni  and  S  haematobium  (Wegner,  1984).  However,  a  lower  cure 
rate  of  36-38%  has  been  reported  in  S.  mansoni  infection  in  Senegal  and  strains  of  lower 
susceptibility  to  praziquantel  have  been  isolated  (Gryseels  et  al.,  1994).  Other  resistant 
strains  have  been  isolated  from  Egypt  (Ismail  et  al.,  1996).  In  vitro  tests  on  these 
isolates  and  laboratory-selected  isolates  support  the  conclusion  that  a  degree  of 
resistance  to  PZQ  can  occur  in  S  mansoni,  but  the  levels  of  drug  resistance  found  so  far 
are  low  (Doenhoff  et  aL,  2002).  Furthermore,  although  praziquantel  is  very  effective 
against  cercaria,  invasive  stages  and  adult  schistosomes,  it  has  been  shown  to  have  a 
significantly  lower  efficacy  against  the  immature  stages  of  schistosomes,  between  I  to  4 
weeks  after  infection  (Xiao  et  al.,  1985;  Sabah  et  al.,  1986). 
1.7.4  Roll-3128  and  Rol5-5458 
Roll-3128  and  Ro15-5458  are  benzodiazepine  derivatives  which  showed 
antischistosomal  effects.  A  single  oral  dose  of  80mg  kg-1  of  Rol  1-3128  showed  90% 
cure  rates  of  mice  or  hamsters  infected  with  either  S  mamoni  or  S  haematobium. 
Rol  1-3128  was  active  against  all  stages  of  schistosomes  (Bickle  and  Andrews,  1985). 
However,  in  a  pilot  clinical  study  in  humans,  a  subcurative  dose  caused  severe  and 
long-lasting  sedation,  ataxia  and  muscle  relaxation  (OBoyle  et  al.,  1985).  ROIS-5458 
was  administered  at  two  dose  levels  (25mg  and  15mg  kg"  body-weight)  to  S.  mansoni 
infected  vervet  monkeys.  It  dramatically  reduced  the  faecal  egg-output,  worm  burden 
and  tissue  egg  load  (Suliaman  et  al.,  1989).  In  S.  haematobium  infection,  R015-5458 
was  used,  in  comparison  with  PZQ,  for  treatment  of  hamsters  at  different  stages  of 
infection.  R015-5458  was  more  effective  against  4-week  infection  than  PZQ.  After  8 
40 and  12  weeks  of  infection  both  drugs  showed  remarkable  anti-schistosome  effects 
(Guirguis,  2003). 
1.7.5  Artemisinin  derivatives 
Arternisinin  is  the  active  principle  derived  from  the  leaves  of  Artemisia  annua.  The 
main  anti-schistosomal  derivatives  of  arternesinin  are  artemether  and  artesunate 
(Utzinger  et  al.,  2003).  Artemisinin  derivatives  are  characteristically  active  against  the 
immature  stages,  I  to  3  weeks  after  infection,  of  S.  mansoni,  S.  japonicum  and  S. 
haematobium  with  less  effect  on  the  very  early  invasive  and  the  adult  worms  (Utzinger 
et  al.,  200  1  b;  Utzinger  et  aL,  2001  c).  Hence,  artemether  has  been  used  as  a  prophylactic 
agent  against  S.  mansoni,  S.  japonicum  and  S.  haemalobium  with  significant  reduction 
in  prevalence  (Xiao  et  aL,  2002;  N'Goran  et  al.,  2003). 
Furthermore,  artesunate  has  been  tried  with  praziquantel  as  a  combination 
chemotherapy  for  the  control  of  S  mansoni  and  S.  haemalobium  resulting  in  higher  cure 
rates  as  compared  to  placebo,  praziquantel  alone  or  artesunate  alone  (De  Clercq  et  al., 
2000;  Borrmann  et  al.,  2001).  The  usual  dose  of  artemether  for  human  prophylaxis 
against  schistosomiasis  is  6mg  kg-1  every  2  to  4  weeks  for  periods  of  up  to  6  months. 
This  regimen  has  reduced  the  neurotoxicity  which  is  the  main  adverse  effect  of  the  drug 
(Utzinger  et  al.,  2003). 
1.7.6  Myrrh  (Mirazid) 
in  the  last  few  years,  myrrh  which  is  an  oleo-gum  resin,  derived  from  the  stem  of 
Commiphora  molmol  is  said  to  be  effective  against  S  haematoblum  and  S.  mansoni  with 
cure  rates  of  up  to  91.7%  after  single  course  of  10mg  kg-1  every  day  orally  for  3  days. 
The  cure  rate  increased  to  98%  after  a  second  course.  The  drug  was  well  tolerated  with 
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been  licensed  and  released  for  the  treatment  of  human  schistosomiasis  in  Egypt. 
Nothing  is  known  about  its  mode  of  action,  however,  the  product  data  sheet  indicates 
that  it  causes  separation  of  adult  worm  pairs  with  a  consequent  shift  of  female  worms  to 
the  liver  where  they  are  destroyed.  It  also  indicated  that  Mirazido  improves  the  clinical 
picture  of  the  treated  individuals  one  week  of  the  treatment.  However,  there  has  been 
significant  debate  in  the  scientific  community  about  the  true  efficacy  of  Mirazido  with 
very  low  cure  rates  being  reported  (Fenwick  et  al.,  2003). 
In  summary,  there  is  a  consensus  that  praziquantel  is  central  to  the  treatment  of  human 
schistosomiasis  and  it  has  been  used  on  a  large  scale  for  a  long  duration.  'Me  limited 
emergence  of  schistosome  strains  with  lower  susceptibility  to  praziquantel  and  the  fear 
of  the  spread  of  praziquantel-resistant  strains  have  made  it  very  important  to  find 
alternatives  and  to  investigate  any  drug  with  potential  activity  against  schistosomes. 
The  work  in  this  thesis  has  been  designed  to: 
Investigate  the  in  vitro  anti-schistosomal  activities  of  Mirazido,  compared  to  the 
standard  drug  praziquantel,  against  adult  worms  and  schistosomula,  stages  of  S. 
mansoni. 
*  Investigate  the  in  vivo  anti-schistosomal  activities  of  Mirazido,  compared  to 
praziquantel,  against  S.  mansoni  in  mice. 
*  Try  to  elucidate  the  mode  of  action  of  Mirazido  in  terms  of  the  effects  on 
viability  and  the  damage  it  causes. 
42 *  Investigate  the  effects  of  Mirazieand  praziquantel  on  the  expression  of 
different  proteins  of  adult  S.  mansoni. 
Investigate  the  impact  of  Mirazido  and  praziquantel  on  the  immune  response  of 
mice  in  response  to  S.  mansoni  infection. 
Investigate  the  different  recognition  patterns  of  S.  haemalobium  antigens  in 
human  infections  before  treatment,  after  treatment  and  aller  re-infection. 
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comparative  study  of  the  effects  of  Mirazido 
and  praziquantel  on  schistosomula  and  adult 
worms  of  Schistosoma  mansoni  and  on  murine 
immune  responses  to  infection, 2.1  Introduction 
2.1.1  Schistosoma  mansoni:  the  tegument 
Schistosomes  infect  their  mammalian  hosts  by  direct  penetration  of  the  skin.  As 
cercariae  penetrate  the  skin  of  a  suitable  host,  they  begin  to  undergo  substantial 
changes.  These  changes  include  the  loss  of  the  outer  glycocalyx  and  substitution  of  their 
outer  trilaminate  membrane  with  a  heptalaminate  membrane.  These  structural  changes 
start  to  be  evident  30  minutes  after  penetration  and  manifest  as  loss  of  the  glycocalyx, 
decrease  in  the  number  of  cercarial  spherical  bodies  and  appearance  of  vacuoles  with 
membranous  contents  in  tegumental.  matrix.  However,  the  outer  membrane  of  the  30- 
min  schistosomula  is  trilaminate.  In  the  3-h  schistosomula  the  outer  membrane  is  almost 
heptalaminate  and  the  tegument  contains  small  membranous  bodies  and  few  discoid 
bodies  (Hockley,  1973;  Hockley  and  McLaren,  1973).  In  this  context  it  has  been 
suggested  that  the  gross  changes  that  occur  during  schistosomula  transformation  are 
accompanied  with  modification  of  the  surface  membrane  lipid  from  a  gel  phase  with 
restricted  mobility  to  a  liquid  crystalline  phase  with  increased  motility  (Foley  et  al., 
1988). 
The  changes  in  the  parasite  tegument  continue  as  the  parasites  develop.  When  S. 
mansoni  has  fully  matured  the  tegument  of  the  adult  male  is  approximately  4ýLrn  thick 
and  is  bound  externally  by  a  surface  membrane.  While  the  surface  membrane  is 
normally  heptalaminate,  some  areas  of  membrane  showing  a  trilaminate  or  even  a 
multilaminate  appearance  can  be  identified  using  transmission  electron  microscopy.  The 
surface  membrane  serves  as  an  interface  between  the  parasite  and  the  surrounding 
environment.  The  tegument  is  bounded  internally  by  a  trilaminate  basal  membrane 
which  separates  the  tegument  from  the  underlying  muscle  layer.  'IIiis  I  Onni  thick  basal 
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tegumental  cytoplasm  consists  of  an  electron-dense  granular  matrix  in  which 
membranous  bodies,  discoid  bodies  and  mitochondria,  may  be  recognised.  'Me  inclusion 
bodies  are  formed  in  sub-tegumental  cells  (cytons)  located  beneath  the  muscle  layers 
and  are  transferred  to  the  tegumental  cytoplasm  through  tortuous  cytoplasmic 
connections  connecting  the  cells  with  the  tegument  (Hockley,  1973;  Hockley  and 
McLaren,  1973;  McLaren,  1980).  The  role  of  the  inclusion  bodies  is  not  clear,  however, 
the  membranous  bodies  fuse  with  the  outer  membrane  and  may  contribute  to  its 
formation  during  penetration,  while  the  discoid  bodies  may  contribute  to  membrane 
maintenance  and  turnover  (McLaren,  1980;  Skelly  and  Shoemaker,  2001). 
In  the  area  posterior  to  the  ventral  sucker,  the  dorsal  surface  of  the  male  worm  is 
covered  with  large  tubercles  covered  with  spines.  The  tubercles  are  few  in  number  in 
the  lateral  and  posterior  parts  of  the  dorsal  surface.  In  these  regions  and  between  the 
tubercles,  the  surface  of  the  worm  is  ridged  and  in  the  depressions  between  the  ridges 
there  are  numerous  distinct  pits.  Small  numbers  of  individual  spines  and  sensory 
papillae  are  present  between  the  ridges.  A  characteristic  feature  of  male  schistosomes 
and  one  from  which  their  name  derives  is  the  cleft  (schist)  in  the  body  (soma).  This 
groove  is  the  normal  location  for  the  female  worm  during  pairing  and  is  designated  the 
gynaecophoric  canal.  The  surface  of  the  gynaecophoric  canal  lacks  tubercles  and  is 
ridged  and  covered  with  many  small,  irregularly  arranged  spines.  The  surface 
topography  of  female  worms  is  less  dramatic  than  that  of  male  worms.  The  surface  of 
the  female  worm  lacks  tubercles  and  only  a  few  spines  are  present  mainly  at  the 
posterior  end  (Race  et  al.,  1971;  Hockley,  1973). 
The  tegument  of  schistosomes,  particularly  the  surface  membrane,  is  of  fundamental 
importance  for  parasite  survival  in  the  blood  stream  of  its  hosts.  It  plays  a  role  in 
nutrient  uptake  and  in  evasion  of  the  hosts'  immune  responses  (Chappell,  1974;  Levy 
46 and  Read,  1975;  MacGregor  and  Kusel,  1989).  The  tegument  is  metabolically  highly 
active  and  undergoes  continuous  turnover  and  replacement.  The  in  vitro  rate  ofturnover 
of  the  outer  bilayer  of  adult  S.  mansoni  has  been  studied  and  estimated  to  have  a  half- 
life  of  2-3  hours  (Wilson  and  Barnes,  1977). 
The  tegument  of  the  schistosome  contains  inclusion  bodies  including  discoid  (DII)  and 
membranous  (MB)  bodies.  Beneath  the  tegument  are  the  circular  (CM)  and  the 
longitudinal  muscles.  The  subtegumental  cells  (SC)  are  located  beneath  the  muscle 
layers  and  they  have  cytoplasmic  connections  (C)  with  the  tegument. 
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Figure  2.1  Ultrastructure  of  the  male  worm  ofS.  mansoni. The  surface  of  adult  male  ofS.  mansoni  has  many  tubercles  J)  which  are  covered  with 
spines  (S).  Between  the  tubercles  the  surface  is  ridged  with  a  few  scattered  spines  and 
sensory  organs  (SO). 
The  composition  of  the  two  bilayers  of  the  outer  tegumental  membrane  has  been  shown 
to  be  very  different.  The  first  clear  evidence  of  differences  between  the  layers  was  the 
selective  requirement  of  the  outer  layer  for  uranyl  acetate  fixation  while  the  inner  layer 
could  be  fixed  with  ordinary  fixatives  (I  lockley  and  McLaren,  1973).  Freeze  Fracture 
studies  of  the  tegument  ofS.  mansoni  have  shown  that  the  intra-membranous  particles 
are  more  numerous  in  the  outermost  monolayer  than  the  inner-most  111onolaycr  adjacent 
to  the  cytoplasm  (McLaren  el  al.,  1978).  Furthermore,  Foley  and  colleagues  (1986) 
have  shown  that  lipid  probes  diffuse  freely  in  the  external  monolayer  of  the  outer 
tegument  membrane  of  S.  mansoni  whereas  in  the  inner  layers  they  have  a  restricted 
diffusion  (Foley  et  al.,  1986).  This  may  be  a  consequence  ofthe  outer  membrane  being 
composed  of  micron-scale  liquid  crystalline-phase  lipid  domains  that  lack  significant 
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Figure  2.2  Surface  topography  of  adult  maleV.  mansoni  worm. amounts  of  trans-membrane  proteins  (Caulfield  et  aL,  1991)  while  the  lateral  diffusion 
of  the  inner  bilayer  is  limited  by  the  insertion  of  glycosylphosphatidylinositol-anchored 
glycoprotein  antigens  (Camacho  et  aL,  1995). 
In  addition  to  its  critical  role  in  the  survival  of  the  parasite,  the  tegument  of 
schistosomes  is  also  potentially  important  as  a  target  for  the  action  of  many  anti- 
schistosomal.  drugs,  most  importantly  praziquantel  (Andrews  et  al.,  1983;  Cioli  et  al., 
1995).  The  effects  of  the  anti-schistosomal  agents,  praziquantel  (PZQ)  and  Mirazido,  on 
the  tegument  of  S  mansoni  are  a  major  focus  of  this  thesis. 
2.1.2  Mirazido  as  an  anti-schistosomal  drug 
Mirazido  (MZD)  is  the  trade  name  of  myrrh  which  is  an  oleo-gum  resin  derived  from 
the  plant,  CommiPhOra  MIMI-  In  ancient  Egypt,  myrrh  was  one  of  the  constituents 
exploited  to  preserve  mummies  (Buckley  and  Evershed,  2001).  In  the  recent  years,  there 
have  been  a  number  of  studies  on  the  biological  activity  of  myrrh  and  as  a  result,  many 
medicinal  uses  have  been  proposed  for  it.  The  anti-schistosomal  activities  of  myrrh 
were  first  reported  by  Sheir  and  colleagues.  They  treated  204  Egyptian  schistosomiasis 
patients,  171  infected  with  S.  mansoni,  4  with  S.  haematoblum  and  29  with  mixed  S 
mansoni  and  S.  haematobium.  Iley  reported  an  average  parasitologic  cure  rate  of 
91.7%  after  a  single  course  of  treatment  and  98%  after  a  second  course  of  the  drug.  The 
drug  was  effective  against  both  S.  mansoni  and  S.  haematobium.  They  also  reported 
complete  relief  of  symptoms  in  90.7%  of  patients  (Sheir  el  al.,  2001).  In  another  study 
on  human  schistosomiasis,  treatment  with  MZD  at  a  dose  of  600mg  per  day  for  six  days 
was  reported  to  have  97.4  and  96.2%  cure  rates  against&  haematobium  and  S.  mansoni, 
respectively  (Abo-Madyan  et  aL,  2004).  They  also  reported  "a  marvellous  clinical  cure 
without  any  side  effects"  after  this  treatment  regime.  Furthermore,  MZD  has  been 
shown  to  have  strong  anti-schistosomal  properties,  in  vitro,  against  S.  mansoni  adult 
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tegumental  damage  of  the  parasite  in  the  form  of  tegumental  disruption,  oedema  and 
loss  of  the  spines  covering  the  tubercles  (Hassan  et  aL,  2003). 
In  addition  to  its  activity  against  schistosomes,  MZD  has  been  also  reported  to  be 
effective  against  human  fascioliasis  at  a  dose  of  12mg  kg-1  of  body  weight  daily  for  6 
consecutive  days.  All  treated  patients  showed  a  pronounced  improvement  of  their 
general  conditions  and  symptoms  and  stopped  passing  eggs  in  their  stools  (Massoud  et 
al.,  2001a).  A  similar  fasciolicidal  effect  of  MZD  has  been  reported  in  sheep.  A  total 
dose  of  600mg  gave  a  cure  rate  of  83.3  %,  while  a  dose  of  900  to  1200mg  gave  a  100% 
cure  rate  (Haridy  et  al,  2003).  MZD  was  also  reported  to  be  cffective  against  human 
and  sheep  dicrocoeliasis  dendriticum  with  a  cure  rate  of  100%  (Al-Mathal  and  Fouad, 
2004). 
Other  reported  properties  of  myrrh  include;  molluscicidal  activities  against 
Biomphalarla  alexandrina,  Bulinus  truncatus  and  Lymnaea  cailliaudi  (Allam  et  al., 
2001;  Massoud  and  Habib,  2003),  larvicidal  activity  against  Culex  pipiens  larvae 
(Massoud  et  al.,  2001b),  anti-inflammatory  effect  (Kimura  et  al.,  2001),  local 
anaesthetic,  anti-bacterial  and  anti-fungal  properties  (Dolara  et  aL,  2000)  and  smooth 
muscle  relaxing  properties  (Andersson  et  al.,  1997). 
In  Egypt,  MZD  has  been  licensed  for  use  for  the  treatment  of  human  schistosomiasis 
and  fascioliasis  and  it  has  been  said  to  be  safe  and  well  tolerated  with  few  side  effects 
(Sheir  et  al.,  2001;  Massoud  et  al.,  2004).  However,  in  other  trials  of  treatment  of 
human  schistosomiasis,  low  cure  rates  have  been  reported  and  the  previously  reported 
high  cure  rate  seems  to  be  difficult  to  reproduce  (Fcnwick  et  al.,  2003).  Furthermore,  in 
a  multicentre  study  for  treatment  of  S.  mansoni  in  mice  indicated  that  MZD  is  not 
effective  against  adult  schistosomes  (Botros  et  al.,  2004).  To  clarify  this  situation,  the 
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standard  drug  PZQ,  against  S.  mansoni  both  in  vitro  and  in  vivo. 
2.2  Materials  and  methods 
2.2.1  Drugs  and  reagents 
Drugs 
The  extract  of  Commiphora  molmol  (myrrh)  used  in  the  experiments  is  produced  by 
Pharco  Pharmaceuticals  (Egypt).  It  is  sold  as  a  "purified"  extract  in  capsules  of  300mg 
although  details  of  the  extraction  process  and  subsequent  processing  are  not  available.  It 
licensed  and  marketed  as  Mirazide  for  the  treatment  of  human  schistosomiasis  and 
fascioliasis  in  Egypt.  Praziquantel  was  obtained  as  a  powder  from  Bayer  (Germany). 
Both  MZD  and  PZQ  were  dissolved  in  dimethyl,  sulfoxide  (DMSO)  to  make  stock 
solutions  of  I  00mg  ml". 
Reagents 
Unless  otherwise  stated,  all  reagents  used  in  the  experiments  were  purchased  from 
Sigma-Aldrich  Company  Ltd,  Dorset,  England.  Details  of  the  solutions  are  provided  in 
the  appendix. 
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2.2.2  Parasites 
Recovery  of  adult  S.  mansoni  worms 
The  Puerto  Rican  strain  of  S  mansoni  is  maintained  in  Professor  John  Kusel's 
laboratory  (University  of  Glasgow)  by  routine  infection  of  female  TO  mice.  Adult 
worms  were  recovered  by  perfusion  of  6-8  week-infected  mice  according  to  the  method 
of  Smithers  and  Terry  (1965).  Six  to  eight  weeks  after  infection,  mice  were  killed  by  an 
intra-peritoneal  injection  of  0.2ml  (60mg  ml")  of  Sagatal.  The  abdominal  and  thoracic 
cavities  of  the  mice  were  exposed  by  dissection  and  the  mice  were  suspended  against  a 
vertical  perspex  sheet.  An  incision  was  made  in  the  portal  vein  and  heparinised  RPMI- 
1640  medium  was  pumped  into  the  heart  using  a  50ml  disposable  syringe.  The  worms 
passed  through  an  incision  in  the  portal  vein  and  were  collected  on  a  sheet  of  muslin 
gauze  and  washed  in  RPMI-  1640  before  use  in  the  experiments. 
Mechanical  transformation  of  schistosomula 
The  method  used  for  mechanical  transformation  of  schistosomula  is  a  modification  of 
that  of  Colley  and  Wikel  (1974).  Schistosoma  mansoni  cercariae  freshly  shed  from 
Biomphalaria  galabrata  snails  were  transferred  to  a  plastic  universal.  By  chilling  the 
cercariae  on  ice  for  15  minutes,  their  motility  is  reduced  and  they  rapidly  sank  to  the 
bottom  of  the  container.  This  facilitated  their  concentration  in  smaller  volumes.  Water 
was  then  removed  until  approximately  Iml  remained  and  9ml  of  pre-warmed  (370C) 
RPMI-1640  was  added.  The  cercariae  were  then  aspirated  10  times  using  a  10ml 
syringe  and  21  -gauge  needle  to  shear  off  their  tails.  The  schistosomula  were  washed 
twice  in  RPMI-  1640  and  left  for  2  hours  at  3  7*C  to  complete  their  transformation  before 
use. 
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Adult  S.  mansoni  worms  were  incubated  in  complete  RPMl-  1640  medium  (RPMI-  1640 
+  10%  Foetal  calf  serum  (FCS)  +  2%  penicillin/streptomycin  +  2%  Fungizone,  all  from 
Gibco  Limited,  Paisley,  Scotland)  with  various  concentrations  (3,6,12,25,50,100  and 
200pg  ml-1)  of  either  PZQ  or  MZD.  Ten  worm  pairs,  consisting  of  one  male  and  one 
female,  were  incubated  in  a  volume  of  I  ml  in  each  well  of  a  24-well  tissue  culture  plate 
(Microplate,  IWAKI,  Japan).  As  controls,  worms  were  incubated  in  media  containing 
1%  DMSO.  The  plates  were  incubated  at  37'C  in  a  humid  atmosphere  with  5%  C02. 
Damage,  changes  in  shape,  changes  in  motility  and  unpairing  of  adult  worms  were 
assessed  using  an  inverted  light  microscope  (Leitz  DIAVERT"). 
2.2.4  Assessment  of  the  viability  of  schistosomula  of  S.  mansoni  after  in 
vitro  exposure  to  pranquantel  or  Mirazidlý 
Toluidine  blue  exclusion  test 
Schistosomula  were  incubated  in  96-well  tissue  culture  plates  (Microplate,  IWAKI, 
Japan).  Two  hundred  schistosomula  were  incubated  in  I  ml  of  medium  containing  either 
MZD  or  PZQ  at  concentrations  of  3,6,12,25,50,100  and  20OAgml".  As  controls, 
schistosomula  were  incubated  in  media  containing  1%  DMSO.  The  viability  and 
integrity  of  schistosomula  were  assessed  by  their  ability  to  exclude  the  toluidine  blue 
dye  1,2,4  and  8  hours  after  exposure.  One  percent  of  a  methanolic  solution  of  toluidine 
blue  (Fisher  Scientific  UK  LTD,  Leics,  UK)  was  spread  over  glass  slides  and  allowed  to 
dry.  Schistosomula  were  then  placed  onto  these  slides  and  examined  using  a  Leitz 
(DIALUX  model  22EB)  light  microscope.  Normal  schistosomula  remained  unstained 
whereas  damaged  ones  became  stained  with  the  dye  (Dessein  et  al.,  1983). 
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was  obtained  by  using  the  Hoechst  test. 
Hoechst  test 
The  effect  of  both  drugs  on  the  viability  of  schistosomula  was  further  investigated  using 
the  Hoechst  33258  dye.  Hoechst  33258  dye  is  relatively  membrane  impermeable  and 
can  access  the  cells  through  damaged  membranes.  It  specifically  binds  to  the  DNA 
where  it  fluoresces  (Modha  et  aL,  1997).  Two  hundred  schistosomula  were  incubated 
for  4h  in  Iml  of  medium  containing  either  MZD  or  PZQ  at  concentrations  of  50,100 
and  200lig  ml-1.  As  controls,  schistosomula  were  incubated  in  media  containing  1% 
DMSO.  Hoechst  33258  was  added  (2pg  ml")  during  the  last  20  minutes  of  incubation. 
Schistosomula  were  then  mounted  on  slides  and  examined  using  a  fluorescent 
microscope  (Leitz  Laborlux  S  with  3-1  PLEOMOPAK  fluorescence  illuminator).  Tle 
damaged  areas  of  the  parasites  gave  a  blue  fluorescence. 
2.2.5  Fluorescent  Recovery  After  Photobleaching  (FRAP) 
Another  method  that  has  been  used  to  investigate  the  effect  of  the  drugs  on  the  surface 
membrane  of  the  schistosomes  is  FRAP.  FRAP  allows  the  assessment  of  membrane 
fluidity  as  an  indirect  indication  of  membrane  function.  For  FRAP,  the  sample  to  be 
examined  is  probed  with  a  fluorescent  substance  and  then  an  attenuated  laser  beam  is 
focused  to  a  small  spot  on  the  sample.  The  initial  fluorescence  level  inside  the  spot  is 
measured  and  the  laser  is  momentarily  de-attenuated  to  bleach  irreversibly  the 
molecules  within  the  spot.  The  recovery  of  fluorescence  inside  the  spot  is  a 
consequence  of  the  difflusion  of  unbleached  molecules  from  outside  the  spot.  FRAP  thus 
provides  two  measures  of  diffusibility;  the  fmction  (percentage  recovery)  of  molecules 
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1997). 
Incorporation  of  the  fluorescent  lipid  analogue 
Lipid  motility  on  the  surfaces  of  worms  was  examined  by  probing  adult  worms  and 
schistosomula  with  a  fluorescent  lipid  analogue,  5-N-octadecanoyl  aminofluorescein 
(AF18)  (Molecular  Probes  Europe  BV,  PoortGebouw,  The  Netherlands).  Schistosoma 
mansoni  adult  males  and  schistosomula  were  incubated,  as  before,  with  either  MZD  or 
PZQ  at  concentrations  of  200ýtg  ml-1  (as  a  high  drug  concentration)  and  20pg  ml-1  (as  a 
low  drug  concentration).  As  controls,  parasites  were  incubated  in  media  containing  1% 
DMSO.  Twenty  adult  males  or  200  schistosomula  were  incubated  in  Iml  of  complete 
RPMI-1640  medium  at  370C  and  5%  C02.  After  4  and  24  hours  of  incubation,  5PI  of  an 
ethanolic  solution  containing  I  Opg  of  the  AF-18  probe  were  added  to  each  well  and  the 
parasites  were  incubated  for  another  15  minutes.  Then,  parasites  were  washed  3  times 
with  RPMI-1640  to  remove  any  unbound  probe.  Worms  were  re-suspended  in  I  OOgI  of 
RPMI,  placed  on  a  glass  slide  and  immobilised  by  addition  of  I  OPI  of  carbachol  (I  Omg 
ml-1).  When  myrrh  was  used,  100pl  of  carbachol  (10mg  ml")  was  required  to 
immobilise  worms  (see  discussion). 
Lipid  mobility  assessment 
Measurement  of  the  diffusion  of  lipid  molecules  in  adult  worm  and  schistosomula 
membranes  was  carried  out  according  to  the  method  outlined  by  Foley  et  al.  (1986). 
Fluorescence  was  measured  over  a  small  and  defined  spot  of  1.2[Lm  diameter  on  the 
surface  of  the  labelled  parasite  using  an  attenuated  argon  laser  (LEXEL  model  85) 
attached  to  a  microscope  (Ortho  11).  The  power  of  the  laser  was  increased  for  70ms  to 
irreversibly  bleach  a  proportion  of  the  fluorescent  molecules  in  the  spot,  and  the 
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mobile  fraction  (percentage  recovery),  and  the  lateral  diffusion  coefficient  of  lipid 
molecules  were  measured  in  5  spots  on  the  tubercles  of  the  dorsal  tegument  of  each 
adult  worm,  just  behind  the  head  region.  For  measurements  on  schistosomula,  a  spot 
was  selected  in  the  central  portion  of  the  body. 
2.2.6  Scanning  Electron  Microscopy  (SEM) 
Adult  worms  and  schistosomula  of  S  mansoni  were  incubated  with  either  MZD  or  PZQ 
at  concentrations  of  200pg  ml-1  and  20pg  ml-1  for  MZD  and  200,20  and  5pg  ml-I  for 
PZQ.  As  controls,  parasites  were  incubated  in  media  containing  1%  DMSO  (the  drug 
solvent).  Either  twenty  adult  worms  or  200  schistosomula  were  incubated  in  Iml  of 
complete  RPMI-1640  medium  at  37'C  and  5%  C02.  After  4,24  and  72h  of  incubation, 
treated  and  control  parasites  were  fixed  in  2.5%  glutaraldehyde  buffered  with  O.  IM 
phosphate  for  lh  and  then  washed  3  times  for  5min  each  time  with  O.  IM  phosphate 
buffer  rinse  (containing  2%  sucrose).  The  samples  were  secondarily  fixed  in  1% 
osmiurn  tetroxide  for  I  h,  washed  3  times  for  10  minutes  each  time  with  distilled  water, 
fixed  in  0.5%  aqueous  uranyl  acetate,  in  the  dark,  for  I  hour  and  then  washed  again  with 
distilled  water.  Then  samples  were  dehydrated  in  ascending  grades  of  alcohol,  30,50, 
70,90  and  100%  and  finally  in  dried  absolute  alcohol,  for  10  minutes  each  time.  After 
critical  point  drying  with  liquid  C02,  the  specimens  were  mounted  on  metal  stubs  with 
double-sided  copper  tape.  They  were  coated  with  gold  using  a  Polaron  SC515  SEM 
coating  system  and  examined  using  a  Phillips  SEM  500  electron  microscope.  The 
procedures  were  carried  out  as  recommended  by  Hayat  (1989). 
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worms  after  exposure  to  praziquantel  or  Mirazid2' 
Adult  S.  manson!  were  incubated  with  either  MZD  or  PZQ  at  concentrations  of  200  and 
20pg  ml-1.  As  controls,  parasites  were  incubated  in  media  containing  1%  DMSO  (the 
drug  solvent).  Twenty  adult  worms  were  incubated  in  Iml  of  complete  RPMI-1640 
medium  at  37'C  and  5%CO2.  Four  and  24h  after  incubations,  treated  and  control 
parasites  were  fixed  in  2.5%  glutaraldehyde  buffered  with  O.  IM  phosphate  for  lh  and 
then  washed  3  times  for  5min  each  time  with  O.  IM  phosphate  buffer  rinse  (with  2% 
sucrose).  The  samples  were  secondarily  fixed  in  1%  osmium  tetroxide  for  1h,  washed  3 
times  for  10min  each  time  with  distilled  water,  fixed  in  0.5%  aqueous  uranyl  acetate,  in 
the  dark,  for  lh  and  then  washed  again  with  distilled  water.  Then  samples  were 
dehydrated  in  ascending  grades  of  alcohol,  3  0,50,70,90  and  100%  and  finally  in  dried 
absolute  alcohol,  for  10min  each  time.  The  specimens  were  washed  with  propylene 
oxide  3  times  for  5min  each  time  and  further  dehydrated  by  incubation  in  a  1:  1  volume 
to  volume  mix  of  propylene  and  araldite.  Specimens  were  left  overnight  on  a  rotator 
until  the  propylene  oxide  was  evaporated  leaving  pure  araldite,  which  was  replaced  by 
fresh  araldite  and  left  overnight.  Samples  were  then  embedded  in  moulds  and  left  to 
polymerise  at  60'C  for  48h.  Sections,  60-80nm  thick,  were  cut  using  an  ultramicrotome 
(Reichert  Ultracut)  and  stained  with  2%  methanolic  uranyl  acetate  for  Smin  followed  by 
Reynold's  lead  citrate  for  another  5  minutes.  Specimens  were  viewed  using  a  TEM 
(Zeiss  902). 
2.2.8  Calcium  labelling  with  Fluo  3  AM 
Fluo-3  AM  cell  permeant  (Molecular  Probes  Europe  BV,  PoortGebouw,  The 
I 
Netherlands)  is  a  fluorescent  probe  which  fluoresces  intensely  when  it  binds  calcium.  Its 
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cell,  it  is  metabolised  to  an  impermeable  compound  that  leaks  out  only  slowly.  Fluo-3 
AM  is  purchased  as  a  powder  in  50pg-vials.  The  contents  of  each  vial  were  dissolved  in 
50ptl  of  DMSO.  Either  twenty  S.  mansoni  adult  worms  or  200  schistosomula  were 
incubated  in  Iml  of  complete  RPMI-1640  medium  to  which  5[d  containing  5pg  of  Fluo- 
3  AM  was  added.  They  were  incubated  for  2  hours  at  37*C  in  5%  C02.  MZD  or  PZQ 
was  then  added  to  the  parasites  to  achieve  a  concentration  of  200pg  ml"  for  either  drugs 
and  incubation  continued.  As  controls,  parasites  were  incubated  with  1%  DMSO.  After 
15min,  30min,  1,2  and  4h  of  exposure  to  the  drugs,  parasites  were  washed  34  times 
with  RPMI-  1640  to  remove  excess  probe  and  drugs.  The  parasites  were  re-suspended  in 
approximately  100ptl  of  fresh  RPMl  medium  and  deposited  within  silicon  grease 
squares  on  glass  slips  and  covered  with  cover  slides  for  quantitative  measurements.  All 
measurements  were  carried  out  using  a  fluorescent  microscope  (Leitz  Laborlux  S  with 
3-1  PLEOMOPAK  fluorescence  illuminator).  Fluorescence  was  quantified  using  a  Leitz 
MPV  compact  photometer  with  MPV-COMBI  control  electronics  attached  to  a  PC 
(Silicon  Valley)  installed  with  MPV-STAT  software  for  data  and  statistical  analysis 
(Leica). 
The  experiment  was  repeated  but  with  the  adult  worms  being  exposed  to  the  drugs  prior 
to  fluo-3  AM  labelling.  One  and  4  hours  after  exposure  to  MZD  or  PZQ  at  200pg  ml", 
parasites  were  washed  with  RPMI  medium  3-4  times,  to  remove  the  drugs.  They  were 
then  labelled  with  fluo-3  AM  for  2h  as  before.  The  parasites  were  washed  again  with 
medium  and  quantitative  fluorescent  measurements  were  calculated  as  mentioned 
previously. 
58 In  vivo  experiments 
2.2.9  Design  of  the  experiment 
Thirty  female  TO  mice  were  infected  by  subcutaneous  injection  of  150  cercariae  (per 
mouse)  of  the  Puerto  Rican  strain  of  S.  mansoni.  Six  weeks  after  infection,  they  were 
divided  into  3  groups;  a  control  infected  group  (10  mice)  left  without  any  treatment,  a 
MZD  group  (10  mice)  treated  with  400mg:  kg-1  of  body  weight  daily  dose  of  MZD  given 
orally  for  3  consecutive  days  and  a  PZQ  group  (10  mice)  treated  with  a  single  dose  of 
400mg  kg-1  of  body  weight  of  praziquantel  given  orally.  A  fourth  group  of  control  non- 
infected  mice  (5  mice)  were  included  as  control  for  cytokine  assays  (see  figure  2.3). 
Two  weeks  after  treatment,  mice  were  perfused  for  recovery  of  adult  worms.  The  whole 
liver  of  each  mouse  was  dissected,  weighed,  a  piece  was  dissolved  in  KOH  to  assess 
egg  numbers  in  liver  tissue  and  the  rest  of  the  liver  was  fixed  for  histopathology 
sectioning.  Spleen  and  mesenteric  lymph  nodes  (LNs)  were  dissected,  washed  with 
RPMI  and  processed  for  lymphoblastogenesis  and  cytokine  assays.  Further  technical 
details  of  the  methodologies  are  given  below. 
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Figure  23  Design  of  the  In  vivo  experiments. 
Sub-cutaneous  injection  (SQ,  post  infection  (PI)  and  lymph  nodes  (LNs). 
2.2.10  Recovery  of  adult  S.  mansoni  worms 
The  process  of  liver  perfusion  and  recovery  of  adult  worms  was  carried  out  as 
mentioned  previously  (see  section  2.2.2).  The  worms  recovered  from  each  mouse  were 
collected  in  a  universal  container  containing  RPMI-1640  medium  supplemented  with 
10%  FCS.  The  worms  were  placed  into  a  Petri  dish  and  they  were  counted  using  a 
dissecting  microscope.  The  worms  of  each  group  were  then  pooled  (for  the  proteomic 
analysis)  and  washed  in  40mM  Tris  solution  and  stored  at  -20'C  until  used. 
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A  piece  from  each  liver  was  excised,  weighed  and  placed  in  a  labelled  universal  tube 
containing  10ml  of  5%  KOH  solution.  The  tubes  were  incubated  for  24h  at  37T.  The 
content  of  each  tube  was  mixed  thoroughly  with  an  equal  volume  of  10%  formol  saline 
solution  and  then  centrifuged  at  60g  for  I  min.  The  residues  were  re-suspended  in  6ml  of 
phosphate  buffered  saline  (PBS)  and  mixed  thoroughly.  A  200ptl  was  then  placed  on  a 
glass  slide  and  the  eggs  were  counted.  Duplicate  counts  were  made  and  the  mean 
number  of  eggs  per  gram  of  liver  tissue  was  calculated. 
2.2.12  Liver  histology 
Tle  liver  samples  were  fixed  in  neutral  buffered  formol  saline  over  night  at  room 
temperature.  They  were  washed  under  gently  running  tap  water  and  then  passed  in 
ascending  grades  of  alcohol  (2  x  30min  in  70%,  4x  30min  in  90%  and  4x  30min  in 
100%  alcohol).  The  samples  were  incubated  in  tissue-clear  solution  (2  x  15min)  and 
then  in  paraffm  wax  (2  x  2h).  Samples  were  then  embedded  in  cassettes  using  fresh 
paraffin  wax.  The  specimens  were  trimmed,  cooled  on  ice  and  then  sectioned  at  5[tm 
using  a  microtome  (Leica  RM2035).  'Me  sections  were  floated  on  distilled  water  at 
36'C,  mounted  on  poly-l-lysine  coated  microscope  slides  and  dried  over  night  at  36*C. 
For  general  tissue  structure  sections  were  stained  by  haematoxylin  and  eosin  (H&E). 
The  sections  were  de-waxed  in  tissue  clear  solution  and  then  hydrated  in  decreasing 
concentrations  of  alcohol  (100,90  and  70%).  The  sections  were  washed  in  gently 
running  tap  water  and  then  stained  with  Mayer's  haernatoxylin  for  5min.  They  were 
washed  in  gently  running  tap  water  and  then  stained  with  eosin  stain  for  2min.  The 
excess  stain  was  washed  in  gently  running  tap  water  and  then  the  sections  were 
dehydrated  in  increasing  concentrations  of  alcohol  (70,90  and  100%).  The  sections 
61 were  cleared  again  in  tissue  clear  and  then  mounted  in  synthetic  mounting  media.  The 
nuclei  stain  blue  and  all  other  structures  stain  pink/red. 
The  collagen  fibres  were  stained  with  picro-sirius  red  F3B  dye  according  to  the  method 
of  Junqueira  et  aL  (1979).  Briefly,  the  sections  were  hydrated  in  water  and  stained  with 
picro-sirius  red  for  lh.  They  were  then  washed  in  two  changes  of  acidified  water  and 
dehydrated  in  3  changes  of  absolute  alcohol.  The  sections  were  cleared  in  tissue  clear 
solution  and  mounted.  In  ordinary  brightfield  microscopy,  collagen  fibres  stain  red  on  a 
yellow  backgound. 
Eosinophils  were  localised  using  the  picro-sirius  red  technique  according  to  the  method 
of  Llewellyn  (1970).  The  sections  were  hydrated  in  water  and  stained  using  Mayer's 
haematoxylin  for  Imin.  They  were  washed  gently  under  running  water  until  the  stain 
became  blue.  They  were  rinsed  in  alcohol  and  then  transferred  to  picro-sirius  red  for  I- 
2h.  The  sections  were  washed  thoroughly  under  gently  running  water.  They  were  then 
dehydrated  in  absolute  alcohol,  cleared  in  tissue  clear  and  mounted.  Eosinophil  granules 
stain  bright  red,  nuclei  stain  blue  and  the  background  colourless.  Ile  eosinophils  in  the 
high  power  field  (HPF)  surrounding  the  egg  of  each  granuloma  was  counted.  Only 
granulomas  surrounding  a  single  egg  were  included. 
2.2.13  Extraction  of  lymphocytes 
The  spleens  and  mesenteric  lymph  nodes  (LNs)  were  dissected  and  collected  in  labelled, 
sterile  universal  tubes  containing  RPMI-1640.  The  spleens  of  each  group  of  mice  were 
pooled  in  a  single  tube.  Similarly  the  LNs  were  pooled  in  another  tube.  The  spleens  and 
LNs  were  pressed  with  a  sterile  syringe  plunger  through  a  fine  sieve  in  a  Petri  dish 
containing  15ml  of  RPMI-1640-  The  Petri  dishes  were  tilted  to  allow  cell  clumps  to 
settle  and  the  supernatants  were  collected  in  50ml-sterile  tubes,  supplemented  to  30ml 
62 with  RPMI-  1640  and  centrifuged  for  7min  at  180g  and  4'C.  Residues  from  spleens  were 
re-suspended  in  6ml  of  RPMl  and  added  gently  to  a  universal  tube  containing  4ml  of 
Lymphoprep  (1.077  ±  0.001g/ml)  (Nycomed  Pharma  AS,  Oslo,  Norway).  Then  they 
were  centrifuged  at  40C  for  40min  at  220g.  The  lymphocytes  were  collected  using  a 
glass  pipette  and  placed  in  a  universal  tube.  The  cells  from  the  spleens  and  LNs  were 
then  washed  twice  for  7min  each  time  at  180g  at  18-25'C.  After  the  last  wash,  cells 
were  re-suspended  in  Iml  of  RPMI-1640.  A  10pl  sample  from  each  tube  was  diluted 
with  190AI  of  2.5%  solution  of  trypan  blue.  The  cells  were  counted  using  an  improved 
Neubauer  haemocytometer.  After  calculating  the  total  number  of  cells  in  each  tube,  they 
were  diluted  with  RPMI-  1640  to  achieve  a  working  concentration  of  Ix  107  cellshnl. 
2.2.14  Lymphocyte  proll  ration  assay 
Lymphocytes  from  spleens  and  LNs  of  each  group  were  cultured  in  96-well  tissue 
culture  plates.  Blastogenesis  was  assessed  by  incubation  of  lymphocytes  with  5ýtg  ml-1 
of  Concanavalin  A  (ConA)  or  25pg  ml-1  of  either  S.  mansoni  soluble  worm  antigens 
(SWAP)  or  soluble  egg  antigens  (SEA)  (150ýtl  of  complete  RPMI-1640  +  25PI  of  cell 
suspension  containing  2.5  x  105  cells  +  25ýd  of  antigen)  with  unstimulated  cells  as 
control  (175ýd  of  complete  RPMI-1640  +  251d  of  cell  suspension).  Assays  were  run  in 
triplicate.  The  plates  were  incubated  at  37'C,  5%  C02  and  humidity.  After  5  days, 
0.2ýtCi  of  radioactive-thymidine  (Amersharn  Biosciences  UK  Ltd,  Buckinghamshire, 
UK)  was  added  to  each  well  and  further  incubated  for  18  hours.  At  the  end  of 
incubations,  the  plates  were  harvested  and  isotype  incorporation  by  the  cells  measured 
using  a  liquid  scintillation  counter  (Wallac  1450  Microbetaý  Trilux). 
63 2.2.15  Cytokine  assays 
Culture  of  lyniphocytes  and  splenocytes  with  different  antigens 
Lymphocytes  were  cultured  as  described  previously  and  the  supernatants  were  collected 
after  5  days  of  incubation.  Aliquots  of  150[d  of  supernatant  were  collected  from  each 
well  and  stored  in  sterile  tubes  at  -800C  until  they  were  used. 
Cytokine  detection  and  estimation  by  Duoset(&  enzyme  linked  immuno-sorbent 
assay  (ELISA) 
DuoSet'9  kits  for  detection  of  IL-4,  IL-10,  IL-13  and  INF-y  cytokines  were  purchased 
from  R&D  Systems  Europe  Ltd,  Abingdon,  UK.  The  protocol  used  was  that  defined  by 
the  supplier.  The  plates  were  coated  with  1001il  of  capture  antibodies,  41Lg  ml-1  for  IL-4, 
IL-13  and  IFN-y  and  2jig  ml"  for  IL-10,  at  room  temperature  overnight.  They  were 
washed  three  times  with  wash  buffer,  0.05%  Tween  20  in  PBS,  pH  7.2.  They  were 
blocked  with  200[d  of  block  buffer  (1%  BSA,  5%  sucrose  in  PBS  with  0.05%  Na  N3) 
sealed  at  room  temperature  for  two  hours  and  washed  as  before.  I  00gl  of  each  sample 
and  standard  dilution  were  loaded  per  well.  Samples  were  run  in  duplicate.  Seven  two- 
fold  dilutions  of  the  standard  were  used  starting  with  10OOpg  ml"'  for  IL4,20OOpg  ml" 
for  IL-10  and  IFN-y  and  2500pg  ml"  for  IL-13.  They  were  sealed  and  incubated  for  2 
hours  at  room  temperature.  The  plates  were  washed  and  100tLI  of  detection  antibodies, 
0.2ýtg  ml-1  for  IL-4  and  IL-13  and  0.4pg  ml-1  for  IL-10  and  IFNy  were  loaded  and 
incubated  for  2  hours  at  room  temperature.  Excess  antibodies  were  washed  away  with 
wash  buffer  and  a  100til  of  streptavidin-HRP  was  loaded  per  well.  Plates  were  then 
incubated  for  20  minutes  at  room  temperature,  away  from  direct  light.  The  plates  were 
washed  as  before  and  a  1001A  of  substrate  solution  (1:  1  mixture  Of  11202  and 
64 tetramethylbenzidine)  was  added  to  each  well  and  were  further  incubated  for  another  20 
minutes  at  room  temperature,  away  from  direct  light.  The  reactions  were  then  stopped 
with  50ýtl  of  2N  H2SO4.  Optical  densities  were  determined  immediately  using  a 
microplate  reader  (DYNEX  MRX  Revelationo)  set  to  450rim  with  wavelength 
correction  set  to  540run. 
2.2.16  Statistical  analysis 
All  statistical  tests  were  carried  out  on  the  means  using  the  analysis  of  variance 
(ANOVA)  test  with  P<0.05  as  the  criterion  of  significance.  When  there  was  a 
significant  difference  it  was  followed  by  the  student  Wests  for  pair  wise  comparisons 
between  different  groups.  The  MINITAB  software  (version  12)  were  utilised  for  this 
purpose. 
2.3  Results 
Results  of  the  in  vitro  experiments 
2.3.1  Effects  of  Mirazid"'  and  praziquantel  on  the  viability  of 
schistosomula  of  S.  mansoni 
Toluidine  blue  dye  exclusion  test 
The  effects  of  MZD  on  schistosomula  were  assessed  using  toluidine  blue  dye  exclusion. 
Schistosomula  were  incubated  with  either  MZD  or  PZQ  at  concentrations  of  3,6,12, 
25,50,100  and  200pg  ml"  and  their  ability  to  exclude  toluidine  blue  dye  were  observed 
microscopically  1,2,4  and  8  hours  of  exposure  to  the  drugs.  Control  schistosomula 
were  incubated  in  medium  with  the  solvent  only  (1%  DMSO). 
65 At  all  times,  most  of  the  control  schistosomula  retained  their  ability  to  exclude  the  dye 
and  remained  unstained.  In  the  drug  exposed  groups,  although  most  of  the 
schistosomula  exposed  to  either  MZD  or  PZQ  showed  increased  granularity  and 
decreased  motility,  only  stained  parasites  were  regarded  as  damaged  or  dead.  The 
characteristic  feature  of  schistosomula  exposed  to  PZQ  was  blebbing  in  the  area  around 
the  mouth  of  the  parasites.  At  lower  concentrations,  3,6,12,25pg  ml",  neither  drug  had 
any  visible  effects  on  the  ability  of  parasites  to  exclude  the  dye.  Even  after  8  hours  of 
exposure,  the  numbers  of  stained  parasites  were  not  significantly  different  from  that 
found  in  the  controls.  After  2h  of  exposure,  only  MZD  at  a  concentration  of  200pg  ml" 
caused  a  significant  decrease  in  the  viability  of  schistosomula  (P=0.037).  After  4h  of 
exposure,  MZD  at  concentrations  of  200,100  and  50pg  ml-1  had  highly  significant 
(P<0.01)  effect  on  parasites  viability  (63,25  and  10%  of  schistosomula  were  stained, 
respectively).  This  effect  progressed  with  time  and  after  8h  of  exposure  91,37  and  18% 
of  schistosomula  were  stained,  respectively  (see  figure  2.4). 
After  4h  of  exposure  to  PZQ,  only  PZQ  at  a  concentration  of  20OAg  ml"  caused  a 
significant  impainnent  (P=0.013)  of  the  ability  of  schistosomula  to  exclude  toluidine 
blue  (11%  of  schistosomula  were  stained).  After  8h  of  exposure  to  praziquantel  at 
concentrations  of  200pg  ml-1  and  100pg  in]"  there  was  significant  impairment  (P<0.01 
and  P=0.032)  of  the  ability  of  the  parasites  to  exclude  the  dye  (16%  and  7%  of 
schistosomula  were  stained). 
These  results  indicate  that  MZD  has  a  strong  damaging  effect  presumably  on  the 
membranes  of  schistosomula,  resulting  in  their  inability  to  exclude  toluidine  blue  dye. 
PZQ  has  a  modest  effect.  With  both  drugs  the  effects  are  dose  and  time  dependent  with 
the  highest  effect  evident  after  8  hours  of  exposure  to  a  concentration  of  200pg  ml". 
66 Hoechst  test 
The  effect  of  MZD  or  PZQ  on  the  viability  of  schistosomula  of  S.  mansoni  was  further 
confirmed  using  the  Hoechst  33258  dye.  Schistosomula  were  incubated  with  either  drug 
for  4h  with  the  dye  added  during  the  last  20  minutes  of  incubation  and  then  they  were 
examined  under  the  fluorescent  microscope.  The  percentage  of  damaged  parasites  of 
each  group  was  calculated. 
Control  schistosomula  were  unstained.  After  exposure  to  MZD  at  concentrations  of 
200pg  ml-1  and  I  OOpg  ml-1,65%  and  25%  of  schistosomula  were  fluorescent  (P<0.01). 
After  exposure  to  MZD  at  a  concentration  of  50pg  ml",  15%  of  schistosomula  were 
fluorescent  (P=0.012).  After  exposure  to  PZQ  at  concentrations  of  200pg  ml-1  and 
I  Oopg  ml-1,19%  (P<0.0  1)  and  9%  (P=0.02)  of  schistosomula  were  fluorescent. 
These  results  (not  shown)  confinned  the  results  of  the  toluidine  blue  test  that  MZD  is 
more  effective  than  PZQ  against  the  schistosomula  stage  of  S.  mansoni. 
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Figure  2.4  Effect  of  Mirazide  and  praziquantel  on  the  viability  of  schistosomula  of  S.  mansoni 
assessed  by  the  toluidine  blue  exclusion  test. 
Schistosomula  of  S.  mansoni  were  incubated  with  either  PZQ  or  MZD  at  concentrations 
of  100pg  ml-1  and  200pg  ml-1.  One,  2,4  and  8  hours  after  exposure,  their  ability  to 
exclude  toluidine  blue  dye  was  determined.  The  columns  represent  the  mean 
percentages  of  damaged  (stained)  schistosomula  ±  95%  confidence  interval.  MZD 
200pg  ml-1  (M  200),  MZD  100pg  ml-'  (M  100),  PZQ  200pg  ml-1  (PZQ  200),  PZQ 
100pg  ml-1  (PZQ  100)  and  control  schistosomula  incubated  with  1%  DMSO  (Control). 
All  groups  consisted  of  500  schistosomula  and  these  results  represent  the  mean  of  five 
experiments. 
2.3.2  Effects  of  Mirazido  and  praziquantel  on  adult  worms  of  S. 
mansoni 
Adult  wonns  of  S.  mansoni  were  cultured  with  either  MZD  or  PZQ  at  concentrations  of 
3,6,12,25,50,100  and  200pg  ml-1.  Worms  were  observed  under  an  inverted  light 
microscope  immediately  after  exposure  and  at  15min,  30min  and  at  1,2,4,8,24  and 
48h  after  exposure.  Control  worms  were  incubated  in  medium  with  1%  DMSO.  Control 
worms  remained  alive  and  moved  normally.  The  female  worms  started  to  lay  eggs 
between  18  and  24h  of  incubation. 
The  earliest  changes,  caused  within  seconds  of  exposure  to  PZQ,  were  muscular 
contractions  and  rapid  coiling  of  worms,  at  all  PZQ  concentrations  used.  The  worms 
contracted  becoming  shorter  and  thicker  than  the  control  parasites.  The  coiled  worms 
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lh  2h  4h  8h began  to  uncoil  30-60  minutes  later  although  they  remained  shorter  and  thicker  than  the 
control  parasites  at  all  times.  Worm  motility  started  to  diminish  within  15-30  minutes  of 
exposure.  Motility  decreased  progressively  with  time.  Surface  blebbing  became  evident 
between  1-2h  of  exposure  to  concentrations  of  200,100  and  50pg  ml-1  and  became 
evident  at  all  PZQ  concentrations  after  4h  of  exposure  (see  table  2.1). 
The  earliest  effect  of  MZD  was  separation  of  adult  S.  mansoni  worms.  This  started  as 
early  as  15  minutes  after  exposure  to  concentrations  of  200pg  ml-1  and  100pg  ml-1. 
With  time  the  number  of  worm  separations  increased.  At  200Pg  ml"  and  100Pg  ml", 
MZD  caused  an  initial  increase  of  motility  and  an  increase  in  length  of  the  parasites 
compared  to  the  control  group.  This  increase  in  motility  was  accompanied  by  increased 
regurgitation  of  intestinal  contents  of  the  worms,  especially  by  the  female  worms, 
causing  increased  turbidity  of  the  media.  Worm  motility  returned  to  control  levels  after 
3  to  4  hours  of  exposure.  At  a  MZD  concentration  of  200pg  ml-1,  worm  motility  began 
to  decrease  after  8  hours  of  exposure.  This  decrease  in  motility  progressed  with  time. 
MZD  at  concentrations  of  I  OOpg  ml-1  and  50pg  ml-1  caused  a  decrease  in  worm  motility 
18  and  48h  after  exposure,  respectively.  At  concentrations  of  200Pg  ml-1  and  100Pg  ml' 
1.  surface  blebbing  became  evident  between  18-24h  after  exposure.  At  concentrations 
ranging  between  3  and  25pg  ml-1,  MZD  seemed  to  have  little  effect  on  adult  worms. 
They  showed  no  obvious  evidence  of  damage  and  the  female  worms  started  to  lay  eggs 
after  24h  of  incubation. 
These  results  indicate  that  while  PZQ  is  very  effective  against  adult  S  mansoni  worms, 
MZD  seems  to  be  effective  only  at  high  concentrations  and  has  obvious  effects  only 
after  a  considerable  duration  of  exposure.  However,  at  high  concentrations  MZD  caused 
rapid  separation  of  wonn  pairs  but  it  is  impossible  from  these  data  to  determine  whether 
the  effect  of  MZD  on  pairing  was  due  to  a  differential  effect  of  the  drug  on  male  or 
female  worms.  Other  evidence  from  SEM  studies  indicates  that  both  male  and  female 
69 worms  are  likely  to  be  affected  though  specific  changes  in  the  gynaecophoric  canal  of 
male  worms  may  be  significant  (see  section  2.3.7). 
Table  2.1  Observations  of  the  effect  of  MirazidO  and  praziquantel  on  adult  worms  of  S.  mansonL 
Adult  worms  were  exposed  to  either  MZD  or  PZQ  at  concentrations  of  3,6,12,25,50, 
100  and  200pg  ml".  Worms  were  observed  at  15min,  30min  and  at  1,2,4,8,24  and  48 
hours. 
TIME  PRAZIQUANTEL  MIRAZID  CONTROL 
Coiling  of  worms  at  all  Increased  motility  at  200pg  Control  worms 
concentrations.  This  was  ml-1  and  I  00jig  ml-1  with  an  were  alive 
in  15  apparent  immediately  after  increase  in  worms'  length.  At 
"  1 
throughout  the 
m  worm  exposure  although  200gg  mI-  and  I  OOgg  ml  experiment. 
worms  remained  coiled  at  separation  of  paired  worms.  Worms  showed 
15min. 
-  -  -  - 
no  abnormal 
Uncoiling  of  worms.  ae-nd,  100tigml-'  m  r  r  At  200tig  movements  and 
Decreased  worm  motility.  finther  separation  of  paired  began  to  lay 
30min  Worms  thick  and  short.  worms.  eggs  after  18-24 
hours  of 
Further  decrease  in  worm.  At  200pg  ml-'  and  I  OOgg  ml-'  incubation. 
1h  motility,  separation  of  paired  worms 
Surface  blebbing  at  At  200pg  ml-'  and  I  OOgg  mi" 
concentrations  of  200,100  worm  separation.  Worms' 
2h  and  50pg  ml-1.  motility  returns  back  to 
normal. 
Worms  non-motile.  At  200gg  ml-'  all  worm  pairs 
-  Surface  blebbing  at  all  separated.  At  I  OOpg  ml  4h 
concentrations.  worm  separation  increased. 
Worm  paralysed.  More  At  200pg  ml-'  decreased 
8h  surface  blebbing.  motility. 
Extensive  surface  blebbing  At  200gg  ml-'  and  I  OOpg  ml-' 
24h 
and  paralysis.  sluýgish  motility.  At  200pg 
ml  and  I  OOgg  ml"  surface 
blebbing. 
Complete  paralysis  of  At  200jig  mV  worm 
worms.  Severe  surface  paralysis.  At  100pg  ml"  and 
48h  blebbing.  50pg  ml-1  slupgish  motility. 
At  200gg  m1'  and  I  OOgg  ml" 
surface  blebbing  increased. 
70 2.3.3  Unpairing  effect  of  Mirazid"'  on  adult  S.  mansoni  worms 
Based  on  the  previous  observations,  the  unpairing  effect  of  MZD  was  fixther 
investigated.  Paired  adult  S.  mansoni  worms  were  incubated  with  MZD  at 
concentrations  of  50,100  and  200pg  ml-1  and  were  observed  using  an  inverted  light 
microscope  at  15min,  30min  and  at  1,2,3,6  and  12h  after  exposure.  Control  worm 
pairs  were  incubated  in  mediurn  with  1%  DMSO. 
Control  worms  remained  paired  and  after  12  hours  of  incubation  only  15%  of  them 
were  separated.  With  MZD  at  200pg  ml-1  and  I  OOpg  ml"  worm  separation  was  evident 
as  early  as  15  minutes  after  exposure  (28.9  and  13%,  respectively).  The  separation  of 
worm  pairs  was  highly  significant  for  both  groups  compared  to  the  control  group 
(P<0.01).  After  30  minutes  of  exposure  to  MZD  at  200pg  ml"  and  100pg  ml-1  40.2% 
and  17.6%  of  worm  pairs  were  separated,  respectively.  One  hour  after  exposure,  MZD 
at  200pg  ml-1  and  100pg  ml"  caused  separation  of  52  and  23.7%  of  worm  pairs, 
respectively.  Additional  worm  separation  occurred  gradually  and  6h  after  exposure,  all 
worms  (100%)  were  separated  at  200pg  mI-1  and  47.9%  were  separated  at  100Pg  ml-1. 
After  12h  of  exposure  to  MZD  at  100pg  ml-1,59%  of  worm  pairs  were  separated  (see 
figure  2.5).  With  MZD  at  50pg  ml-1  worm  separations  were  not  significantly  different 
from  those  of  the  control  group  throughout  the  duration  of  the  experiment. 
A  similar  experiment  (data  not  shown)  was  conducted  using  PZQ.  However,  the 
rapidity  with  which  PZQ  acts  on  the  parasites  precludes  observations  of  an  effect  on 
worm  pairing  over  time.  The  worm  unpairing  effect  of  MZD  appears  to  be  at  least  in 
part  dependent  upon  continued  worm  motility. 
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Figure  2.5  Unpairing  effect  of  Mirazid*  on  S.  mansoni  adult  worms. 
Adult  worm  pairs  were  incubated  with  MZD  at  100pg  ml-1  or  200pg  ml-1  and  were 
observed  for  separation  at  15min,  30min,  1,2,3,6  and  12h  after  exposure.  Figures 
represent  the  mean  percentage  of  adult  worm  separation  ±  95%  confidence  interval. 
MZD  200pg  ml-1  (M  200),  MZD  100)ig  ml-1  (M  100)  and  control  worms  incubated  with 
1%  DMSO  (Control).  (Note;  x-axis  scale  intervals  are  not  proportional).  All  groups 
consisted  of  30  worm  pairs  and  these  results  represent  the  mean  of  five  experiments. 
2.3.4  Effects  of  Mirazide  and  praziquantel  on  the  membrane  fluidity  of 
schistosomula  of  S.  mansoni  as  determined  by  fluorescent 
recovery  after  photobleaching  (FRAP) 
The  outcome  of  a  S.  mansoni  infection  is dependent  upon  the  host  parasite  relationship 
and  the  parasite  surface  is  the  primary  interface  for  this  interaction.  It  has  been 
suggested  that  the  outer  layer  of  the  membrane  consists  of  a  sheet  of  phospholipids  and 
sterols  that  is  shed  continuously  releasing  potentially  antigenic  material  and  bound 
antibodies  (Wilson  and  Barnes,  1977).  The  effect  of  MZD  or  PZQ  on  the  fluidity  of  the 
outer  membrane  of  schistosomula  was  investigated  using  the  FRAP  technique.  Only 
two  concentrations  of  the  drugs  were  used,  200pg  ml-1  as  a  high  concentration  which 
appeared  to  have  such  dramatic  effects  in  the  previous  experiments  and  20Pg  ml-'  as  a 
low  concentration  which  appeared  to  have  no  significant  effect  in  the  previous 
experiments.  The  membranes  of  schistosomula  were  labelled  with  a  fluorescent  lipid 
72 
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Time analogue  AF-  18.  They  were  then  treated  with  MZD  or  PZQ  at  200ýtg  ml-1  and  20  Vg  ml-1 
for  both  drugs.  As  controls,  schistosomula  were  incubated  with  1%  DMSO.  Four  hours 
after  exposure,  the  membrane  was  bleached  with  a  1.21im  diameter  laser  beam  and  the 
recovery  after  photobleaching  (the  mobile  fraction)  and  the  lateral  diffusion  coefficients 
were  calculated  using  MPV-COMBI  software  program.  All  treated  groups  showed  a 
highly  significant  reduction  (P<0.01)  in  the  percentage  recovery  of  fluorescence  after 
photobleaching  compared  to  the  control  group.  The  average  percentage  recoveries  were 
49%  for  the  control  group,  25.5%  for  MZD  200pg  ml-1,29%  for  MZD  20Pg  ml"',  28% 
for  PZQ  200pg  ml"  and  31.5%  for  PZQ  20gg  ml-1.  There  were  no  significant 
differences  among  the  treated  groups  (see  figure  2.6).  The  average  lateral  diffusion 
coefficients  were  6.9  ±  4.1  x  10-8  for  the  control,  3±1.7  x  10-8  for  MZD  200Pg  ml*',  3.3 
±  2.1  x  10-8  for  MZD  20pg  ml",  3.2  ±  3.1  x  10-8  for  PZQ  200jig  ml"  and  3.5  ±  2.1  x  10" 
gcniý  sec-1  for  PZQ  20pg  ml-1.  These  results  indicate  that  MZD  and  PZQ  caused  a 
decrease  in  the  fluidity  of  the  surface  membrane  of  schistosomula  of  S.  mansoni  and 
these  effects  could  interfere  with  the  survival  mechanisms  of  the  parasites. 
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Figure  2.6  Effect  of  Mirazid4o  and  praziquantel  on  the  membrane  fluidity  of  schistosomula  of  S. 
mansoni. 
Four  hours  after  exposure  of  the  AF-  18  labelled  schistosomula  to  MZD  or  PZQ  at 
200pg  ml-1  and  20pg  ml-1,  their  membranes  were  bleached  with  a  laser  beam  and  the 
percentage  recovery  was  assessed.  The  columns  represent  the  percentage  recovery  of 
fluorescence  after  laser  photobleaching  ±  95%  confidence  intervals.  Control 
schistosomula  incubated  with  1%  DMSO  only  (Control),  MZD  200pp  ml-1  (M200), 
MZD  20pg  ml-1  (M20),  PZQ  200pg  ml-1  (PZQ200),  PZQ  20pg  ml-  (PZQ20).  All 
groups  consisted  of  100  schistosomula  and  these  results  represent  the  mean  of  3 
experiments. 
2.3.5  Effects  of  Mirazido  and  praziquantel  on  the  membrane  fluidity  of 
adult  S.  mansoni  male  worms  as  determined  by  FRAP 
The  membranes  of  adult  male  worrns  were  labelled  with  a  fluorescent  lipid  analogue 
AF-18.  Then  they  were  treated  with  MZD  or  PZQ  at  200pg  ml-1  and  20pg  ml-1.  Four 
and  twenty  four  hours  after  exposure,  the  membrane  was  bleached  with  a  1.2gm 
diameter  laser  beam  and  the  percentage  fluorescence  recovery  after  photobleaching  was 
calculated  using  MPV-COMBI  software  program.  Control  worms  were  incubated  in 
medium  supplemented  with  the  1%  DMSO  (drug  solvent). 
74 After  4  hours  of  exposure,  all  drug  exposed  groups  showed  highly  significant  reductions 
in  the  percentage  of  fluorescence  recovery  after  photobleaching  compared  to  the  control 
group  (p<0.01).  The  average  percentage  recovery  was  72%  for  the  control,  33%  for 
MZD  at  200pg  ml",  38%  for  MZD  20pg  ml",  32%  for  PZQ  at  200pg  ml"  and  41%  for 
PZQ  20pg  ml-1.  The  average  lateral  diff-usion  coefficients  were  1.8  ±  8.8  x  10-7  for  the 
control,  6.1  ±  5.9  x  10-8  for  MZD  200pg  ml",  7.3  ±  7.7  x  10-8  for  MZD  20Pg  ml-1,8.4  ± 
7.5  x  10-8  for  PZQ  200[ig  n-d"  and  1.07  ±  8.2  x  10-7  cm2  sec"  for  PZQ  20pg  ml"'  (see 
table  2.2). 
After  24  hours  of  exposure,  all  drug  exposed  groups  showed  highly  significant 
reductions  in  the  percentage  of  fluorescence  recovery  after  photobleaching  compared  to 
the  control  group  (p<0.01).  The  average  percentage  recovery  was  56.5%  for  the  control, 
28%  for  MZD  200jig  ml",  34%  for  MZD  20pg  ml-1,22%  for  PZQ  200pg  ml-1  and 
26.5%  for  PZQ  20pg  ml-1  (see  figure  2.7).  There  were  highly  significant  differences 
between  PZQ  200pg  ml-1  and  MZD  200jig  ml-1  (P<0.01)  and  between  PZQ  20pg  ml-1 
and  MZD  20[tg  ml-1  (P<  0.01).  The  average  lateral  diffusion  coefficients  were  1.74  ± 
8.6  x  10-7  for  the  control,  5.9  ±7x  10-8  for  MZD  200pg  in]",  9.4  ±  7.7  x  10-8  for  MZD 
20pg  ml-1,3.4  ±  2.1  x  10-8  PZQ  200[ig  mI-1  and  7.1  ±  7.2  x  10-8cmý  sed"  for  PZQ  20pg 
ml-1  (see  table  2.2).  These  results  indicate  that  both  MZD  and  PZQ  caused  reductions  in 
the  membrane  fluidity  of  adult  male  S.  mansoni  and  that  after  24h  of  exposure  PZQ  had 
a  greater  effect  than  MZD. 
75 4h  24h 
Control  parasites  1.8  ±  8.8  x 
10-7  CM2  sec-'  1.7  ±  8.6  x 
1()-7  CM2  sec-  1 
MZD  200pg  ml-'  6.1  ±  5.9  x 
10-8  CM2  sec-'  5.9  ±7x  1()-8  CM2  sec-  1 
MZD  20pg  ml-'  7.3  ±  7.7  x 
1()-8  CM2  sec-'  9.4  ±  7.7  x 
10-8  CM2  sec-' 
PZQ  200pg  ml-'  8.4  ±  7.5  x 
10-8  CM2  sec-'  3.4  ±  2.1  x 
10-8  CM2  sec-' 
PZQ  20pg  ml-'  1.1  ±  8.2  x 
10-7 
1 
CM2  sec-'  7.1  ±  7.2  x 
1()-8  CM2 
1 
sec-' 
Table  2.2  Effect  of  Mirazide  and  praziquantel  on  the  lateral  diffusion  co-efficient  of  the  fluorescent 
membrane  of  adult  S.  mansoni  worms. 
Four  and  twenty  four  hours  after  exposure  of  the  AF-  18  labelled  schistosomula  to  MZD 
or  PZQ  at  200pg  ml-1  and  20pg  ml-1,  their  membranes  were  bleached  with  a  laser  beam 
and  the  lateral  diffusion  co-efficient  was  assessed.  This  table  represents  the  mean  lateral 
diffusion  co-efficient  for  each  group  ±  95%  confidence  intervals. 
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Figure  2.7  Effect  of  Mirazide  and  praziquantel  on  the  membrane  fluidity  of  adult  males  of  S. 
mansoni. 
Adult  worms  were  labelled  with  AF-18  and  then  exposed  to  either  MZD  or  PZQ  at 
concentrations  of  200pg  ml-1  and  20pg  ml-1.  After  24h  of  exposure,  the  membrane  of 
the  parasite  was  bleached  with  a  laser  beam  and  the  percentages  recovery  were 
calculated.  The  columns  represent  the  percentage  recovery  of  fluorescence  after  laser 
photobleaching  ±  95%  confidence  intervals.  Control  worms  incubated  with  1%  DMSO 
only  (Control),  MZD  200)lg  ml-  I  (M200),  MZD  20pg  ml-1  (M20),  PZQ  200pg  ml-1 
(PZQ200)  and  PZQ  20pg  ml-1  (PZQ20).  All  groups  consisted  of  50  adult  male  worms 
and  these  results  represent  the  mean  of  3  experiments. 
76 23.6  Scanning  electron  microscopy  (SEM)  of  schistosomula  of  S. 
mansoni  after  exposure  to  Mirazid  0  or  praziquantel 
Schistosomula  of  S.  mansoni  were  incubated  with  MZD  or  PZQ  at  200pg  ml"  and  20pg 
ml".  Control  schistosomula  were  incubated  in  medium  supplemented  with  1%  DMSO. 
After  4  and  8  hours  of  exposure,  schistosomula  were  fixed  and  processed  for  SEM  (see 
section  2.2.6). 
Control  schistosomula  retained  their  normal  structure  and  showed  no  obvious  changes. 
Four  hours  after  exposure,  MZD  at  200pg  ml"  caused  tegumental  damage  and 
protrusion  of  hair-like  extensions  from  the  outer  surfaces  of  schistosomula  in  a  high 
proportion  but  not  all  of  the  parasites.  Eight  hours  after  exposure,  the  damage  was 
severe  with  sloughing  of  the  tegument  of  the  schistosomula  leaving  exposed  areas 
(possibly  basal  membrane  or  muscle)  behind.  With  MZD  at  20pg  ml-1,  the  surfaces  of 
schistosomula  were  similar  to  those  of  controls. 
With  PZQ  at  200pg  ml-1  the  surface  of  schistosomula  showed  evidence  of  blebbing, 
particularly  near  the  oral  sucker,  with  schistosomula  adopting  irregular  contracted 
shapes  after  4  and  8h  of  exposure.  At  20pg  ml-1  of  MZD  or  PZQ,  the  surfaces  of  treated 
schistosomula  were  apparently  unaffected  exhibiting  morphologies  similar  to  those  of 
control  schistosomula  (see  figure  2.8). 
These  results  showed  that  MZD  at  200pg  ml-1  caused  a  substantial  damage  to  the 
surface  of  schistosomula  of  S.  mansoni,  this  damage  increased  with  time  supporting  the 
results  of  the  previous  experiments  that  MZD  is  more  effective  than  PZQ  against  the 
schistosomula  stage  of  S.  mansoni. 
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Figure  2.8  Scanning  electron  microscopy  of  schistosomula  oLV.  mansoni  after  exposure  to  Mirazid" 
or  praziquantel. 
Schistosomula  of  S  mansoni  were  exposed  to  MZD  and  PZQ  at  concentrations  of' 
200pgml-1  and  20ýLg  ml-1.  After  4  and  8  hours  ofcxposure,  schistosomula  were  fixed, 
processed  for  SEM  and  examined  using  an  electron  microscope  (Phillips  SIN  500).  (A) 
Control  schistosomula  incubated  with  1%  DIVISO  for  4h,  (11)  MZD  200[tg  inl-1  4h  after 
exposure,  (C)  PZQ  200pg  ml-1  4h  after  exposure,  (D)  control  schistosomula  incubated 
with  the  drug  solvent  for  8h,  (E)  MZD  200pg  ml-1  8h  aftcr  exposure  and  (F)  PZQ  200fig 
ml-1  8h  after  exposure.  The  scale  bars  measure  10ýtm  fior  (A),  (11),  (C),  (F)  and  (F)  and 
20tim  for  (D). 
78 2.3.7  Scanning  electron  microscopy  (SEM)  of  adult  worms  of  S. 
mansoni  after  exposure  to  Mirazido  or  praziquantel 
Adult  worms  of  S.  mansoni  were  incubated  with  MZD  at  200gg  ml-1  or  20Ag  ml-1  or 
PZQ  at  200,20  and  5pg  ml-1.  Control  worms  were  incubated  in  medium  supplemented 
with  1%  DMSO.  After  4,24  and  72  hours  of  incubation,  adult  worms  were  fixed  and 
processed  for  SEM  (see  section  2.2.6). 
Four  hours  after  exposure  to  MZD  at  200pg  ml-1  male  worms  demonstrated  surface 
blebbing  (small  diameter)  and  a  partial  loss  of  the  spines  from  the  tubercles.  At  this 
concentration,  female  worms  showed  considerable  swelling  of  the  tegument  such  that 
the  spines  appeared  to  be  deeply  embedded  within  it.  Damage  appeared  to  be 
progressive  and  by  24  hours  of  exposure,  MZD  at  200gg  ml-1  caused  loss  of  the  surface 
ridges  between  the  tubercles,  loss  of  some  tubercular  spines  and  more  surface  blebbing 
in  both  adult  male  and  female  worms.  After  72  hours,  MZD  at  200pg  ml"  caused  severe 
damage  to  the  surfaces  of  the  parasites  with  complete  sloughing  of  the  surfaces  across 
much  of  the  length  of  the  adult  worms.  After  4  hours,  MZD  at  20jig  ml-1  had  no  evident 
effects  on  the  surface  of  adult  worms,  however  it  caused  surface  blebbing  of  the  surface 
of  the  gynaecophoric  canals  of  male  worms.  After  24  hours  of  exposure,  MZD  at  20pg 
ml-'  caused  some  loss  of  the  surface  ridges  between  the  tubercles  and  loss  of  some 
tubercular  spines  of  male  worms  and  induced  surface  blebbing  of  female  worms.  At  this 
concentration,  the  damage  was  more  evident  after  72  hours  after  exposure  (see  figure 
2.9-12). 
The  most  striking  effect  of  PZQ  was  surface  blebbing  shown  by  both  male  and  female 
worms.  On  female  worms  blebbing  was  mainly  confined  to  the  anterior  region  of  the 
parasite,  behind  the  ventral  sucker  whereas  the  effect  on  male  worms  was  widespread. 
Blebbing  was  evident  within  4  hours  of  exposure  even  to  PZQ  at  Spg  rnl"  and  increased 
79 progressively  with  time.  After  72  hours,  blebbing  was  evident  across  all  surfaces  of  the 
male  worms  but  there  was  little  evidence  of  any  sloughing. 
Given  concerns  about  the  potential  development  of  drug  resistance  among  parasites 
(and  other  microbial  pathogens),  combination  therapies  are  often  employed  to  reduce 
the  likelihood  of  its  emergence.  This  consideration  led  us  to  examine  the  effect  on 
worms  of  simultaneous  exposure  to  both  PZQ  and  MZD-  Surprisingly,  the  surface 
damage  observed  when  using  both  drugs  was  less  than  that  observed  when  either  drug 
was  used  in  isolation. 
In  conclusion,  both  MZD  and  PZQ  cause  dose  and  time-dependent  damage  to  the 
surfaces  of  adult  wonns  of  S.  mansoni  though  higher  doses  of  MZD  than  PZQ  are 
required  to  cause  damage  to  the  worms. 
80 Figure  2.9  Scanning  electron  microscopy  of  adult  male  worms  of  'V.  mansoni  after  4  hours  of 
exposure  to  Mirazid()  or  praziquantel. 
Adult  male  worms  of  S.  mansoni  were  exposed  to  diff'crent  concentrations  of'  MZD  or 
PZQ.  Four  hours  after  exposure,  worms  were  fixed.  processed  and  Ior  SIN  and 
examined  using  an  electron  microscope  (Phillips  SFM  500).  (A)  Control  adult  male 
incubated  with  1%  DMSO,  (B)  MZD  20jig  mi-1,  (C)  MZD  200pg  ml-'  and  (D)  PZQ 
20pg  m1_1  - 
Scale  bar  I  Opm. 
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Figure  2.10  Scanning  electron  microscopy  of  adult  male  worms  of  V.  mansoni  after  24  hours  of 
exposure  to  Mirazid"or  praziquantel. 
Adult  male  worms  of  ý;.  mansoni  were  exposed  to  different  concentration  of'  MZD  or 
PZQ.  After  24  hours  of  exposure,  worms  were  fixed,  processed  fi  cxamincd  )r  SIN  and 
using  an  electron  microscope  (Phillips  SEM  500).  (A)  Control  adult  male  incubatcd 
with  1%  DMSO,  (13)  MZD  20[tg  ml-1  (C)  MZD  200ltg  ml-1  and  (D)  PZQ  5Vg  ml-'. 
Scale  bar  I  Opm. 
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Figure  2.11  Scanning  electron  microscopy  of  adult  male  worms  of  V.  mansoni  after  72  hours  of 
exposureto  Mirazid"'  or  praziquantel. 
Adult  male  worms  of  S.  mansoni  were  exposed  to  difilerent  concentration  of  MZD  or 
PZQ.  After  72  hours  of  exposure,  worrns  were  fixed,  processed  Ior  SIN  and  examined 
using  an  electron  microscope  (Phillips  SEM  500).  (A)  Control  adult  male  incubated 
with  1%  DMSO,  (B)  MZD  20pg  ml-1,  (C)  MZD  200[ig  ml-1  and  (D)  PZQ  5fig  inl-1. 
Scale  bar  I  Opm. 
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Figure  2.12  Scanning  electron  microscopy  of  adult  female  worms  of  S.  mansoni  after  exposure  to 
Mirazid"'  or  praziquantel. 
Adult  female  worms  were  exposed  to  different  concentrations  ofMZD  or  PZQ.  AI`tcr  4 
and  24  hours  of  exposure,  worms  were  fixed,  processed  lor  SIN  and  examined  using 
an  electron  microscope  (Phillips  SEM  500).  (A)  Control  lernale  exposed  to  I%o  DMSO 
for  4h,  (B)  MZD  200pg  ml-1  4h  after  exposure,  (C)  PZQ  5pg  ml-'  4h  after  exposure  and 
(D)  MZD  20[ig  ml-'  24h  after  exposure.  Scale  bar  I  Opm. 
2.3.8  Transmission  electron  microscopy  of  adult  worms  of  S 
,.  mansoni 
after  exposure  to  Mirazid'.  )  or  praziquantel 
Having  investigated  the  surface  eflIects  ofMZD  and  PZQ  through  S11'.  M,  a  more  dctalled 
investigation  of  damage  was  launched  in  a  series  of'  experiments  designed  to  permit 
examination  of  worm  ultrastructure  using  transmission  electron  microscopy  ('11',  M). 
Adult  worms  ofS.  mansoni  were  incubated  with  dill'erent  concentrations  ofMZI)  and 
" 
.  '- 
- 
84 PZQ  (200ýtg  ml-1  and  20[ig  ml-').  Control  worms  were  incubated  in  medium 
supplemented  with  1%  DMSO.  After  4  and  24h,  adult  worms  were  fixed  and  processed 
for  TEM.  Control  worms  retained  their  normal  structure  and  showed  no  signs  of 
damage  throughout  the  experiment. 
Four  hours  after  exposure  to  MZD  at  200pg  ml",  both  adult  male  and  female  worms 
showed  sub-tegumental  vactiolisation.  The  vacuoles  were  of  variable  sizes  and 
originated  from  beneath  the  basal  lamina  of  the  tegument  and  extended  into  the 
tegumental  cytoplasm.  The  tegumental  cytoplasm  showed  increased  numbers  of  discoid 
bodies.  There  was  no  or  little  evidence  of  damage  to  the  parasites'  musculature  and 
parenchyma.  Parasites  exposed  to  MZD  at  20pg  ml-1  showed  little  damage  and  their 
structure  was  similar  to  that  of  control  parasites  (see  figure  2.13).  Twenty-four  hours 
after  exposure,  worms  exposed  to  MZD  at  200pg  ml-1  showed  an  increase  in  the  number 
of  the  sub-tegumental  vactioles  and  an  increase  in  the  number  of  discoid  bodies  and 
membranous  vesicles  in  the  tegument  cytoplasm.  Worms  exposed  to  WD  at  20Ag  ml', 
showed  a  small  increase  in  the  number  of  discoid  bodies  and  membranous  vesicles  in 
the  tegument  cytoplasm.  There  was  no  or  very  little  evidence  of  damage  to  the 
parasites'  musculature  and  parenchyma  at  either  drug  concentration  (see  figure  2.14). 
On  the  other  hand,  PZQ  caused  sub-tegumental  vacuolisation  and  substantial  damage 
and  loss  of  integrity  of  the  musculature  and  parenchyma  of  both  adult  male  and  female 
worms.  The  effects  were  evident  after  4h  of  exposure  to  both  drug  concentrations  and 
greatest  after  24h  of  exposure  to  PZQ  at  200pg  mi-I.  The  male  worms  showed  more 
extensive  damage  than  the  adult  females  at  all  the  concentrations  used. 
These  observations  showed  that  there  is  an  apparent  overlap  in  the  type  of  damage 
caused  by  the  drugs.  Both  drugs  cause  sub-tegumenW  vacuolisation  of  both  male  and 
female  worms  of  S.  mansoni.  However,  though  the  damage  caused  by  MZD  was  mainly 
as confined  to  the  tegument  of  the  parasites  in  the  form  of  multiple  sub-tegumental 
vacuoles  and  small  increase  in  the  number  of  the  discoid  and  membranous  bodies.  In 
contrast,  the  damage  caused  by  PZQ  affects  the  musculature  and  parenchyma  as  well  as 
the  tegument. 
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Figure  2.13  Transmission  electron  microscopy  of  adult  male  worms  ofV.  man.  %oni  after  4  hours  of 
exposure  to  Mirazid")  or  praziquantel. 
Adult  male  wonns  of  . 
S.  mansoni  were  exposed  to  M/D  or  PZQ  a(  concentrations  of 
200pg  ml-1  and  20pg  ml-1.  Four  hours  after  exposure,  wornis  were  fixed,  processed  l'or 
TEM  and  examined  using  a  TEN  (Zeiss  902).  (A)  Control  male  wornis  exposed  to  I  IVo 
DMSO  only,  (B)  MZD  20[tg  ml-1,  (C)  MZD  200pg  ml-'  and  (D)  P/Q  200pg  nil-'.  Scale 
bars  measure  5[tm  for  (A),  (B)  and  (C)  and  10[tin  for  (D).  '['he  arrows  poln(  to  Sub- 
tegumental  vacuolisation.  The  stars  point  to  muscle  and  parenchymal  damage. 
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Figure  2.14  Transmission  electron  microscopy  of  adult  male  worms  of  S.  maitsoni  after  2411  after 
exposure  to  Mirazid.  )  or  praziquantel. 
Adult  male  worms  of  S.  mansoni  were  exposed  to  M/D  or  PZQ  at  concentrations  of' 
200pg  nil-'  and  20[tg  ml-'.  After  24  hours  of  exposure,  won-ns  were  fixed,  processed  for 
TEM  and  examined  using  a  TEM  (Zeiss  902).  (A)  Control  male  worms  exposed  to  I  'Yo 
DMSO  only,  (B)  MZD  20[tg  nil-',  (C)  MZD  200pg  nil-'  and  (D)  PZQ  200[tg  nil-1.  Scale 
bars  measure  10ýtm  flor  (A),  (C)  and  (D)  and  5fim  for  (11).  The  arrows  point  to  sub- 
tegumental  vacuolisation.  The  stars  point  to  muscle  and  parenchymal  damage. 
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Figure  2.15  Transmission  electron  microscopy  of  adult  female  worms  after  24  hours  of  exposure  to 
Mirazid(')  or  praziquantel. 
Adult  female  worms  of  ý'.  mansoni  were  exposed  to  either  MZD  or  PZQ  at  a 
concentration  of  200pg  ml-1.  After  24  hours  ofcxposurc,  worms  were  fixed,  processed 
for  TEM  and  examined  using  a  TEM  (Zeiss  902).  (A)  Control  Icinalc  worms  exposed  to 
1%  DMSO  only,  (B)  MZD  200pg  ml-1,  (C)  MZD  200pg  ml-'  and  (D)  P/Q  200pg  nil-1. 
Scale  bar  5ýtm-  The  arrows  point  to  sub-tegumental  vacuolisation.  The  stars  point  to 
muscle  and  parenchymal  damage. 
2.3.9  Effect  of  Mirazid"'  and  praziquantel  on  intra-parasite  calcium 
While  the  precise  modes  ol'action  of'  M/D  and  PZQ  havc  yet  to  be  determined,  it  has 
been  suggested  that  the  eflects  of'  PZQ  are  in  part  a  result  of'  changes  in  calcium  flux 
(Cioli  el  al.,  1995).  To  investigate  the  effects  of'  PZQ  and  M/D  on  calcium  balance 
within  the  parasites,  we  exploited  fluo-3  AM  which  is  a  specific  fluorescent  dyc  that 
88 increases  its  fluorescence  when  it  binds  calcium.  Schistosomula  and  adult  worms  of  S. 
mansoni  were  labelled  with  fluo-3  AM  and  then  treated  with  either  MZD  or  PZQ  at  a 
concentration  of  200pg  ml-1.  Control  parasites  were  incubated  with  media  containing 
1%  DMSO.  Thirty  minutes,  1,2  and  4h  after  exposure,  the  amount  of  fluorescence 
(indicating  the  level  of  intracellular  calcium)  was  measured  using  the  fluorescent 
microscope. 
Schistosomula  exposed  to  PZQ  or  MZD  for  30  minutes  showed  no  significant 
difference  in  the  fluorescence  compared  to  the  control  parasites.  One  and  two  hours 
after  exposure,  MZD  caused  highly  significant  increases  in  the  fluorescence  (P<0.01) 
compared  to  the  control  group  while  PZQ  caused  no  significant  effect  (see  figure  2.16). 
Adult  worms  exposed  to  PZQ  for  30  minutes  showed  a  highly  significant  increase  in  the 
fluorescence  in  both  male  and  female  worms  compared  to  both  the  control  and  MZD 
groups  (P<0.01).  MZD  on  the  other  hand  caused  a  non  significant  increase  in  the 
fluorescence  of  male  worms  (P=0.27)  and  a  significant  increase  in  the  fluorescence  of 
female  worms  (P--0.036). 
One,  2  and  4  hours  after  exposure,  both  MZD  and  PZQ  caused  highly  significant 
increases  in  the  fluorescence  in  both  male  and  female  worms  compared  to  the  control 
group  (P<0.01).  However,  the  increases  of  fluorescence  observed  in  worms  treated  with 
pZQ  were  always  highly  significant  compared  to  MZD  in  both  male  and  female  worms 
(P<0.01)  (see  figure  2.17). 
When  adult  worms  were  treated  with  either  MZD  or  PZQ  first,  washed  and  then 
labelled  with  the  fluorescent  dye,  the  results  were  significantly  different.  Adult  worms 
exposed  to  MZD  or  PZQ  for  I  and  4  hours  showed  highly  significant  increases  in  the 
fluorescence  of  both  male  and  female  worms  compared  to  the  control  group  (P<0.01). 
89 However,  in  this  case  worms  exposed  to  MZD  showed  a  highly  significant  increase  in 
the  fluorescence  of  both  male  and  female  worms  compared  to  worms  exposed  to  PZQ 
(P<0.01)  (see  figure  2.18). 
These  results  indicate  that  both  PZQ  and  MZD  cause  an  increase  of  the  intra-parasite 
calcium  levels.  Some  aspects  of  similarities  of  the  effect  of  both  drugs  on  the  tegument 
of  schistosomes  taken  together  with  these  results  might  indicate  that  both  drugs  could 
exhibit  their  effects  at  least  partially  through  changes  in  calcium  fluxes. 
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Figure  2.16  Effect  of  I  hour  of  exposure  to  Mirazidqo  or  praziquantel  on  the  intra-parasite  calcium 
of  schistosomula  of  S.  mansoni. 
Schistosomula  were  labelled  with  fluo-3  AM  and  then  treated  with  either  MZD  or  PZQ 
at  200pg  ml-'  for  lh  before  their  fluorescence  was  quantified  using  a  fluorescent 
microscope.  The  columns  represent  the  quantities  of  fluorescence  ±  95%  confidence 
intervals.  Control  schistosomula  exposed  to  1%  DMSO  only  (Control),  MZD  200pg  ml- 
1  (M  200)  and  PZQ  200pg  ml-1  (PZQ  200).  All  groups  consisted  of  100  schistosomula 
and  these  results  represent  the  mean  of  3  experiments. 
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Figure  2.17  Effect  of  2  hours  of  exposure  to  Mirazid*  or  praziquantel  on  the  intra-parasite  calcium 
of  adult  worms  of  S.  mansoni. 
Adult  male  and  female  worins  were  labelled  with  fluo-3  AM  and  then  treated  with 
either  MZD  or  PZQ  at  200pg  ml-'  for  2h.  The  fluorescence  was  quantified  using  a 
fluorescent  microscope.  The  columns  represent  the  quantities  of  fluorescence  ±  95% 
confidence  intervals.  Control  male  worins  exposed  to  1%  DMSO  (in  Control),  male 
worms  exýosed  to  MZD  at  200pg  ml-1  (m  MZD),  male  worms  exposed  to  PZQ  at 
200pg  ml-  (in  PZQ),  control  female  worms  exposed  to  1%  DMSO  (f  Control),  female 
worms  exposed  to  MZD  at  200pg  ml-1  (f  MZD)  and  female  worms  exposed  to  PZQ  at 
200pg  MI-1  (f  PZQ).  All  groups  consisted  of  30  males  and  30  females  and  these  results 
represent  the  mean  of  4  experiments. 
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Figure  2.18  Effect  of  1  hour  of  exposure  of  adult  worms  of  S.  mansoni  to  Mirazide  or  praziquantel 
prior  to  labelling  with  fluo-3  AM. 
Adult  male  and  female  worms  were  treated  with  either  MZD  or  PZQ  at  200pg  ml-I  for 
lh,  washed  and  labelled  with  fluo-3  AM.  The  fluorescence  was  quantified  by 
fluorescent  microscope.  The  columns  represent  the  quantities  of  fluorescence  ±  95% 
confidence  intervals.  Control  male  worms  exposed  to  1%  DMSO  only  (m  Control), 
male  worms  exposed  to  MZD  at  200pg  ml-1  (m  MZD),  male  worrns  exposed  to  PZQ  at 
200pg  ml-I  (m  PZQ),  control  female  worms  exposed  to  1%  DMSO  only  (f  Control), 
female  worrns  exposed  to  MZD  at  200pg  ml-1  (f  MZD)  and  female  worms  exposed  to 
PZQ  at  200pg  ml-1  (f  PZQ).  All  groups  consisted  of  30  males  and  20  females  and  these 
results  represent  the  mean  of  3  experiments. 
91 2.3.10  Effect  of  calcium  chelation  with  EDTA  on  calcium  labelling  of 
adult  S.  mansom  after  exposure  to  Mirazid  @ 
The  effect  of  calcium  chelation.  with  EDTA  on  calcium  labelling  after  exposure  of  adult 
male  S.  mansoni  to  mirazid  has  been  examined  to  test  the  possibility  that  MZD  can 
cause  an  increase  of  calcium  uptake  by  schistosomes.  One  group  of  adult  worms  was 
incubated  for  15minutes  with  ImM  solution  of  EDTA  prior  to  their  treatment  with 
MZD  at  200pg  ml"  for  I  and  2h.  The  second  group  was  treated  with  MZD  without 
EDTA  and  the  third,  the  control  group,  was  incubated  in  medium  supplemented  with 
1%  DMSO.  Parasites  were  washed  and  labelled  with  fluo-3  AM.  Fluorescence 
quantification  was  carried  out  as  before  (see  section  2.2.8). 
After  I  and  2  hours  of  exposure  to  MZD  at  200pg  ml-1,  adult  worms  showed  a  highly 
significant  increase  of  fluorescence  compared  to  the  control  group  (P<0.01).  Parasites 
incubated  with  EDTA  prior  to  exposure  to  MZD  for  I  and  2  hours,  showed  a  highly 
significant  reduction  in  fluorescence  (P<0.01)  compared  to  parasites  treated  with  MZD 
alone,  however,  they  showed  a  highly  significant  increase  in  fluorescence  compared  to 
the  control  group  (P<0.01)  (see  figure  2.19). 
These  results  indicate  that  MZD  causes  an  increase  of  intra-parasite  calcium  as 
indicated  by  the  increase  of  fluorescence  and  that  EDTA  at  least  partially  interfere  vvith 
MZD-induced  calcium  re-distribution. 
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Figure  2.19  Effect  of  calcium  chelation  with  EDTA  on  calcium  labelling  after  exposure  of  adult 
worms  of  S.  mansoni  to  Mirazid4o 
Worms  were  exposed  to  MZD  at  200pg  ml-1  for  lh  with  or  without  prior  incubation 
with  ImM  solution  of  EDTA.  They  were  washed,  labelled  with  fluo-3  AM  and 
fluorescence  was  quantified  using  fluorescent  microscope.  The  columns  represent  the 
quantities  of  fluorescent  (in  arbitrary  units)  ±  95%  confidence  intervals.  Control  worms 
incubated  with  the  solvent  only  (Control),  adult  worms  exposed  to  MZD  200pg  ml-1 
without  EDTA  (MZD)  and  adult  worms  treated  with  ImM  of  EDTA  prior  to  exposure 
to  MZD  200pg  ml-1  (MZD+EDTA).  All  groups  consisted  of  35  males  and  these  results 
represent  the  mean  of  3  experiments. 
Results  of  the  in  vivo  experiments 
2.3.11  Effect  of  praziquantel  and  Mirazide  on  worm  burden 
Mice  infected  with  S.  mansoni  were  treated  with  either  MZD  or  PZQ  6  weeks  after 
infection.  One  group,  control  infected,  was  left  without  treatment.  Two  weeks  after 
treatment  (8-weeks  after  infection),  mice  were  killed  and  perfused  (see  section  2.2.2)  for 
worm  recovery. 
The  number  of  worms  recovered  from  mice  treated  with  MZD  at  3  doses  each  of  400mg 
kg-1  was  not  significantly  different  from  that  of  the  non-treated  mice  (see  table  2.3).  On 
the  other  hand,  mice  treated  with  PZQ  at  a  single  dose  of  400mgkg-'  showed  a  highly 
significant  reduction  in  the  numbers  of  both  male  and  female  worms  (P<0.01).  The 
93 worms  recovered  from  mice  treated  with  PZQ  were  smaller  in  size  while  those 
recovered  from  MZD  treated  mice  were  not  different  from  controls. 
These  results  showed  that  although  PZQ  was  an  effective  anti-schistosomal  drug  against 
adult  worms  of  S.  mansoni,  MZD  did  not  seem  to  have  significant  effects  in  vivo. 
Group 
Mean  male  worm 
burden 
Mean  female  worm 
burden 
Control  non-teated  group  36  ±  3.1  7.6  ±  0.9 
Mirazide  treated  group  35.8  ±  3.6  5.8  ±  0.3 
Praziquantel  treated  group  16.5  ±  4.8  1.4  ±I 
Table  2-3  Number  ot  worms  recoverea  aiter  periusion  oi  mice. 
Control  mice  and  mice  treated  with  either  MZD  or  PZQ  were  perfused  2  weeks  after 
treatment  and  the  worms  recovered  were  counted.  The  table  presents  the  mean  number 
of  male  and  female  worms  for  each  group  ±  standard  error.  All  groups  consisted  of  10 
mice. 
2.3.12  Effect  of  treatment  of  infected  mice  with  either  Mirazidlo  or 
praziquantel  on  the  egg  burden  in  liver  tissue 
After  perfusion  of  mice  a  piece  of  each  liver  was  weighed  and  digested  with  KOII.  The 
digested  tissue  was  centrifuged  and  the  eggs  were  re-suspended  in  PBS.  Egg  counting 
was  carried  out  using  a  light  microscope. 
The  number  of  eggs  per  gram  of  liver  tissue  of  the  MZD-treated  mice  showed  a  slight 
reduction  (16%  reduction)  and  this  reduction  was  not  significantly  different  from  that  of 
the  control  non-treated  mice  (P=0.39).  In  contrast  the  number  of  eggs  per  gram  of  liver 
tissue  of  the  PZQ-treated  mice  showed  a  highly  significant  decrease  compared  to  that  in 
the  infected  non-treated  mice  (P<0.01)  (see  figure  2.20). 
94 Most  of  the  eggs  in  the  livers  of  PZQ  treated  mice  appeared  to  be  granular  and  dark  in 
colour  while  that  of  both  MZD  treated  mice  or  infected  non-treated  mice  were  bright 
and  showed  normal  morphology. 
These  results  showed  that  PZQ  caused  a  decrease  in  the  number  of  eggs  deposited  per 
gram  of  liver  tissues  of  infected  mice.  This  reduction  can  be  as  a  result  of  anti-fecundity 
effects  of  the  drug  or  secondary  to  the  decrease  in  the  number  of  female  worms  after 
treatment.  On  the  other  hand,  treatment  with  MZD  did  not  cause  any  significant 
reduction  in  the  number  of  eggs  per  gram  of  liver. 
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Figure  2.20  Egg  burden  per  gram  of  liver  tissue  of  mice  infected  with  S.  mansoni  and  treated  with 
either  Mirazid"  or  praziquantel 
After  killing  of  mice,  a  piece  of  each  liver  was  weighed  and  digested  in  KOH.  The  eggs 
were  counted  using  a  dissecting  microscope.  The  columns  represent  the  number  of  eggs 
per  gram  of  liver  tissue  ±  95%  confidence  interval.  Control  non-treated  mice  (Control), 
Mirazido  treated  mice  (MZD)  and  praziquantel  treated  mice  (PZQ).  All  groups 
consisted  of  10  mice. 
2.3.13  Effect  of  treatment  of  infected  mice  with  either  Mirazid"'  or 
praziquantel  on  the  total  tissue  egg  load 
After  killing  the  infected  mice,  a  piece  of  the  liver  and  the  whole  gut  of  each  mouse 
were  digested  with  KOH.  They  were  then  processed  exactly  as  mentioned  previously. 
95 The  number  of  eggs  in  the  whole  liver  was  added  to  the  number  of  eggs  in  the  gut  to 
represent  the  total  tissue  egg  load. 
Mice  treated  with  PZQ  showed  a  highly  significant  decrease  in  the  total  tissue  egg  load 
compared  to  the  infected  non-treated  mice  and  to  MZD-treated  group  (P<0.01).  In 
contrast,  the  total  tissue  egg  load  in  mice  treated  with  MZD  was  not  significantly 
different  from  that  of  the  infected  non-treated  mice  (P=0.6  I)  (see  figure  2.2  1  ). 
These  results  showed  that  while  treatment  of  S.  mansoni  infected  mice  with  PZQ  caused 
a  reduction  in  the  number  of  eggs  deposited  in  the  tissues  of  infected  mice  which  will  be 
reflected  as  a  reduction  of  the  pathology,  treatment  with  MZD  caused  no  significant 
change  in  the  total  tissue  egg  burden. 
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Figure  2.21  Total  tissue  egg  burden  of  mice  infected  with  S.  mansoni  after  treatment  with  either 
Mirazid4o  or  praziquantel. 
After  killing  of  the  mice,  the  gut  and  a  piece  Of  liver  were  digested  in  KOH  and  their 
total  egg  count  was  calculated.  The  columns  represent  the  mean  of  total  number  of  eggs 
in  mice  tissues  ±  95%  confidence  interval.  Control  non-treated  mice  (Control),  Mlrazidlý 
treated  mice  (MZD)  and  praziquantel  treated  mice  (PZQ).  All  groups  consisted  of  10 
mice. 
96 2.3.14  Effect  of  treatment  of  infected  mice  with  either  Mirazido  or 
praziquantel  on  the  diameter,  content  and  structure  of  liver 
granulomas 
Mice  were  killed  2  weeks  after  treatment.  A  piece  of  the  liver  of  each  mouse  were  fixed, 
processed  for  histology  and  stained  with  H&E.  Ile  diameter  of  granulomas  was 
measured  using  a  light  microscope  with  graduated  eye-pieces.  The  mean  of  the 
diameters  of  granulomas  of  each  mouse  were  used  for  the  statistical  analyses. 
There  was  no  significant  difference  in  the  diameter  of  liver  granulomas  of  treated  or 
non-treated  mice.  The  average  diameter  of  liver  granulomas  were  362  ±  23prn  for 
control  non-treated  mice,  381  ±  15pm  for  mice  treated  with  PZQ  and  355.5  ±  28pm  for 
mice  treated  with  MZD.  Granulomas  surrounding  adult  worms  were  observed  in  the 
livers  of  mice  treated  with  PZQ  (see  figure  2.22). 
The  fibrous  tissue  of  the  granulomas  was  arranged  into  three  layers;  an  interlacing 
fibrous  tissue  layer  with  a  cellular  infiltrate,  a  concentric  layer  of  fibrous  tissue  and  an 
outer  layer  of  inflammatory  cells  with  a  less  organised  fibrous  tissue  network.  The 
arrangement  of  collagen  fibres  in  the  liver  granulomas  of  mice  treated  with  MZD  tended 
to  be  less  organised  and  not  fully  arranged  in  concentric  layers  surrounding  the 
granulomas  compared  to  that  in  the  control  and  PZQ-treated  mice.  While  the  number  of 
eosinophils  in  liver  granulomas  of  mice  MZD  treated  mice  (78  ±  9/11PF)  was  slightly 
less  than  the  control  mice  (84  ±I  I/HPF)  or  mice  treated  with  PZQ  (91  ±  14/liPF),  this 
difference  was  not  significant. 
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Figure  2.22  Effect  of  treatment  of  mice  infected  with  S.  mansoni  with  either  Mirazido  or 
praziquantel  on  the  diameter  of  liver  granulomas. 
After  killing  of  mice,  a  piece  of  liver  was  processed  for  histology  and  stained  with 
H&E.  The  diameter  of  the  granulomas  was  measured  using  a  light  microscope.  The 
columns  represent  the  average  of  the  diameter  liver  granulomas  of  each  group  ±  95% 
confidence  intervals.  Infected  non-treated  mice  (Control),  PZQ  treated  group  (PZQ)  and 
MZD  treated  group  (MZD).  All  groups  consisted  of  10  mice. 
98 Figure  2.23  Sections  of  S.  mansoni  egg  granuloma  in  the  livers  of  infected  treated  or  un-treated 
mice  (Haematoxylin  and  Picro  Sirius  red  stain). 
Liver  sections  were  processed  and  stained  Picro  Sirius  red  to  localise  collagen  fibres. 
Egg  granuloma  in  liver  section  from  infected  un-treated  mouse  (A),  egg  granuloma  in 
liver  section  from  PZQ  treated  mouse  (B),  egg  granuloma  in  liver  section  from  MZD 
treated  mouse  (C)  and  worm  granuloma  in  liver  section  from  PZQ  treated  mouse  (D). 
2.3.15  Effect  of  treatment  of  infected  mice  with  either  Mirazide  or 
praziquantel  on  lymphoblastogenesis  and  cytokine  production 
After  killing  of  the  mice,  lymphocytes  from  mesenteric  LNs  and  spleen  from  each 
group  were  stimulated  in  vitro  with  ConA,  SWAP  and  SEA.  Control  cells  were  cultured 
without  stimulation.  After  5  days  of  culturing,  the  supernatants  were  collected  for 
cytokine  assays  for  IL-4,  IL-10,  IL-13  and  IFN-y.  A  blastogenesis  assay  was  carried  out 
using  radioactive  thymidine  and  the  rate  of  cell  multiplication  was  assessed  by 
measuring  the  cellular  radioactivity.  All  cells  were  stimulated  to  multiply  with  ConA 
indicating  their  viability.  Although  lymphocytes  from  LNs  and  spleen  of  Infected 
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CD treated  and  infected  un-treated  mice  were  reactive  to  both  SWAP  and  SEA,  the  level  of 
reactivity  was  less  in  mice  treated  with  either  PZQ  or  MZD. 
Levels  of  IL-4  and  IL-13  were  lower  in  LNs  and  spleen  cells  from  MZD  or  PZQ  treated 
mice  than  infected  un-treated  mice  in  response  to  stimulation  with  SEA  and  SWAP.  The 
difference  was  greatest  in  spleen  cells  stimulated  with  SEA.  V;  Mle  spleen  cells  from 
infected  un-treated  mice  produced  high  levels  of  IFN-y,  levels  of  IFN-y  from  spleen 
cells  of  MZD  or  PZQ  treated  mice  were  below  the  cut  off  level  for  the  assay. 
Furthermore,  LNs  from  MZD  treated  and  un-treated  mice  produced  lower  levels  of  IFN- 
y  in  response  to  stimulation  with  SEA  compared  to  the  levels  produced  after  stimulation 
with  SWAP.  In  both  cases  the  level  of  IFN-y  from  LNs  of  PZQ  treated  mice  were  below 
the  cut  off  level  for  the  assay. 
Levels  of  IL-  10  from  spleen  cells  of  PZQ  treated  mice  were  similar  to  those  of  untreated 
animals  in  responsc  to  stimulation  with  eithcr  SWAP  or  SEA.  Howcvcr,  LNs  from  PZQ 
treated  mice  produced  higher  levels  of  IL-10  than  un-treated  animals  after  stimulation 
with  either  SWAP  or  SEA.  Spleen  cells  and  LNs  from  MZD  treated  mice  produced 
lower  levels  of  IL-10  in  response  to  stimulation  with  either  SWAP  or  SEA  compared  to 
the  un-treated  animals. 
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Table  2.4  Levels  of  different  cytokines  produced  by  spleen  and  LNs  cells  from  infected  mice. 
Cells  from  spleen  and  LNs  were  culture  in  vitro  and  stimulated  with  different  antigens. 
Five  days  after  culture,  levels  of  different  cy-tokines  were  measured  using  ELISA.  The 
levels  were  measured  in  pgml".  Un-infected  mice  (Control),  infected  un-treated  mice 
(infected),  MZD  treated  mice  (MZD),  PZQ  treated  mice  (PZQ). 
100 2.4  Discussion 
Despite  all  efforts  that  have  been  made  to  control  schistosomiasis  this  disease  remains  a 
major  health  problem  in  the  tropics  and  subtropics.  Chemotherapy  is  considered  to  be 
the  keystone  of  any  control  programme  against  schistosomiasis,  with  praziquantel  being 
the  drug  of  choice  because  it  is  effective  against  all  schistosome  species,  it  is  easy  to 
administer,  it  is  safe  with  few  and  transient  side  effects  and  most  importantly  is  now 
cheap  (Hagan  et  al.,  2004).  However,  the  appearance  of  schistosome  strains  with  lower 
susceptibility  to  praziquantel  has  highlighted  the  need  for  other  anti-schistosomal  drugs 
(Kusel  and  Hagan,  1999;  Doenhoff  et  al.,  2002).  Furthermore,  praziquantel  has  modest 
effects  against  the  immature  stages  of  schistosomes  (Andrews,  1981;  Sabah  el  al., 
1986).  In  the  last  few  years,  Mirazido  has  been  licensed  and  released  for  the  treatment 
of  human  schistosomiasis  in  Egypt.  Since  then,  there  has  been  much  debate  about  its 
anti-schistosomal  effects.  In  this  study,  the  anti-schistosomal  activities  of  Mirazie, 
compared  to  those  of  praziquantel,  were  investigated  both  in  vitro  and  in  vivo  against 
early  schistosomula  and  adult  stages  of  S.  mansoni. 
The  effects  of  MZD  and  praziquantel  on  the  viability  of  schistosomula  of  S.  mansoni 
were  assessed  using  the  toluidine  blue  exclusion  test.  This  test  is  appropriate  for 
assessment  of  viability  of  schistosomula  since  results  are  not  different  from  those 
obtained  using  the  morphology  and  mobility  parameters.  It  has  the  advantage  of  being 
quick  and  easy  to  perform  (Gold,  1997).  In  this  study,  the  viability  of  schistosomula 
exposed  to  MZD  at  concentrations  of  200,100  and  50pg  ml-'  was  significantly  reduced 
after  4  and  8  hours  after  exposure.  PZQ  caused  less,  but  significant,  impairment  in  the 
viability  of  schistosomula  at  concentrations  of  200pg  ml"  and  100pg  nil".  Ile  effects 
of  both  drugs  were  time  and  dose  dependent.  However,  the  most  striking  feature  of 
schistosomula  exposed  to  PZQ  was  the  blebbing  around  or within  the  oral  sucker  of  the 
101 parasites  that  was  evident,  under  light  microscope,  within  lh  of  exposure  to  PZQ  at 
concentrations  of  200,100  and  50gg  ml-1.  The  results  of  the  toluidine  blue  exclusion 
test  were  confirmed  with  the  results  of  the  Hoechst  test.  The  number  of  worms  stained 
with  Hoechst  dye,  indicating  damage,  was  significantly  increased  after  exposure  to  the 
high  doses  of  either  MZD  or  PZQ.  Based  on  the  results  of  the  toluidine  blue  exclusion 
test,  two  concentrations  were  used  in  the  rest  of  experiments  on  schistosomula.  The 
200ýtg  ml-1  was  used  as  a  high  and  effective  concentration  and  the  20tig  ml-1  was  used 
as  a  low  concentration  that  did  not  show  any  significant  effects  in  the  toluidine  blue  test 
but  may  have  other  effects  not  detectable  with  this  method.  SEM  revealed  that  in 
schistosomula  exposed  to  MZD  there  was  surface  damage  within  4h  of  in  vitro  exposure 
to  the  high  concentrations  of  the  drug.  The  changes  were  progressive  with  time.  After 
8h  of  exposure,  parts  of  the  surface  of  schistosomula  were  sloughed  leaving  bare  areas. 
PZQ  on  the  other  hand  caused  limited  surface  blebs  and  irregular  contractions  of  the 
parasites  after  4  and  8h  of  exposure.  These  results  are  in  agreement  with  the  results  of 
(Xiao  et  al.,  1985).  They  reported  that  the  immature  stages  were  less  susceptible  to  PZQ 
in  vitro  and  that  in  early  schistosomula  stages  about  2  to  4h  of  exposure  is  required  to 
cause  limited  small  blebs  around  the  oral  sucker  and  on  the  surface  of  the  parasites. 
Similarly,  in  vivo  studies  showed  that  artemether  (Utzinger  et  al.,  2001a)  and  Rol5- 
5458  (Guirguis,  2003)  were  more  effective  against  the  immature  stages  of  schistosomes 
compared  to  PZQ.  However,  Andrews  reported  that  all  stages  of  S.  mansoni  are  equally 
affected  after  in  vitro  exposure  to  PZQ  (Andrews,  1981).  However,  higher 
concentrations  of  PZQ  were  used  in  this  study  than  reported  in  the  previous  studies 
because  the  current  study  was  designed  to  investigate  the  efficacy  of  MZD  and  to 
compare  it  to  that  of  PZQ. 
The  earliest  observed  in  vitro  effect  of  MZD  on  adult  wonns  of  S.  mansoni  was 
enhanced  worm  motility  with  an  increase  in  their  length  and  subsequent  separation  of 
102 worm  pairs.  The  increased  worm  activity  observed  in  this  study  accords  well  with  the 
observations  of  Hassan  and  colleagues.  They  reported  that  MZD  induced  contractions 
of  the  somatic  muscles  of  adult  S.  mansoni  worms  (Hassan  et  al.,  2003).  Increased 
worm  activity  has  been  reported  after  in  vitro  exposure  to  other  drugs,  for  instance, 
hycanthone  (Senft  and  Hillman,  1973),  oxamniquine  (Chavasse  et  al.,  1978)  and  low 
doses  of  PZQ  (Chavasse  et  al.,  1979;  Xiao  et  al.,  1985).  The  increase  in  motility  after 
exposure  to  hycanthone  and  oxamniquine  was  attributed  to  the  blockade  of 
acetylcholine  receptors  caused  by  the  drugs,  With  subsequent  suppression  of  the 
inhibitory  effects  of  acetylcholine  (Hillman  and  Senft,  1975).  A  similar  effect  may  be 
produced  by  MZD.  In  support  of  this  idea  is  the  observation  that  a  higher  concentration 
of  carbachol  (a  cholinergic  compound)  was  needed  to  stop  worm  motility  during  the 
FRAP  experiments  in  the  worms  treated  with  MZD. 
Worm  separation  was  evident  as  early  as  15  minutes  after  exposure  to  the  high  doses  of 
MZD  (200pg  ml-1  and  I  OOpg  ml-1).  'Me  separation  progressed  with  time  to  the  extent 
that  all  worm  pairs  were  separated  after  6h  of  exposure  to  MZD  at  a  concentration  of 
200pg  MI-1.  The  exact  mechanism  of  worm  separation  is  not  known.  A  possible 
explanation  is  that  it  could  be  a  result  of  the  increased  and  irregular  worm  motility. 
However,  separation  of  worm  pairs  continued  to  progress  with  time  even  though  worm 
motility  had  returned  to  normal  after  3-4h  of  exposure.  Another  possible  cause  of  worm 
separation  is  the  preferential  tegumental.  damage  observed  in  scanning  electron 
microscopy.  Surface  blebs  were  observed  only  on  the  surface  of  gynaecophoric  canals 
of  male  worms  after  4h  of  in  vitro  exposure  to  MZD  at  a  concentration  of  20pg  ml*'. 
This  damage  could  interfere  with  the  interaction  between  male  and  female  worms  and 
promote  their  separation.  These  results  accord  with  the  in  vivo  results  observed  by 
Badria  and  colleagues  (2001)  who  reported  that  MZD  induces  separation  of  S  mansoni 
worm  pairs  (Badria  et  al.,  2001). 
103 After  lengthy  in  vitro  exposure  of  adult  worms  of  S.  mansoni  to  MZD  at  high  doses, 
there  was  a  marked  damage  to  the  surface  of  the  parasites  manifested  by  the  loss  of 
tubercular  spines,  loss  of  the  surface  ridges  between  the  tubercles  and  surface  blebbing. 
Both  male  and  female  worms  appeared  to  be  equally  affected.  Ile  damage  became 
extensive  in  the  form  of  sloughing  of  parts  of  the  surface  of  the  parasites  after  3  days  of 
exposure.  These  observations  agree  with  the  observation  of  Hassan  and  colleagues. 
They  showed  that  MZD  causes  tegumental  damage  of  the  parasite  in  the  form  of 
tegumental  disruption,  oedema  and  loss  of  the  spines  covering  the  tubercles  (Hassan  et 
aL,  2003). 
The  earliest  observed  effects  after  in  vitro  exposure  of  adult  worms  to  PZQ  were 
contractions  and  coiling  of  worms  that  became  evident  within  seconds  of  exposure. 
After  30  minutes  of  exposure,  worms  uncoiled  and  remained  shorter  and  thicker  than 
the  controls.  These  results  are  in  agreement  with  the  observations  described  by  (Pax  et 
al.,  1978),  (Xiao  et  al.,  1985)  and  (Pica-Mattoccia  and  Cioli,  2004).  All  PZQ 
concentrations  used  in  this  study  caused  marked  surface  damage  in  the  form  of 
extensive  surface  blebbing.  The  damage  was  widely  spread  in  male  worms  compared  to 
a  localised  patchy  damage  in  female  worms.  These  results  accord  with  previous  findings 
that  adult  S.  mansoni  worms  exposed  to  PZQ  showed  surface  damage  and  vesicle 
formation  which  is  more  extensive  in  male  worms  (Becker  et  al.,  1980;  Mehlhorn  et  al., 
1981;  Staudt  el  al.,  1992).  Similar  surface  damage  was  observed  in  adult  S  mansoni 
worms  recovered  from  mice  treated  with  PZQ.  The  worms  showed  surface  damage  that 
was  more  extensive  in  male  worms  than  that  in  female  worms  (Shaw  and  Erasmus, 
1983;  Shaw  and  Erasmus,  1987;  Shaw,  1990).  However,  Gonnert  and  Andrews  reported 
that  both  male  and  female  worms  of  S.  mansoni  are  equally  susceptible  to  the  effects  of 
pZQ  (Gonnert  and  Andrews,  1977).  Unexpectedly,  in  the  present  study,  after  72h  of 
exposure  of  adult  S.  mansoni  worms  to  both  MZD  (at  a  concentration  of  200pg  ml") 
104 and  PZQ  (at  a  concentration  of  S[Lg  ml-1)  at  the  same  time,  the  damage  was  less  than 
when  the  parasites  were  exposed  to  either  drug  individually.  However,  the  effect  of 
PZQ  prevailed.  This  may  indicate  that  the  drugs  can  interfere  with  each  other  either 
chemically  or  physiologically. 
When  considering  membrane  fluidity  as  an  indirect  indication  of  membrane  functions, 
both  MZD  and  PZQ  caused  significant  reduction  of  the  mobile  fraction  of  the  lipid 
molecules  and  of  the  lateral  diffusion  coefficient  of  both  male  and  female  worms  and 
schistosomula  of  S.  mansoni.  These  results  are  in  agreement  with  the  results  of  Lima 
and  colleagues.  They  have  shown  that  while  both  (PZQ-)  and  (PZQ+)  caused  reduction 
in  the  velocity  of  the  lipid  molecules,  only  (PZQ-)  caused  a  reduction  in  the  mobile  lipid 
fraction.  They  suggested  that  PZQ  inserts  itself  in  the  membrane  and  thus  acts  as  a 
barrier  for  membrane  fluidity  and  this  insertion  change  the  organisation  of  the  tegument 
and  this  may  be  one  of  the  ways  PZQ  exerts  its  action.  'Me  altered  lipid  organisation 
could  lead  to  conformational  changes  in  calcium  pumps  allowing  an  enhanced  entrance 
of  calcium  ions  (Lima  et  al.,  1994).  In  other  biological  systems,  membrane  fluidity  is 
important  in  regulating  enzyme  activity  (Rimon  et  al.,  1978)  as  well  as  the  rate  of 
second  messenger  production  (Atlas  et  aL,  1980).  PZQ  and  MZD,  by  reducing  the 
membrane  fluidity  of  the  parasites,  may  interfere  with  some  mechanisms  important  for 
their  survival. 
After  exposure  to  PZQ  at  concentrations  of  200pg  ml-1  and  20Pg  ml'I,  adult  worms  of  S. 
mansoni  showed  ultra-structural  damage  in  the  form  of  sub-tegumental  vacuolisation 
and  disruption  of  the  musculature  and  parenchyma  of  both  male  and  female  worms.  The 
damage  was  more  evident  in  male  worms  than  in  the  female  worms.  These  results 
corresponded  with  the  previously  reported  ultra-structural  damage  of  adult  S.  mansoni 
worms  exposed  to  PZQ  (Becker  et  aL,  1980;  Mehlbom  et  al.,  1981).  Similar  changes 
were  reported  in  worms  recovered  from  mice  treated  with  PZQ  (Mehihom  et  aL,  1981; 
105 Shaw  and  Erasmus,  1983;  Shaw  and  Erasmus,  1987).  On  the  other  hand,  MZD  at  high 
concentrations  (200[igml-')  caused  sub-tegumental  vacuolisation  of  both  male  and 
female  worms.  Tle  damage  was  evident  after  4h  of  exposure  and  progressed  with  time. 
There  was  no  evidence  of  parenchymal  or muscular  damage  even  after  24h  of  exposure 
of  adult  worms  to  the  high  concentration  of  MZD.  This  provides  evidence  that  while 
PZQ  may  act  directly  on  the  tegument  and  on  the  muscle  and  parenchyma  as  a 
consequence  of  increased  calcium  influx,  MZD  may  act  only  locally  on  the  tegument. 
However,  these  ultrastructural  changes  of  the  tegument  of  schistosomes  are  not  an 
exclusive  feature  of  PZQ  or  MZD  as  they  have  been  reported  with  other  anti- 
schistosomal  agents  including  Astiban  (Otubanio,  1981),  hycanthone  (Hillman  et  al., 
1977),  oxamniquine  (Popiel  and  Erasmus,  1984;  Fallon  et  al.,  1996)  and  artemisinin 
derivatives  (Xiao  et  al.,  2000;  Yjao  et  al.,  2001;  Shuhua  et  al.,  2002). 
Although  the  mode  of  action  of  PZQ  is  not  yet  exactly  determined,  there  is  good 
evidence  that  PZQ,  at  least  in  part,  exerts  its  action  by  increasing  calcium  influx.  The 
increase  in  intra-parasite  calcium  may  in  turn  be  responsible  for  the  increased  muscular 
contraction  and  the  tegumental  damage  (Pax  et  al.,  1978;  Day  el  al.,  1992).  Similarly, 
increased  calcium  uptake  has  been  reported  in  the  liver  fluke  Opisthorchis  viverrini  in 
response  to  praziquantel  treatment  (Ruenwongsa  et  al.,  1983).  In  this  context,  voltage- 
gated  calcium  channels  (formed  of  an  alpha  chain  and  a  beta  chain)  have  been  described 
in  schistosomes.  The  beta  subunits  of  schistosome  voltage-gated  calcium  channels  have 
been  shown  to  confer  PZQ  sensitivity  to  an  otherwise  PZQ-insensitive  mammalian 
calcium  channel,  indicating  that  a  possible  target  for  PZQ  action  is  the  interaction 
between  beta  subunits  and  pore-forming  alpha  I  subunits  in  schistosomes  (Kohn  et  al., 
2001  a;  Kohn  et  aL,  2003). 
106 In  the  present  study,  the  amount  of  intra-parasite  calcium  was  indicated  by  the  quantity 
of  fluorescence  after  labelling  of  calcium  with  fluo-3.  It  has  been  shown  that  the 
intensity  of  fluo-3-related  fluorescence  depends  on  the  Ca2'  concentration  and  that  this 
fluorescence  can  be  used  as  a  cytoplasmic  or  cytosolic  C2+  indicator  (Kao  et  al.,  1989). 
In  S.  mansoni,  it  was  shown  that  compounds  which  increase  intra-parasite  calcium 
concentration  increase  fluo-3/Ca2+  fluorescence  and  compounds  that  chelate  calcium 
decrease  the  fluorescence  (Sato  et  al.,  2004).  In  the  present  study,  both  PZQ  and  MZD 
caused  a  significant  increase  in  the  intra-parasite  calciurn  of  both  adult  male  and  female 
worms  of  S.  mansoni.  The  increase  in  calcium  was  greater  and  was  evident  earlier  with 
exposure  to  PZQ  than  with  exposure  to  MZD.  This  corresponds  with  the  previous  in 
vitro  experiments  indicating  that  PZQ  is  more  effective  than  MZD  against  adult  worms 
of  S.  mansoni.  However  when  adult  worms  were  exposed  to  either  drug,  washed  and 
then  labelled  with  fluo-3,  the  fluorescent  labelling  of  the  intra-parasite  calcium  was 
significantly  higher  in  worms  exposed  to  MZD  than  PZQ.  This  can  be  explained  by  the 
finding  that  the  binding  of  PZQ  to  the  tissues  of  schistosomes  can  be  easily  reversed 
after  incubation  in  drug-free  medium  (Andrews,  1981)  to  the  extent  that  45%  and  93% 
of  the  14  C-PZQ  radioactivity  was  lost  fi-om.  schistosomes  after  5min  and  30min, 
respectively,  after  transfer.  to  a  drug-free  medium  (Andrews  et  aL,  1983).  Similarly,  the 
effects  of  praziquantel  have  been  shown  to  be  reversed,  at  least  in  part,  when  the 
parasites  were  moved  to  a  drug-free  medium  (Andrews,  1981;  Xiao  et  al.,  1985;  Pica- 
Mattoccia  and  Cioli,  2004).  On  the  other  hand,  the  binding  of  MZD  to  schistosome 
tissues  could  be  stronger  and  last  longer  promoting  long  lasting  effects  on  the  parasite 
calcium  distribution. 
Exposure  of  schistosomula  of  S  mansoni  to  MZD  caused  an  increase  in  the  labelling  of 
intra-parasite  calcium.  PZQ,  on  the  other  hand,  caused  no  significant  change  in  the 
labelling  of  intra-parasite  calciwn.  This  indicates  that  the  effect  of  MZD  on  both  adult 
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distribution  in  the  parasite  while  with  PZQ  different  mechanisms  could  be  responsible 
for  its  actions.  In  support  of  the  idea  that  MZD  may  act  by  increasing  intra-parasite 
calcium,  when  adult  worms  were  incubated  with  ImM  EDTA  and  5mM  EDTA  for 
20min  before  exposure  to  MZD,  there  was  a  significant  reduction  of  intra-parasite 
calcium  compared  to  the  worms  exposed  to  MZD  without  prior  exposure  to  EDTA 
(P<0.01). 
When  S.  mansoni-infected  mice  were  treated,  6  weeks  after  infection,  with  MZD  (at  a 
dose  of  400mg  kg-1),  there  was  no  significant  difference  in  the  number  of  worms 
recovered  after  perfusion  compared  to  the  infected  un-treated  mice.  The  recovered 
worms  were  mostly  paired  and  did  not  show  any  gross  morphological  changes.  There 
was  no  significant  difference  in  the  number  of  eggs  per  grain  of  liver  tissue  or  in  the 
total  number  of  eggs  deposited  in  the  tissues  of  infected  mice  compared  to  the  infected 
un-treated  animals.  At  the  dose  used  in  the  present  study,  MZD  was  safe  and  there  were 
no  deaths  or  signs  of  toxicity  in  the  treated  mice.  These  results  provide  no  evidence  that 
MZD  had  in  vivo  anti-schistosomal  effects  against  adult  worms  of  S.  mansoni. 
These  results  agree  with  the  results  of  Botros  and  colleagues.  They  tried  several  doses 
of  MZD  and  myrrh  (180  to  10000mg  kg")  against  different  strains  of  S.  mansoni 
(Egyptian,  Puerto  Rican  and  Brazilian)  in  different  hosts  (mice  and  hamsters).  The 
greatest  observed  reductions  in  the  number  of  worms  recovered  were  observed  in  mice 
infected  with  the  Puerto  Rican  strain  (36%  reduction),  mice  infected  with  the  Egyptian 
strain  and  treated  with  myrrh  (26%  reduction)  and  mice  infected  with  the  Egyptian 
strain  and  treated  with  MZD  (19%  reduction).  There  was  no  reduction  in  the  number  of 
recovered  worms  in  hamsters  infected  with  the  Puerto  Rican  strain  or  in  mice  infected 
with  the  Brazilian  strain  and  treated  with  myrrh.  There  was  no  significant  reduction  in 
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treatment  with  either  MZD  or  myrrh  (Botros  et  al.,  2004). 
However,  the  results  of  the  present  study  are  in  contrast  with  those  of  Badria  and 
colleagues.  They  reported  a  76%  reduction  of  the  number  of  worms  recovered  from 
mice  infected  with  the  Egyptian  strain  of  &  mansoni  after  treatment  with  either  myrrh  or 
MZD.  They  also  reported  an  increase  in  the  percentage  of  mature  stages  of  eggs 
deposited  in  the  tissues  of  infected  mice  compared  to  immature  stages  as  a  result  of 
cessation  of  new  egg  production  (Badria  et  al.,  2001).  One  possible  explanation  for  this 
distinction  is  the  difference  in  the  schistosome  strain  or  the  strain  of  mice  used  in  both 
experiments.  While  Badria  and  colleagues  used  the  Egyptian  stain  of  S.  mansoni  to 
infect  male  albino  mice,  in  the  present  study,  the  Puerto  Rican  strain  was  employed  to 
infect  female  TO  mice.  However,  Botros  and  colleagues  reported  a  little  effect  on  any 
of  the  strains  of  S.  mansoni  they  used. 
One  other  possibility  is  the  composition  of  MZD.  MZD  is  an  extract  of  myrrh  that  can 
be  obtained  from  different  species  of  the  plant  Commiphora.  It  has  been  shown  that 
myrrh  is  a  very  complex  mixture  of  compounds  and  that  myrrh  derived  from  one 
species  of  Commiphora  is  different  from  that  obtained  from  another  species  (El  Ashry 
et  aL,  2003).  Myrrh  from  C  molmol  contains  23-40%  resin  (myrrhin),  2-8%  volatile 
oils  (myrrhol)  and  40-60%  bitter  principle  (Al-Awadi  et  al.,  1991).  The  complex 
composition  of  myrrh  may  be  difficult  to  ensure  consistency  of  contents  from  batch  to 
batch.  However,  the  batch  of  MZD  used  in  this  study  was  different  from  that  used  by 
Botros  and  colleagues  who,  themselves,  used  several  batches  of  MZD  in  their 
multicentre  studies  but  they  all  confirmed  the  inefficacy  of  MZD  against  S.  mansoni. 
Another  possible  explanation  for  difference  between  the  results  of  the  present  study  and 
those  reported  by  Badria  and  colleagues  is  the  methodology  for  counting  adult  worms. 
Whereas  in  the  studies  reported  herein  and  those  of  Botros  and  colleagues  used  the 
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the  other  hand,  used  a  different  method  for  counting  the  worms  in  portal  and  mesenteric 
veins.  They  used  a  3x  lens  to  count  worms  in  situ  (Botros  et  al.,  2004),  and  this  is  likely 
to  be  less  accurate. 
PZQ  on  the  other  hand,  at  a  single  dose  of  400mg  kg-1,  caused  a  significant  reduction  in 
the  number  of  recovered  worms.  The  recovered  worms  were  smaller  in  size  compared 
to  worms  recovered  from  other  groups.  There  was  a  significant  reduction  in  the  number 
of  eggs  deposited  in  the  liver  and  guts  of  infected  and  treated  animals.  These  results  are 
in  agreement  with  the  well  documented  effects  of  PZQ  accumulated  through  enormous 
number  of  studies  carried  out  on  different  schistosome  species  and  using  different 
experimental  animals  (Pellegrino  et  al.,  1977;  Tanaka  et  aL,  1989;  Ghandour  et  aL, 
1990;  Khalil  et  al.,  1995;  Botros  et  al.,  2004). 
The  apparent  discrepancy  between  the  in  vitro  and  in  vivo  results  of  the  present  study 
may  be  attributed  to  the  pharmacokinetics  of  MZD.  The  pharmacokinetics  of  the  drug  is 
not  known.  It  is  possible  that  MZD  is  not  readily  absorbed  from  the  gut  of  mice,  it  is 
rapidly  metabolised  into  inactive  compounds,  or  it  is  rapidly  cleared  from  the 
circulation  after  being  absorbed.  In  either  case,  the  active  compound  of  MZD  will  not 
be  available  in  the  circulation  and  will  not  have  access  to  the  parasite  or  it  will  be 
available  only  for  a  short  duration.  Another  explanation  is  that  the  mode  of  action  of 
MZD  is  through  direct  contact  with  the  parasite  and  a  prolonged  contact  with  high  doses 
of  MZD  is  required  which  can  be  easily  obtained  and  controlled  in  vitro.  However,  it 
might  be  very  difficult  to  reach  the  same  dose  for  prolonged  duration  to  obtain  the  same 
results  that  were  obtained  in  vitro  as  it  was  shown  that  increasing  the  dose  of  MZD  was 
lethal  to  mice  (Botros  et  aL,  2004). 
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a  dose  of  300mg  kg-1  for  two  doses  to  mice  infected  with  S  manson!  it  caused  a  non 
significant  reduction  in  the  number  of  recoverd  worms,  a  significant  decrease  in  the  egg 
burden  per  gram  of  liver  tissue  (P<0.043)  and  a  non  significant  reduction  in  the 
diameters  of  liver  granulomas  and  in  the  number  of  eosinophils  in  the  granulomas  (data 
not  shown).  However,  this  sort  of  prolonged  slow  release  of  the  drug  which  promoted 
prolonged  contact  with  the  liver  of  mice  and  with  the  parasites  caused  liver  changes 
which  were  manifested  as  gross  swelling,  dark  colouration  and  roundness  of  the  edges 
of  the  liver.  On  the  microscopic  level  there  was  increased  deposition  of  collagen  fibres 
causing  thickness  of  the  liver  capsule. 
Furthermore,  SEM  and  TEM  revealed  that  while  PZQ  affects  the  surface  as  well  as  the 
musculature  and  parenchyma  of  the  schistosome  parasites,  MZD  only  affects  the 
tegument,  without  any  obvious  deeper  effects.  This  pattern  of  lesions  caused  by  in  vitro 
exposure  to  MZD  may  support  the  idea  that  MZD  acts  locally  through  direct  contact 
with  the  tegument  of  the  parasite.  In  this  context,  it  was  reported  that  some  detergents 
such  as  Triton  X-  100  caused  disruption  of  the  tegument  of  S  mansoni  that  never  extend 
deeper  to  the  basement  membrane.  There  was  a  disturbed  distribution  of  some  ions 
including  calcium  which  was  accumulated  into  the  parasite  tissues  to  levels  double 
those  of  control  parasites  (Depenbusch  et  aL,  1983).  ne  later  effects  on  calcium 
distribution  are  similar  to  those  reported  in  parasites  after  in  vitro  exposure  to  MZD  in 
the  current  study.  The  last  possible  explanation  of  this  discrepancy  is  that  in  the  in  vivo 
study  the  effect  of  MZD  was  assessed  against  the  adult  stage,  and  not  the  immature 
stages,  of  S.  mansoni.  It  was  shown  from  the  in  vitro  study  that  adult  worms  are  less 
affected  by  MZD  than  the  immature  larval  stage.  In  this  context,  other  drugs  particularly 
artemcther  was  shown  to  have  significant  effects  against  immature  developing 
III schistosome  but  modest  effects  against  adult  worms  both  in  vivo  and  in  vitro  (Yiao  and 
Catto,  1989;  Lescano  et  al.,  2004). 
One  of  the  most  striking  reported  advantages  of  treatment  of  human  schistosomiasis 
with  MZD  is  the  improvement  of  symptoms  shortly  after  treatment  (Sheir  et  aL,  2001; 
Abo-Madyan  et  al.,  2004).  The  main  pathological  features  of  schistosome  infections  are 
attributed  to  development  of  inflammatory  granulomas  around  the  deposited  eggs  in 
different  tissues  of  the  hosts  and  the  resulting  fibroses  (Boros,  1989;  Auriault  et  aL, 
1996;  Fallon,  2000).  The  possibility  that  MZD  can  act  by  modulating  the 
immunopathology  of  schistosomiasis  and  hence  improving  the  symptoms  of  the  disease 
was  also  investigated  in  this  study.  The  mean  diameter  of  liver  granulomas  and  the 
structure  of  granulomas  were  investigated  as  parameters  of  the  immunopathology. 
There  was  no  significant  difference  in  the  diameter  of  liver  granulomas  of  infected  mice 
of  different  groups.  The  mean  size  of  granulomas  in  the  liver  of  mice  treated  with  PZQ 
was  slightly  higher  than  that  in  the  non-treated  and  in  the  MZD-treated  mice.  Similar 
observations  were  reported  by  Mehlhom  and  colleagues.  They  reported  that  the  mean 
diameters  of  liver  granulomas  of  mice  infected  with  S  manson!  and  treated  with  PZQ 
were  350pm  one  hour  after  treatment,  increased  to  380prn  2  weeks  after  treatment  and 
decreased  to  140gm  12  weeks  after  treatment.  In  infected  non-treated  mice  the  mean 
diameter  ranged  between  350-36OpLm  during  the  same  period  (Mehlhorn  el  al.,  1982). 
The  reason  for  the  slight  increase  in  the  diameter  of  liver  granulomas  of  mice  treated 
with  PZQ  may  be  explained  by  the  possibility  that  most  of  the  granulomas  found  in  this 
group  of  mice  were  fully  developed  (mature)  with'scanty  early  developing  (immature) 
granulomas  as  the  drug  caused  decreased  formation  and  deposition  of  new  eggs.  In  the 
mice  of  the  other  groups,  there  were  mature  and  immature  granulomas  resulting  from 
the  continued  deposition  of  new  eggs  in  the  livers. 
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from  mice  of  different  groups.  However,  the  fibrous  tissues  of  some  granulomas  of  the 
livers  from  mice  treated  with  MZD  tended  to  be  less  than  that  found  in  the  PZQ-treated 
and  in  the  un-treated  mice  and  the  arrangement  of  collagen  fibres  tended  to  be  less 
organised.  In  these  mice,  the  decrease  of  granuloma  diameter,  cosinophils  and  collagen 
fibres  was  associated  with  decreased  levels  of  IL-4,  IL-13,  and  IL-10  in  supernatants 
from  spleen  cells  and  LNs  in  response  to  stimulation  with  either  SEA  or  SWAP.  These 
results  indicate  that  MZD  may  have  a  suppressor  effects  on  the  immune  responses  to 
schistosome  antigens  especially  the  Th2  associated  immune  responses.  Similar  anti- 
inflammatory  effects  were  reported  for  myrrh  (Kimura  et  aL,  2001).  It  is  not  clear  in 
this  study  whether  this  change  in  the  fibrous  tissue  in  the  liver  granulomas  is  beneficial 
or  harmful  for  the  infected  and  treated  animals.  It  has  been  shown  that  the  formation  of 
granulomas  around  the  eggs  helps  to  segregate  them  and  thus  protect  the  liver  cells  from 
exposure  to  their  toxins  (Doenhoff  et  al.,  1986).  On  the  other  hand,  over-development 
of  the  granulomas  and  fibrosis  leads  to  the  main  pathological  consequences  of  the 
disease  (Strickland  and  Ramirez,  2000).  However,  it  is  worth  mentioning  that  in  a 
previous  experiment,  infected  mice  treated  with  intraperitoneal  MZD  showed  a  similar 
pattern  of  granuloma  structure  and  there  was  a  high  mortality  rate  in  this  group  of  mice 
(4  out  of  7  mice  were  dead). 
The  exact  mechanism  of  granuloma  formation  and  fibrosis  is  not  fully  elucidated. 
Several  cytokines  have  been  shown  to  play  a  role  in  this  immunopathological  process. 
For  instance,  IL-4  has  been  shown  to  increase  granuloma  formation  (Yamashita  and 
Boros,  1992;  Jankovic  et  al.,  1999a)  and  to  increase  the  survival  of  infected  hosts  by 
preventing  Thl  skewed  immune  responses  (Brunet  et  al.,  1997;  Fallon  et  al.,  2000a;  La 
Flamme  et  al.,  2001;  Patton  et  al.,  2001).  IL-13  has  been  shown  to  increase  granuloma 
formation  and  more  importantly  to  be  the  main  cytokine  involved  in  fibrogenic 
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al.,  2004;  Kaviratne  et  al.,  2004).  On  the  other  hand,  IL-10  has  been  shown  to  play  an 
important  role  in  the  modulation  of  granulomas,  reducing  fibrosis  and  prevention  of 
over  expression  of  either  Th  I  or  Th2  immune  responses  (Flores-Villanueva  et  al.,  1996; 
Boros  and  Whitfield,  1998;  Zouain  et  al.,  2000;  Sadler  et  al.,  2003;  Hesse  et  al.,  2004; 
Booth  et  al.,  2004).  Although  IFN-y  may  play  a  role  in  the  early  development  of 
granulomas  (Pearce  et  al.,  199  1;  Lukacs  and  Boros,  1992),  it  has  been  shown  that  IFN-y 
plays  a  role  in  the  reduction  of  granuloma  size  and  fibrosis  (Henri  et  al.,  2002;  Booth  et 
al.,  2004). 
In  PZQ  treated  mice,  there  was  a  decreased  production  of  IL4,  IL-13  and  IFN-y  from 
spleen  cells  and  LNs  in  response  to  stimulation  with  either  SWAP  or  SEA.  The  greatest 
reduction  was  that  of  IFN-y.  The  levels  of  IL-10  in  the  supernatant  from  lymphocytes 
from  mesenteric  lymph  nodes  tend  to  be  higher  in  PZQ-treated  mice  in  response  to 
stimulation  with  SEA  and  SWAP.  When  the  levels  of  IL-10  produced  by  LNs  after 
stimulation  with  SEA  or  SWAP  were  compared  to  the  levels  obtained  in  the  absence  of 
stimulation,  there  showed  12  and  7  fold  increase,  respectively.  On  the  other  hand,  LNs 
from  mice  treated  with  MZD  showed  4  and  1.5  fold  increase  and  LNs  from  untreated 
mice  showed  2.5  and  1.5  fold  increase  after  stimulation  with  SEA  or  SWAP 
respectively.  Furthermore,  LNs  from  mice  treated  with  PZQ  produced  II  and  6  fold 
increase  of  IL-13  levels  after  stimulation  with  either  SEA  or  SWAP  compared  to  the 
levels  produced  in  the  absence  of  stimulation.  LNs  from  mice  treated  with  MZD  or 
untreated  mice  showed  only  1.5-2  fold  increase  in  the  level  of  IL-13  after  stimulation 
with  either  SEA  or  SWAP.  These  results  may  indicate  that  PZQ  treatment  favours  the 
stimulation  of  Th2  associated  immune  responses  and  this  response  is  balanced  by  virtue 
of  increased  IL-10  levels.  This  pattern  may  explain  the  slight  increase  in  the  diameter 
and  eosinophils  of  liver  granulomas  in  mice  treated  with  PZQ. 
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with  PZQ  were  reported  in  the  literature.  In  human  schistosomiasis  mansoni,  the  mean 
levels  of  tegument-specific  IL-5  and  IL-  10  increased  about  10-  15  fold,  and  mean  levels 
of  IL-13  increased  about  5  fold.  Levels  of  SEA,  SWA,  and  tegument-induced 
interferon-  gamma,  were  not  significantly  changed  by  treatment,  and,  with  the  exception 
of  IL-10,  which  increased  slightly,  responses  to  SEA  also  remained  largely  unchanged 
(Joseph  et  al.,  2004).  On  the  other  hand,  Fitzsimmons  and  colleagues  investigated  the 
early  changes  in  immune  reactions  after  praziquantel  therapy  in  S.  mansoni  infected 
individuals.  One  day  after  PZQ  treatment,  a  marked  transient  increase  in  plasma  IL-5 
levels  was  observed  in  75%  of  the  subjects.  Blood  cultures  from  the  16  subjects  with  the 
greatest  increase  in  plasma  IL-5  level  displayed  reduced  IL-5,  IL-13,  and  IL-10 
responses  to  SWAP.  They  reported  that  there  was  a  heterogeneity  in  early  immune 
reactions  to  treatment,  identifying  subgroups  who  have  different  patterns  of  reaction  and 
who  may  have  different  capacities  to  mount  different  immune  responses  (Fitzsimmons 
et  al.,  2004).  In  human  schistosomiasis  haematobium,  repeated  treatment  of  infected 
school  children  led  to  high  specific  levels  of  interleukin  (IL)-5  and  low  interferon-y 
production  but  did  not  protect  against  reinfection  (van  den  Biggelaar  et  aL,  2002). 
In  conclusion  the  work  presented  in  this  chapter  has  demonstrated  that 
1.  Both  MZD  and  PZQ  showed  in  vitro  anti-schistosome  activities  against  S. 
mansoni. 
2.  MZD  was  more  effective  against  schistosomula  than  PZQ  in  vitro  but  its 
efficacy  was  less  against  adult  worms. 
3.  Lengthy  exposures  to  high  concentrations  were  necessary  for  the  effects  of 
MZD  to  be  evident. 
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exposure,  the  extent  of  the  damage  was  distinct  for  each  drug. 
5.  Both  MZD  and  PZQ  caused  an  increase  in  the  intra-parasite  calcium  levels. 
6.  MZD  had  no  anti-schistosome  activity  in  infected  mice.  On  the  other  hand  PZQ 
caused  a  significant  reduction  in  wonn  burden  and  liver  and  gut  egg  loads. 
7.  There  were  no  significant  differences  in  the  diameter  or  the  structure  of  liver 
granulomas  in  treated  mice  compared  to  untreated  mice. 
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Effects  of  in  vitro  exposure  to  Mirazido  and 
praziquantel  on  the  soluble  proteome  of  adult 
Schistosoma  mansoni 3.1  Introduction 
3.1.1  Two-dimensional  gel  electrophoresis  and  mass  spectrometry 
The  term  'proteome'  describes  the  total  protein  complement  expressed  by  a  genome 
(Wilkins  et  al.,  1996).  The  separation  and  characterisation  of  the  protein  content  of 
complex  mixtures  has  been  made  possible  with  the  invention  of  the  two-dimensional  gel 
electrophoresis  (O'Farrell,  1975).  As  is  clear  from  the  name,  the  two-dimensional  gel 
electrophoresis  (2-D  electrophoresis)  comprises  two  dimensions  that  separate  proteins 
according  to  two  different  properties. 
In  the  first  dimension,  isoelectric  focusing  (IEF),  proteins  are  separated  according  to 
their  isoelectric  points  (pI)  which  is  determined  by  the  relative  contents  of  acidic 
(negatively  charged)  and  basic  (positively  charged)  residues  of  each  protein.  The 
isoelectric  point  (pl)  is  the  specific  pH  at  which  the  net  charge  of  the  protein  is  zero 
(Berg  et  aL,  2002b).  The  presence  of  a  pH  gradient  is  critical  to  the  IEF  technique.  In  a 
pH  gradient,  under  the  influence  of  an  electric  field,  a  protein  will  move  to  the  position 
in  the  gradient  where  its  net  charge  is  zero.  For  instance,  a  protein  with  a  positive  net 
charge  will  migrate  toward  the  cathode,  becoming  progressively  less  positively  charged 
as  it  moves  through  the  pH  gradient  until  it  reaches  its  pl.  On  the  other  hand,  a  protein 
with  a  negative  net  charge  will  migrate  toward  the  anode,  becoming  less  negatively 
charged  until  it  also  reaches  zero  net  charge.  If  a  protein  should  diffuse  away  from  its 
pl,  it  immediately  gains  charge  and  migrates  back.  This  is  the  'focusing'  effect  of  IEF, 
which  concentrates  proteins  at  their  pIs  and  allows  proteins  to  be  separated  on  the  basis 
of  very  small  charge  differences  (Berkelman  and  Stenstedt,  1998).  The  introduction  of 
the  immobilised  pH  gradient  for  isoelectric  focusing  has  made  the  2-D  electrophoresis 
separations  highly  reproducible  and  has  allowed  greater  amounts  of  protein  to  be  loaded 
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to  sodium  dodecyl  sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  as  a  second 
dimension. 
In  the  second  dimension,  proteins  are  separated  largely  on  the  basis  of  their  molecular 
masses.  The  mixture  of  proteins  is  first  dissolved  in  a  solution  of  sodium  dodecyl  sulfate 
(SDS),  an  anionic  detergent  that  disrupts  nearly  all  noncovalent  interactions  in  native 
proteins.  Anions  of  SDS  more  importantly  bind  to  peptide  chains  at  a  fixed  ratio  of  one 
SDS  anion  for  every  two  amino  acid  residues.  The  complex  mixture  of  SDS  and  the 
denatured  protein  has  a  large  net  negative  charge  that  masks  the  initial  charge  of  the 
protein.  When  such  a  mixture  is  subjected  to  electrophoresis,  small  proteins  move 
rapidly  through  the  gel  whereas  large  proteins  stay  near  the  point  of  application  of  the 
mixture.  The  mobility  of  most  polypeptide  chains  under  these  conditions  is  linearly 
proportional  to  the  logarithm  of  their  mass  (Berg  et  aL,  2002b).  As  an  initial  step  for 
protein  identification  and  comparison,  they  are  stained  with  a  specific  dye.  In  theory, 
the  analysis  of  up  to  15000  proteins  should  be  possible  in  one  gel,  however,  in  practice 
5000  detected  protein  spots  indicates  a  very  good  separation  (Berkelman  and  Stenstedt, 
1998). 
Several  methods  have  been  used  for  protein  identification.  Ile  methods  of  choice  are 
now  based  on  mass  spectrometry  (MS).  They  are  applicable  to  all  proteins,  combining 
the  advantages  of  greater  sensitivity  and  high  throughput  without  the  expensive  running 
costs  of  the  earlier  technologies.  MS  is  a  means  of  accurately  determining  molecular 
mass.  The  molecules  are  ionized  in  the  gas  phase,  accelerated  by  an  electric  field  in  a 
vacuum  and  enter  a  mass  analyser,  which  allows  the  measurement  of  their  mass  to 
charge  ratio  (Ashton  et  aL,  2001).  After  gel  mapping,  spots  are  excised  and  subjected  to 
proteolytic  digestion  e.  g.  by  trypsin  that  cuts  peptide  bonds  C-terminal  to  lysine  or 
arginine  residues  to  create  a  diagnostic  peptide  mixture  (Wilson  et  al.,  2004). 
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made  MS  of  no  value  for  the  investigation  of  these  molecules.  This  difficulty  has  been 
circumvented  by  the  introduction  of  techniques  for  effectively  dispersing  proteins  and 
other  macromolecules  into  the  gas  phase.  These  methods  are  called  matrix-assisted  laser 
desorption  ionisation  (MALDI)  and  electrospray  spectrometry.  With  the  MALDI 
technique,  the  protein  sample  embedded  in  an  appropriate  matrix  is  ionised  by  the 
application  of  a  laser  beam.  The  ions  generated  are  then  accelerated,  using  an  electrical 
field,  through  the  flight  tube  toward  the  detector  with  the  smallest  molecules  traveling 
fastest  and  arriving  first.  Thus  the  time  of  flight  (ToF)  in  the  electric  field  is  a  measure 
of  mass/charge  ratio  (Berg  et  al.,  2002b).  For  protein  spots  that  have  been  excised  from 
2-D  gels,  the  usual  approach  is  to  generate  a  peptide  mass  fingerprint  (PMF).  In  theory, 
this  should  be  diagnostic  of  a  particular  protein  and  searching  a  database  of  full-length 
protein  sequences  for  the  organism  under  investigation  will  lead  to  identification  if  the 
sequence  for  that  protein  is  present  in  the  database  (Wilson  et  al.,  2004). 
In  the  electrospray  mass  spectrometry  (ESMS),  liquid  containing  the  analyte  is  pumped 
at  low  microliter-per-minute  flow  rates  through  a  hypodermic  needle  at  high  voltage,  to 
electrostatically  disperse,  or  electrospray,  small,  micrometer-sized  droplets,  that  rapidly 
evaporate  and  which  impart  their  charge  onto  the  analyte  molecules.  The  molecules  are 
transferred  into  the  mass  spectrometer  with  high  efficiency  for  analysis.  A  wide  range 
of  compounds  can  be  analyzed  by  ESMS;  the  only  requirement  is  that  the  molecule  be 
sufficiently  polar  to  allow  attachment  of  a  charge.  This  includes  proteins, 
oligonucleotides,  sugars,  and  polar  lipids.  For  a  given  compound,  the  signal  strcngth 
(peak  height  in  the  spectrum)  increases  linearly  with  the  analyte  concentration  over  a 
wide  range  until  saturation  occurs  (Mann  et  aL,  2001). 
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The  characterisation  of  parasite  proteomes  is  a  major  task  in  biological  research.  The 
powerful  combination  of  two-dimensional  electrophorcsis  and  mass  spectrometry  can 
identify  selected  parasite  proteins  rapidly  and  cheaply,  providing  a  direct  route  to  the 
cDNA  and  hence  recombinant  protein,  and  requiring  as  little  as  500finol  of  the  original 
protein  (Ashton  et  al.,  2001).  However,  such  a  combination  has  been  available,  for 
schistosomes,  only  in  the  last  few  years  partly  because  of  the  recent  advances  in  the 
sequencing  of  the  schistosorne  genorne.  For  instance,  before  1994,  there  were  only  220 
sequences  in  the  database  for  all  schistosome  species.  With  the  use  of  the  expressed 
sequence  tag  (EST)  strategy  for  schistosomes  now  there  are  over  139064  public  S. 
mansoni  ESTs,  representing  92%  of  the  S.  mansoni  gene  complement  (EI-sayed  et  al., 
2004). 
Using  the  combination  of  two-dimensional  electrophoresis  and  peptide  mass 
fingerprinting  Curwen  and  colleagues  (2004)  compared  the  proteome  profiles  of  the 
soluble  antigen  preparations  from  different  stages  in  the  life  cycle  of  S  mansoni, 
namely,  cercariae  (SCAP),  lung-stage  schistosomula  (SLAP),  adult  worms  (SWAP)  and 
eggs  (SEA).  The  pattern  of  protein  spots  from  preparations  of  different  stages  showed 
great  similarity  especially  between  adjacent  life-cycle  stages  reflecting  in  part  the  slow 
transition  that  occurs  in  schistosome  'stages'  within  the  mammalian  host.  The  MALDI- 
ToF  mass  spectrometric  analyses  of  the  top  40  spots  from  each  gel  revealed  thirty-two 
individual  protein  species,  70%  of  which  were  identified  in  all  the  life  cycle  stages. 
However,  there  were  some  proteins  that  were  unique  for  each  stage.  Amongst  the 
twenty-four  proteins  identified  by  blotting  the  gels  with  sera  from  hosts  with  patent 
infections  or  hosts  vaccinated  with  radiation  attenuated  cercariae  or  parasite  extracts, 
several  of  the  WHO  priority  vaccine  candidates,  including  glutathione-S-tmnsferases, 
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cycle  stages  (Wilson  et  al.,  2004;  Curwen  et  al.,  2004). 
As  an  extension  of  the  study  of  the  effects  of  MZD  and  PZQ  on  S.  mansoni,  the  effect 
of  MZD  and  PZQ  on  the  soluble  proteome  of  adult  wonns  of  S.  mansoni  was  studied. 
3.2  Materials  and  methods 
3.2.1  Reagents  and  Equipment 
Unless  otherwise  stated,  all  the  reagents  and  equipment  used  were  purchased  from 
Amershain  Biosciences  UK  limited,  Buckinghamshire,  UK. 
3.2.2  Exposure  of  adult  S.  mansoni  to  MZD  or  PZQ 
Adult  worms  were  recovered  from  mice  infected  with  the  Puerto  Rican  strain  of  S. 
mansoni.  Adult  worms  (10  worm  pairs/ml-1  of  complete  RPMI-1640)  were  exposed  for 
24h  to  either  PZQ  or  MZD  at  a  concentration  of  200pg  ml-1.  Control  worms  were 
exposed  to  1%  DMSO  (the  drug  solvent).  The  worms  of  each  group  were  then  pooled 
and  washed  three  times  with  40mM  Tris  solution. 
3.2.3  Sample  preparation 
Washed  worms  were  homogenised  using  a  glass  tissue  homogeniser  immersed  in  ice. 
The  whole  worm  homogenate  was  transferred  into  a  universal  tube  and  sonicated  on  ice 
using  a  Soniprep  150  sonicator  for  4  cycles  of  I  minute  each  with  aI  minute  interval 
between  pulses  to  prevent  over  heating  of  the  antigens.  The  supernatant  was  centrifuged 
for  20  minutes  at  700OOg  at  4'C.  The  supernatant  was  collected  in  a  universal  tube  to 
which  a  protease  inhibitor  was  added.  The  protein  was  then  concentrated  with  acetone 
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volume  of  the  sample  and  incubated  at  -20"C  for  2h.  The  protein  was  pelleted  by 
centrifugation  for  20  minutes  at  700OOg  at  4'C.  The  supernatant  acetone  was  gently 
removed  and  the  remaining  acetone  was  air-dried.  Ile  pellet  was  resuspended  in  DIGE 
lysis  buffer  and  stored  at  -700C. 
3.2.4  Preparation  fo  r  the  2-D  fluorescence  difference  gel 
electrophoresis  (2-D  DIGE) 
Determination  of  the  protein  content  of  the  samples 
The  protein  assay  was  carried  out  using  the  2-D  Quant  Kit.  Aliquots  of  different 
quantities  (0,10,20,30,40  and  50pg)  of  bovine  serum  albumin  (BSA)  standard 
solution  were  prepared.  Two  microlitres  of  each  sample  were  placed  in  an  ependorff 
tube  (run  in  duplicate).  A  500pl  of  the  precipitant  reagent  was  added  to  each  tube 
(including  the  standard  curve  tubes).  They  were  mixed  briefly  by  vortexing  and 
incubated  for  2-3  min  at  room  temperature.  A  500pl  co-precipitant  reagent  was  added 
to  each  tube  and  mixed  briefly  by  vortexing.  The  tubes  were  centrifuged  at  I  00OOg  for 
5  min.  The  supernatant  was  decanted  gently  and  the  process  of  precipitation  and 
centrifugation  was  repeated.  The  tubes  were  immediately  removed  from  the  centrifuge 
and  the  supernatants  were  carefully  decanted.  AI  OOPI  of  copper  solution  and  400pI  of 
distilled  de-ionized  water  were  added  to  each  tube.  Tile  precipitated  protein  was 
dissolved  by  brief  vortexing.  A  Iml  volume  of  working  color  reagent  (100  parts  of 
colour  reagent  A  to  I  part  of  colour  reagent  B)  was  added  to  each  tube  and  mixed 
thoroughly.  The  tubes  were  incubated  at  room  temperature  for  15-20min.  The 
absorbance  of  each  sample  and  standard  was  read  using  a  spectrophotomcter  at  a 
wavelength  of  480nm  using  water  as  the  reference.  A  standard  curve  was  generated  by 
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standard  curve  the  protein  concentration  of  the  samples  was  determined. 
Fluorescent  labeling  of  the  samples  with  the  CyDye 
With  the  use  of  the  different  CyDye  TM  fluoros  dyes,  it  is  possible  to  compare  between 
more  than  one  protein  sample  in  the  same  gel.  The  protein  concentration  of  the  samples 
was  adjusted  to  a  5mg  ml-1  concentration.  Aliquots  of  50ýtg  proteins  in  101A  DIGE  lysis 
buffer  were  prepared.  The  pH  was  adjusted  to  between  pl-18  and  pH9.  On  ice,  40pmol  of 
either  CyDye  3  or  CyDye  5  was  added  to  each  aliquot  and  mixed  immediately.  The 
aliquots  were  then  incubated  on  ice  for  30min  in  the  dark.  The  reaction  was  stopped  by 
addition  of  I[tl  of  lOmM  lysine  and  incubation  for  10min  on  ice  in  the  dark.  The 
labelled  samples  were  stored  at  -70'C. 
3.2.5  Isoelectric  focusing  of  the  labelled  samples 
Control  samples  (stained  blue  with  CYDye5)  were  compared  with  either  sample  from 
MZD-treated  or  PZQ-treated  wonns.  A  150pg  of  unlabelled.  proteins  was  added  to  each 
of  the  50ýtg  labelled  proteins  aliquot  and  mixed  well.  For  comparison,  200ýtg  of  the 
sample  from  MZD-treated  or  PZQ-treated  worms  (stained  red)  was  mixed  with  200pg 
of  the  control  sample  (stained  blue)  resulting  in  a  loading  amount  of  400pg  for  each 
immobilised  pH  gradient  (IPG)  strip.  This  amount  of  proteins  was  loaded  in  450111  of 
sample  rehydration  buffer  (see  appendix).  The  rehydration  buffer  with  the  proteins  was 
placed  in  the  Ettan  IPGphor  strip  holder  to  which  a  24cm-IPG  strip,  with  a  p1l  gradient 
pH3-10,  was  gently  positioned,  covered  with  few  drops  of  oily  solution,  to  prevent 
evaporation  of  samples,  and  then  covered  with  the  strip  holder  cover.  The  isoclectric 
focusing  was  carried  out  using  an  Ettan  IPGphor  isoelectric  focusing  system.  The 
isoelectric  focusing  conditions  were  as  follows:  phase  I  as  a  rehydration  phase  and  was 
124 run  under  low  voltage  of  30V  for  10h,  phase  2  at  300V  for  lh,  phase  3  at  600V  for  lh, 
phase  4  at  IOOOV  for  lh,  phase  5  as  a  gradient  phase  was  run  at  8000V  for  3h  and 
30min  and  phase  6  at  8000V  for  8h. 
3.2.6  Equilibration  of  the  sample 
After  completion  of  the  isoýlectric  focusing,  the  IPG  strips  were  carefully  removed  and 
equilibrated  over  two  steps  using  two  different  equilibration  buffers.  The  equilibration 
step  saturates  the  IPG  strip  with  the  SDS  buffer  system  required  for  the  second- 
dimension  separation.  The  equilibration  solution  contains  buffer,  urea,  glycerol, 
reductant,  SDS,  and  dye.  Each  strip  was  placed  in  the  tube  containing  the  first 
equilibration  buffer.  The  tubes  were  shaken  for  15min.  'Me  IPG  strips  were  then  moved 
into  other  tubes  containing  the  second  equilibration  buffer  and  shaken  for  15min.  The 
IPG  strips  were  then  subjected  to  the  SDS-PAGE. 
3.2.7  SDS-PAGE 
After  separation  of  the  protein  mixture  of  the  samples  on  the  basis  of  their  pis  using. 
isoelectric  focusing,  the  proteins  were  then  separated  according  to  their  mass/charge 
using  the  SDS-PAGE.  Twenty-four  centimetre  PAGE  gels  with  12.5%  acrylamide  were 
prepared  (see  appendix).  The  IPG  strip  was  dipped  in  SDS  electrophoresis  buffer  and 
then  carefully  placed  onto  the  top  of  the  PAGE,  avoiding  air  bubbles  between  the  IPG 
strip  and  the  gel.  The  IPG  strip  was  sealed  in  place  with  agarose  sealing  solution  (see 
appendix).  The  gel  cassettes  were  placed  in  the  Ettan  DALT  separation  unit  containing 
SDS  electrophoresis  buffer  (see  appendix).  More  buffer  was  added  until  the  fill  line  was 
reached.  The  clectrophoresis  was  carried  out  at  a  current  of  SW/gel  for  30min  followed 
by  17W/gel  for  4h  and  3  Omin. 
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Each  gel  was  scanned  at  100pm  resolution  on  a  TyphoonTm  9400  Variable  Mode 
Imager  using  580BP30  (Cy3)  and  670BP30  (Cy5)  emission  filters.  The  gels  were 
stained  with  SYPROTM  orange  (Bio-Rad)  (1/10000  solution  in  7.5%  acetic  acid)  to 
ensure  uniform  staining  of  protein  spots.  The  gels  were  destained  in  7.5%  acetic  acid 
and  scanned  using  a  555BP20  filter.  Images  were  analyzed  using  DeCyder  differential 
analysis  software,  v5.0  in  both  the  differential  in  gel  analysis  (DIA)  and  the  biological 
variation  analysis  (BVA)  modules.  Individual  images  were  created  for  the  different  Cy3 
and  Cy5  labeled  gels  and  matched  together  using  DeCyder  software.  Automatic 
detection  was  followed  by  minimal  manual,  and  therefore  subjective,  intervention,  but 
in  some  regions  on  each  gel  spots  were  split  and/or  redrawn.  Parameters  for  minimum 
spot  volume  and  contrast  were  adjusted  and  the  so  called  'spiky  spots'  were  also 
removed.  Two  preparative  gels  were  added  to  the  experimental  study  and  parallel  pick 
lists  that  included  all  spots  of  interest  (i.  e.  those  differcntially  regulated  following 
treatment  with  the  candidate  drug)  were  created.  The  pick  list  was  matched  to  the 
SYPRO  gel  images  and  the  spot  map  was  exported  for  subsequent  spot  handling  prior  to 
mass  spectrometry. 
3.2.9  Automated  spot  handling 
Selected  proteins  were  subjected  to  fully  automated  spot  handling  in  Ettan  Spot 
Handling  Workstation.  A  method  that  included  spot  picking,  digestion,  and  spotting  on 
Ettan  MALDI  target  slides  was  selected  in  the  software,  and  the  whole  procedure  was 
run  automatically  overnight  without  any  manual  intervention  either  within  or  between 
steps.  In  this  automated  procedure,  gel  plugs  were  cut  by  a  2-mm  picking  head  and 
washed  twice  in  50%  methanol  and  50mM  ammonium  bicarbonate  and  once  in  75% 
acetonitrile  before  drying.  For  digestion,  10111  trypsin  solution  (0.2pg  Trypsin, 
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performed  in  two  steps  by  addition  of  50%  acetonitrile  and  0.1%  trifluoroacetic  acid. 
The  pooled  extract  was  finally  dried  prior  to  the  two-step  spotting  procedure,  where  the 
matrix  solution  of  5mg/ml  solution  of  recrystallized  a-cyano4-hydroxycinnarnic  acid  in 
extraction  liquid  was  deposited  on  the  target.  In  the  final  step  before  MALDI-ToF,  a 
tenth  of  the  dissolved  sample  was  mixed  with  the  matrix  layer  on  the  target,  leaving  the 
rest  for  the  electrospray. 
3.2.10  Identification  of  proteins 
Mass  spectrometry  peaks  were  obtained  from  an  Ettan  MALDI-ToF  biospectrometry 
workstation  followed  by  protein  identification  by  peptide-mass  fingerprinting  (PMF) 
(Voyager  DETm  Pro,  Applied  Biosystems,  Framingham,  MA,  USA).  Ile  MALDI  target, 
obtained  from  spot  handling  workstation,  was  loaded  into  the  mass spectrometer. 
Spectra  were  acquired  in  reflector  mode  using  the  Voyager  5.1  software;  all  instrument 
settings  were  optimized  for  sensitivity.  Raw  spectrum  files  were  opened  in  data  explorer 
software  (Applied  Biosytems)  and  calibrated  on  two  internal  peaks  resulting  from 
autolysis  of  trypsin  (mlz  =  842.510  and  2211.104).  Peak  lists  were  then  prepared  from 
each  spectnun  following  application  of  the  process  for  PMF  macro  (modified  from  an 
original  macro  by  Melanie  Lin,  Applied  Biosystems).  '17his  corrects  the  baseline, 
removes  noise  (S.  D.  =  0.7),  de-isotopes  the  peak  list  so  that  only  the  monoisotopic 
peaks  remain  and  outputs  a  list  of  the  remaining  peaks  as  a  text  file,  which  represents 
the  peptide  mass  fingerprint  (PMF)  for  the  original  spot.  The  National  Centre  for 
Biotechnology  Information  non-redundant  protein  (NCBlnr)  database,  was  searched 
with  each  PMF  using  Mascot  Daemon  (Matrixscience,  London,  UK)  with  the  peptidc 
mass  tolerance  set  to  ±  50ppm. 
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mass  spectrometry  (ESTMS)  was  used.  The  tryptic  peptides,  resulting  from  the  spot 
handling  workstation,  were  solubilized  in  0.5  %  formic  acid  and  fractionated  by 
nanoflow  high  performance  liquid  chromatography  (HPLQ  on  a  C18  reverse  phase 
column,  eluting  with  a  continuous  linear  gradient  to  40%  acetonitrile  over  20  minutes. 
Eluate  was  analysed  by  online  electrospray  tandem  mass  spectrometry  using  a  Qstar 
Pulsar  (Applied  Biosystems).  A3  second  survey  scan  preceded  each  MS/MS  data 
collection  cycle  of  4x3  second  product  ion  scans,  giving  a  total  duty  cycle  of  15 
seconds.  Data  was  submitted  to  an  MS/MS  ions  search  via  the  Mascot  search  engine 
(Matrix  Science),  searching  both  locay  established  databases  for  S  manson!  DNA 
sequence  and  the  current  non-redundant  NCBI  database. 
3.3  Results 
3.3.1  2-D  electrophoresis  gel 
As  a  preliminary  step,  different  samples  were  run  at  pH3-7  gradient  in  the  isoelectric 
focusing  and  the  immobilised  strip  was  subjected  to  a  4-12%  gradient  mini  gel.  The 
majority  of  spots  were  similar  in  control  parasites  and  the  drug  treated  parasites.  Few 
spots  showed  different  intensities  between  different  samples.  The  experiment  was 
expanded  by  using  a  wider  pH  range  in  the  isoelectric  focusing  and  the  immobilised 
strip  was  subjected  to  electrophoresis  using  12.5%  24cm  gels.  After  2-D  clectrophoresis 
and  image  analysis,  DeCyder  software  matched  about  3000  spots  in  each  gel.  After 
exclusion  of  the  spiky  spots  the  number  of  spots  were  reduced  to  about  2700.  The 
intensity  of  protein  spots  tended  to  be  less  in  drug  treated  samples  especially  with  MZD. 
This  presumably  is  due  to  lower  protein  contents  of  samples  from  MZD  treated  worms. 
However,  there  were  eight  spots  in  MZD  treated  samples  showing  more  than  a  2-fold 
128 difference  in  their  expression  compared  to  control  worms.  Nine  spots  were  differentially 
expressed  in  PZQ  treated  worrns  by  at  least  a  2-fold  difference  compared  to  the  control 
parasites.  The  different  spots  were  picked  and  processed  for  protein  identification. 
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Figure  3.1  2-D  electrophoresis  gel  of  MZD-treated  samples  compared  to  control  samples.. 
2-D  PAGE  of  MZD-treated  worms  (B)  stained  with  CyDye  3  and  control  parasItes  (A) 
stained  with  Cydye  5.  Only  spots  that  were  at  least  2-fold  up-regulated  (T)  or  down- 
regulated  (1)  are  marked. 
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Figure  3.2  2-D  electrophoresis  gel  of  PZQ-treated  samples  compared  to  control  samples. 
2-D  PAGE  of  PZQ-treated  wonns  (B)  stained  with  CyDye  3  and  control  parasites  (A) 
stained  with  Cydye  5.  Only  spots  that  were  at  least  2-fold  up-regulated  (T)  or  down- 
regulated  (1)  are  marked. 
130 3.3.2  Protein  identification  using  MALDI-ToF 
The  PMF  of  each  picked  protein  spot,  obtained  from  MALDI  ToF  was  searched  in  the 
database.  However,  out  of  the  17  picked  spots,  only  three  proteins  were  identified.  In 
some  cases,  the  same  protein  was  identified  in  two  or  more  adjacent  protein  spots. 
Although  some  protein  spots  were  up  to  13-fold  more  expressed  in  drug  treated  worms, 
protein  identification  of  these  spots  using  either  MALDI-ToF  or  ESTMS  failed  to  reveal 
any  significant  matches.  In  MZD-exposed  worms,  paramyosin  (theoretical  M,  I  OOkDa, 
pI  5.3  1)  was  4-fold  more  expressed  and  actin  (theoretical  M,  42kDa,  pl  5.46)  was  Mold 
less  expressed  compared  to  control  parasites.  In  PZQ-exposed  worms,  fructose  1,6 
bisphosphate  aldolase  (theoretical  M,  40kDa,  pI  7.63)  was  2-fold  more  expressed 
compared  to  control  parasites. 
3.4  Discussion 
Although  PZQ  has  been  the  drug  of  choice  for  treatment  of  schistosome  infection  for 
about  thirty  years,  its  mode  of  action  is  still  not  fully  understood.  With  the  major 
advances  of  the  2-D  electrophoresis  and  mass  spectrometry  techniques,  it  is  now 
possible  to  separate  a  mixture  of  proteins  in  a  sample  with  very  high  resolution  and  by 
accessing  protein  databases  to  identify  the  proteins  of  interest  (Berg  et  aL,  2002b).  This 
powerful  combination  of  techniques  was  used  in  the  present  study  to  investigate  the 
effects  of  in  vitro  exposure  of  adult  S.  mansoni  worms  to  either  PZQ  or  MZD.  Another 
powerful  technique,  DIGE  was  used  for  the  comparison  between  samples  from  worms 
exposed  to  either  drugs  with  samples  from  control  worms  in  one  gel  as  a  reference 
(Berkelman  and  Stenstedt,  1998). 
Protein  separation  using  the  2-D  PAGE  revealed  more  than  3000  protein  spots  in  both 
drug-treated  and  control  parasites.  The  protein  spots  tended  to  be  less  intense  in  drug 
131 treated  parasites  especially  MZD-treated  parasites.  This  is  perhaps  attributed  to  the 
amount  of  protein  loaded  in  the  samples.  In  order  to  avoid  this  possibility,  only  proteins 
that  showed  more  than  2  fold  differences  were  picked.  Of  the  17  spots,  only  3  proteins 
were  matched  using  the  PMF  obtained  from  MALDI  ToF.  Protein  identification  was 
retried  using  ESTMS  but  no  additional  proteins  were  identified.  'I'his  may  be  explained 
by  the  possibility  that  these  spots  might  have  small  amounts  of  proteins.  It  is  estimated 
that  about  500finol  of  the  original  protein  is  essential  to  allow  protein  identification 
(Ashton  et  al.,  2001).  The  decreased  number  of  identified  proteins  may  be  attributed  to 
the  incomplete  status  of  the  genome  of  S.  mansoni.  Against  this,  Curwen  and  colleagues 
compared  the  soluble  proteomes  of  different  life  cycle  stages  of  S  mansoni  and  they 
were  able  to  identify  many  proteins  (Curwen  et  aL,  2004).  However,  in  their  study  they 
set  the  peptide  mass  tolerance  to  ±2  dalton  while  in  the  present  study  it  was  set  to  ±  50 
parts  per  million  which,  as  expected,  limits  the  range  of  proteins  likely  to  be  identified 
by  the  search  tools.  Though  it  would  increase  the  degree  of  confidence  that  the  matches 
are  significant. 
In  the  sample  from  worms  exposed  to  MZD,  two  closely  related  spots  were  4-fold  more 
expressed  compared  to  samples  from  control  worms.  The  database  search  for  the  PMF 
from  these  spots  revealed  homology  with  S.  mansoni  paramyosin. 
Paramyosin  is  a  myofibrillar  protein  and  is  usually  organised  into  the  core  structure  of 
the  thick  filaments  of  the  invertebrate  muscle  where  it  interacts  with  myosin  molecules. 
The  immunolocalisation  studies  of  paramyosin  were  controversial.  Although  it  was 
often  localized  in  the  muscle  of  the  parasite,  it  was  also  localized  in  the  tegument  of 
adults  and  schistosomula  and  in  the  post-acetabular  glands  of  the  ccrcariae  (Kojima, 
2004).  However,  paramyosin  may  be  multifunctional,  playing  a  role  not  only  as 
structural  components  but  also  serving  several  functions  in  the  host-parasite  interaction 
including  interference  with  the  complement  cascade,  impairing  augmentation  of  the  host 
132 inflammatory  response  and  binding  of  host  immunoglobulins,  thus  making  the  parasite 
insusceptible  to  the  immune  system  (Kalinna  and  McManus,  1997). 
In  this  context,  a  surface  protein  of  94kDa  designated  schistosome  complement 
inhibitory  protein-I  (SCIP-1)  exhibits  antigenic  and  functional  similarities  with  the 
human  complement  inhibitor  protein  CD59.  Soluble  SCIP-1,  partially  purified  from 
schistosome  tegument  extracts  using  anti-CD59  antiscra,  was  shown  to  bind  to  purified 
human  C8  and  C9  and  inhibit  lysis  of  sheep  and  rabbit  RBCs  by  human  complement 
(Parizade  et  al.,  1994).  Subsequent  sequence  analysis  of  the  purified  SCIP-1  revealed  it 
to  be  paramyosin.  Furthermore,  native  and  recombinant  paramyosin  was  shown  to  bind 
to  human  C8  and  C9  and  to  inhibit  C9  polymerization  on  RBCs  (Deng  et  aL,  2003). 
Like  CD59,  SCIP-1  (paramyosin)  is  viewed  as  'mopping-up'  any  activated  complement 
at  the  terminus  of  the  pathway  that  may  have  escaped  the  multiple  earlier  inhibitors 
(Skelly,  2004). 
If  the  increased  expression  of  paramyosin  observed  in  the  present  study  occurs  in  vivo, 
in  response  to  drug  treatment,  one  would  speculate  that  this  could  be  a  compensatory 
mechanism  of  the  parasites  in  an  effort  to  avoid  both  innate  and  acquired  immune 
responses  that  exploit  the  complement  system.  Such  immune  responses  might  potentiate 
the  damage  caused  by  the  drug. 
Whatever  the  mechanism  of  increased  expression  of  paramyosin  in  adult  worms  in 
response  to  in  vitro  exposure  to  MZD,  this  observation  might  support  the  hypothesis 
that  some  anti-schistosome  drugs  might  have  a  temporary  immunising  cffect  promoting 
the  stimulation  of  protective  immune  responses. 
Paramyosin  is  a  well-recognized  vaccine  candidate  and  is  one  of  the  vaccine  candidate 
recommended  by  the  WHO.  Pararnyosin,  both  the  native  and  the  recombinant  molecules 
133 from  S.  mansoni,  administered  intradermally  with  BCG  at  total  doses  of  440lig  per 
mouse  were  found  to  confer  significant  resistance  (26-33%)  against  challenge  infection. 
In  addition,  paramyosin  was  shown  to  stimulate  T  lymphocytes  from  vaccinated  mice  to 
produce  lymphokines  especially  IFN-y  that  activate  macrophages  to  kill  schistosomula 
(Pearce  et  aL,  1988).  In  mice,  subcutaneous  immunization  with  S.  japonicum 
paramyosin  with  BCG  or  alum  produced  20-60%  worm  reduction  in  challenge  infection 
(Kojima,  2004). 
Interestingly,  the  reported  preferential  Thi  immune  responses  stimulation  by 
immunization  with  paramyosin  may  fit  with  the  observed  preferential  reduction  of  Tb2- 
related  cytokine  production  by  LNs  and  spleen  cells  from  mice  treated  with  MZD 
(shown  in  chapter  2).  This  reduction  in  Th2  responses  may  be  a  consequence  of  the 
related  boosting  of  the  Thl  immune  responses  by  the  increased  expression  of 
paramyosin. 
Another  protein  spot  was  expressed  3-fold  less  in  samples  from  worms  exposed  to  MZD 
compared  to  control  worms.  Identification  of  this  spot  revealed  a  protein  that  showed 
sequence  homology  to  actin. 
Actins  constitute  a  highly  conserved  family  of  proteins  found  in  all  eukaryotes.  These 
proteins  are  found  predominantly  in  the  cytoplasm  of  cells  where  monomers  polymcrisc 
to  form  microfilamcnts.  Microfilaments  of  actin  participate  in  various  cell  functions 
such  as  muscle  contraction,  cell  cytoskelcton  and  motility  (Shcterlinc  and  Sparrow, 
1994).  In  S.  mansoni,  indirect  immunofluorescence  studies  localized  actin 
predominantly  in  surface  spines  and  tubercles  of  adult  schistosomes  (Abbas  and  Cain, 
1987).  Furthermore,  using  immunoelectron  microscopy,  the  surface  spines  were  shown 
to  be  composed  of  paracrystalline  arrays  of  actin  filaments.  Actin  was  also  present  in 
134 areas  recovering  ftom  damage,  implying  an  important  role  for  this  structural  protein  in 
tegumental  repair  (Matsumoto  et  al.,  1988). 
The  mechanism  of  decreased  expression  of  actin  in  worms  exposed  to  MZD  in  the 
present  study  is  unknown.  However,  after  treatment  of  S  mansoni  with  the  anti- 
schistosome  drug  Ro  15-5458,  the  total  RNA  content  of  parasites  recovered  from  mice 
12,72  and  96h  after  dosing  was  reduced  by  14,30  and  41%,  respectively.  Quantitative 
filter  hybridization  of  blots  of  RNA  extracted  from  treated  and  control  parasites  with 
specific  probes  indicated  a  decline  in  actin  and  superoxide  dismutase  mRNA  as  well  as 
rRNA  of  treated  parasites.  The  decline  was  observed  12h  after  dosing,  48h  before 
parasites  showed  drug-induced  changes  in  other  vital  biological  processes  (Eshete  and 
Bennett,  199  1).  A  similar  mechanism  may  be  involved  after  exposure  to  MZD. 
In  samples  from  worms  exposed  to  PZQ,  there  was  one  protein  spot  that  was  2-fold 
more  highly  expressed  that  control  worms.  Protein  identification  revealed  a  sequence 
homology  with  fructose  1,6  bisphosphate  aldolase.  Fructose  1,6  bisphosphate  a1dolasc  is 
a  key  enzyme  in  the  glycolytic  pathways  and  in  energy  metabolism.  It  catalyses  the 
reversible  aldol  cleavage  of  the  fructose  1,6  bisphosphatc  into  two  trioscs, 
dihydroxyacetone  phosphate  and  glycemldehydc-3-phosphatc  (Berg  el  al.,  2002a). 
Schistosomes  have  a  high  rate  of  metabolism  and  energy  consumption  necessary  for 
several  vital  functions  including  egg  laying,  muscular  activity  and  transport  of  nutrients 
through  the  tegument.  Although  schistosomes  live  intravascularly  with  an  unlimited 
supply  of  oxygen,  most  of  their  metabolic  pathways  including  glycolysis  arc  essentially 
anaerobic  (Coles,  1984).  Immunocytochernical  studies  localized  fructose  1,6 
bisphosphate  aldolase  in  all  tissues  of  adult  schistosomes.  In  malc  worms  it  was  mostly 
localised  in  the  tubercles  and  in  the  subtegumental  region  (El  Dabaa  et  aL,  1998). 
135 The  increased  expression  of  fructose  1,6  bisphosphate  aldolase  in  worms  exposed  to 
PZQ  might  indicate  an  increase  in  glycolysis  and  increased  energy  production.  This 
could  be  attributed  to  the  increased  energy  demands  for  repair  mechanisms.  However, 
this  increased  protein  expression  might  result  in  priming  of  the  immune  response  and 
thus  favour  the  hypothesis  of  an  immunising  role  for  PZQ. 
In  conclusion,  the  present  study  indicated  that  in  vitro  exposure  to  either  PZQ  or  MZD 
caused  changes  in  the  expression  of  some  proteins  in  schistosomes.  However,  the 
results  of  the  present  study  are  preliminary  and  further  studies  are  recommended, 
especially  now  that  the  genome  sequence  of  S.  manson!  is  nearing  completion.  When 
the  genome  has  been  completed,  it  will  facilitate  the  identification  of  more  proteins 
using  mass  spectrometry.  In  any  case  it  is  possible  to  investigate  the  differential 
expression  on  the  genomic  level  with  the  recent  advanced  techniques  including 
Microarrays.  These  studies  will  undoubtedly  reveal  invaluable  information  that  will 
revolutionise  our  understanding  of  the  actions  of  PZQ,  MZD  and  other  drugs. 
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Antibody  isotype  recognition  of  antigens  of 
Schistosoma  haematobium  by  sera  from  infected 
individuals  before  treatment,  after  treatment 
and  after  reinfection 4.1  Introduction 
4.1.1  Humoral  immunity  to  schistosomiasis 
All  stages  in  the  life  cycle  of  the  schistosome  may  be  rccognised  by  antibodies  in  the 
serum  of  infected  humans  (Butterworth  et  al.,  1985;  Hagan  et  al.,  1987).  Such 
antibodies  can  be  detected  in  the  serum  of  various  experimental  animals  and  humans 
within  days  of  infection.  It  is  clear  that  not  all  of  these  antibodies  are  relevant  to 
protective  immunity  and  there  is  a  powerful  evidence  that  some  may  prevent  the 
expression  of  immunity  (Hagan,  1987). 
In  humans  with  schistosomiasis  a  number  of  immuno-epidemiology  studies  have 
demonstrated  that  different  antibodies  are  correlated  with  resistance  to  infection  or  to 
intensity  of  reinfection.  For  instance,  adult  worin  and/or  schistosomula  specific  IgE 
antibodies  (Rihet  et  al.,  1991;  Hagan  et  al.,  1991;  Dunne  et  al.,  1992;  Demeure  et  al., 
1993;  Caldas  et  al.,  2000),  IgA  antibody  (Ndhlovu  et  al.,  1996;  Khalil  et  al.,  1999), 
IgGI  antibody  (Satti  et  al.,  1996)  and  IgM  antibodies  against  a  68kDa  antigen  (King  et 
al.,  1989)  have  been  associated  with  immunity  to  reinfection.  On  the  other  hand,  a 
number  of  studies  have  reported  that  parasite  specific  IgM  (Butterworth  et  al.,  1987; 
Ndhlovu  et  al.,  1996),  IgG4  (Hagan  et  al.,  1991;  Demeure  et  al.,  1993;  Ndhlovu  el  al., 
1996)  and  IgG2  (Demeure  et  al.,  1993;  Satti  et  al.,  1996)  antibodies  have  been 
correlated  with  susceptibility  to  re-infection.  Tle  finding  of  such  associations  has 
stimulated  attempts  to  determine  which  schistosome  antigens  arc  rccogniscd  by 
antibodies  that  may  result  in  protection.  'Me  identification  of  the  putative  'protective 
antigens'  would  be  of  significance  in  attempts  to  develop  a  vaccine  that  could  be  used  to 
artificially  stimulate  protection  through  vaccination. 
138 The  pattern  of  recognition  of  schistosome  antigens  by  antibodies  has  been  described  on 
a  number  of  occasions.  In  some  studies  antigen  recognition  has  been  correlated  with 
resistance  to  re-infection  (Roberts  et  al.,  1987;  Dessein  et  al.,  1988;  King  et  al.,  1989; 
Grzych  et  al.,  1989;  Dunne  et  al.,  1992;  Webster  et  aL,  1996;  Ndhlovu  el  al.,  1996). 
Roberts  and  colleagues  (1987)  used  western  blotting  analyses  to  examine  the  different 
recognition  patterns  of  S.  mansoni  surface  antigens  using  sera  from  Kenyan  children 
previously  infected  with  S  mansoni  and  who  were  classified  as  resistant  or  susceptible 
to  re-infection  after  treatment.  The  antibody  response  to  three  antigens  of  molecular 
mass  100,50  and  27kDa  were  detected  more  frequently  in  the  resistant  than  in  the 
susceptible  group.  However,  Roberts  and  colleagues  concluded  that  the  differences  in 
total  antibody  levels  to  the  tegumental  membrane  preparation  were  insufficient  to 
account  for  the  resistance  or  susceptible  status  of  the  children  (Roberts  et  al.,  1987). 
in  a  similar  study,  Dunne  and  colleagues  (1992)  reported  on  the  different  recognition 
patterns  of  S.  mansoni  antigens.  Using  western  blotting  analyses  with  serum  from 
individuals  classified  as  resistant  or  susceptible  to  reinfection  with  S.  mansonl,  they 
were  able  to  demonstrate  that  the  recognition  of  a  22kDa.  S.  mansoni  antigen  by  IgE 
antibodies  was  correlated  with  lower  intensities  of  reinfection  after  treatment  (Dunne  el 
aL,  1992).  Critically,  the  recognition  of  the  rSm22  (rSm22.6)  by  human  JgG3,  Ig4  and 
IgA  was  found  to  be  increased  in  the  resistant  group,  but  only  the  IgE  response  was 
significantly  correlated  with  resistance  to  reinfection  after  treatment  (Webstcr  et  al., 
1996;  Webster  et  al.,  1998). 
In  another  treatment  and  reinfection  study,  Dessein  and  colleagues  (1988)  showed  that 
IgG  antibodies  from  sera  of  individuals  classiried  as  resistant  to  reinfection  with  S. 
mansoni  recognised  larval  surface  antigens  of  202,165,90  to  92,85,72  and  37kDa. 
Ile  reactivity  of  IgG  against  the  37kDa  antigen  showed  an  association  with  potential 
resistance  to  reinfection  (Dessein  et  al.,  1988).  In  S.  haematobium  infections  both  IgE 
139 and  IgG4  recognised  different  soluble  schistosomula  antigens  but  no  difference  was 
reported  in  the  pattern  of  antigen  recognition  between  the  older  'putatively  resistant'  (,,  t 
20years)  and  the  younger  'putatively  susceptible'  (<  20  years)  individuals  except  for  the 
37kDa  antigen.  IgE  antibody  recognition  of  the  37kDa  antigen  was  higher  in  the  older 
(putatively  resistant)  group  (Ndhlovu,  et  aL,  1996). 
King  and  colleagues  (1989)  studied  the  recognition  pattern  to  S.  mansoni  surface 
antigen  (SmW68)  using  sera  from  Egyptian  individuals  chronically  infected  with  S. 
mansoni.  They  reported  a  negative  correlation  between  the  IgM  response  to  SmW68 
and  the  intensity  of  infection  (King  et  al.,  1989).  Similarly,  IgA  recognition  of  S. 
mansoni  glutathione-S-transferase  (Sm28)  has  been  correlated  with  resistance  to  human 
schistosomiasis  mansoni  infection  (Grzych  et  al.,  1989). 
interestingly,  the  antibody  recognition  pattern  can  be  a  marker  for  detection  of  early 
schistosomiasis  infection.  In  a  study  of  previously  non-exposed  individuals,  the 
recognition  of  S.  mansoni  antigens  of  32-35kDa  with  IgG  I  and  IgG3  antibody  isotypcs 
has  been  reported  to  be  a  potential  marker  for  early  schistosome  infection  (Evengard  et 
aL,  1990).  Similarly,  Shaheen  and  colleagues  (1996)  reported  that  the  IgGI  and  IgG3 
antibody  recognition  of  30-4OkDa  adult  worm  antigens  of  S.  mansoni  was  prominent 
during  the  acute  pre-patent  phase  of  schistosomiasis.  As  the  disease  progressed  to 
chronicity  the  IgGI  and  IgG3  recognition  shifted  to  the  higher  molecular  weight 
antigens  (ý:  80kDa)  (Shaheen  et  aL,  1996). 
4.1.2  Effects  of  chemotherapy  on  antibody  immune  responses  against 
schistosomes 
In  schistosome  infection  there  is  usually  a  delay  of  the  development  of  the  protective 
immune  response.  The  delay  in  the  development  of  protective  immunity  may  be 
140 attributed  to  many  factors.  Some  groups  favour  the  idea  that  blocking  antibodies  (IgM, 
IgG2  and  IgG4)  which  appear  early  in  infection  might  prevent  or  delay  the  onset  of 
protective  response  (Hagan  et  aL,  1991;  Derneure  et  aL,  1993).  Others  have  suggested 
that  children  are  not  able  to  mount  a  protective  response  simply  because  their  immune 
responses  are  not  fully  developed  (the  immunocompetence  hypothesis).  Only  when  their 
immune  responses  mature  are  they  able  to  mount  a  protective  response.  The  modulation 
and  evasion  of  the  immune  system  by  schistosomes  can  be  itself  an  explanation  for  the 
delay  in  development  of  protective  immune  responses  (Barsourn  el  al.,  1982).  One  final 
explanation  is  the  lack  of  availability  to  the  host's  immune  system  of  schistosome 
antigens.  Only  when  parasites  die  are  such  antigens  released  to  the  immune  system. 
During  natural  infection  antigens  are  released  in  small  amounts  over  a  prolonged  time 
period.  Only  when  the  host  has  had  sufficient  experience  of  these  antigens,  a  process 
that  may  take  years,  is  the  immune  response  effectively  armed  to  deal  with  new 
infection.  However,  none  of  these  hypotheses  can  on  their  own  completely  explain  the 
delayed  onset  of  immunity  to  schistosomiasis  and  it  is  likely  that  several  factors  are 
involved  (Hagan  and  Sharaf,  2003).  Praziquantel,  and  probably  other  drugs,  damage  or 
kill  worms  perhaps  exposing  antigens  that  were  previously  concealed,  or  accelerate 
antigen  release  (Harnett  and  Kusel,  1986;  Woolhouse  and  Hagan,  1999)  that  could 
stimulate  protective  immunity.  In  this  context,  treatment  of  schistosome  infections  at  the 
skin  schistosomula  stage  by  Rol  1-3128  resulted  in  immunity  to  reinfection.  Scra  from 
mice  immunized  by  infection  plus  Rol  1-3128  treatment  on  days  I  or  2,  co-prccipitatcd 
essentially  the  same  pattern  of  125  I-labclled  surface  antigens  as  did  serum  from  mice 
vaccinated  with  20  krad  irradiated  cercariae,  viz.  M,  38,32,23and  15kDa  (Bicklc  et  aL, 
1990). 
In  an  early  attempt  to  study  the  effect  of  praziquantel  treatment  on  the  responses  of  S. 
haematobium  infected  Gambians,  Hagan  and  colleagues  (1987)  studied  the  differences 
141 in  antibody  recognition  of  S.  haematobium  whole  worm  homogenate  (WWH)  and 
soluble  egg  antigens  (SEA)  before  treatment,  3  months  after  treatment  and  after 
reinfection.  They  reported  that  antibodies  against  WWH  increased  after  treatment  and 
fell  after  reinfection  while  antibodies  against  SEA  fell  after  treatment  and  increased 
after  reinfection  (Hagan  et  aL,  1987).  However,  they  reached  no  conclusion  as  to 
whether  or  not  particular  antigen  recognition  patterns  were  associated  with  protection 
against  infection. 
in  a  study  of  the  effects  of  praziquantel  treatment  on  the  immune  responses  in  S. 
mansoni  infection  in  occupationally  hyper-exposed  canal  cleaners  in  the  Sudan,  Satti 
and  colleagues  (1996)  reported  that  individuals  resistant  to  re-infection  showed  no 
significant  difference  in  the  levels  of  IgG4  to  WWH  after  treatment.  In  contrast  there 
was  a  significant  increase  in  the  levels  of  IgG4  to  WWH  in  the  susceptible  group. 
Levels  of  specific  IgG4  to  SEA  showed  a  highly  significant  decrease  after  treatment  in 
the  resistant  group.  The  same  antibody  subclass  increased  after  treatment  in  the 
susceptible  group.  However,  none  of  the  groups  studied  after  treatment  showed  a 
significant  change  in  their  specific  IgE  to  WWH  (Satti  et  al.,  1996). 
Further  support  for  the  effect  of  chemotherapy  on  the  immune  response  comes  from  the 
work  of  Mutapi  and  colleagues  (1998).  They  reported  that  treatment  of  S.  haematobium. 
infected  Zimbabwean  children,  5-16  years  old,  with  praziquantel  induced  a  switch  from 
a  predominantly  IgA-specific  antibody  response  to  a  predominantly  IgGI  response, 
similar  to  that  of  adults  naturally  exposed  to  infection  over  many  years  and  supposed  to 
be  resistant  to  re-infection.  The  switch  of  the  immune  response  which  occurs  naturally 
after  several  years  of  exposure  in  this  community  occurred  in  the  children  within  12 
weeks  of  treatment  with  praziquantel  (Mutapi  et  al.,  1998).  The  same  authors  studied 
the  effect  of  praziquantel  and  oxamniquine  on  the  humoral  immune  responses  directed 
against  S  mansoni  soluble  egg  antigens  (SEA)  in  Zimbabwean  children.  The  proportion 
142 of  treated  children  producing  IgE  and  IgG3  increased  six  weeks  post-treatmcnt.  There 
was  also  an  increase  in  the  mean  levels  of  IgE,  IgM  and  IgG3  in  these  children.  At  18 
weeks  post-treatment,  the  proportion  of  treated  children  producing  IgA,  IgE,  and  IgG3 
increased  while  the  proportion  producing  IgGI  and  IgG4  decreased.  Mean  levels  of 
IgA,  IgE,  and  IgG3  were  higher  than  pre-treatment  levels  while  levels  of  IgGI,  IgG4 
and  IgM  were  lower.  Statistical  analyses  showed  that  the  magnitude  of  change  in  levels 
of  IgE,  IgM  and  IgG3  at  6  weeks  post-treatment  and  of  IgE,  IgG3  and  IgG4  at  18  weeks 
post-treatment  were  significantly  greater  in  treated  compared  to  untreated  children. 
There  were  no  significant  differences  in  immune  responses  between  children  treated 
with  praziquantel  and  those  treated  with  oxamniquine  (Mutapi  et  al.,  2003). 
Furthermore,  Grogan  and  colleagues  (1997)  studied  specific  IgG4  and  IgE  responses 
against  S.  haematobium  adult  worm  antigens  and  SEA  in  S  haemaloblum  infected 
individuals  before  and  after  chemotherapy.  In  this  study  there  was  a  substantial  drop  in 
the  IgG4  response  to  SEA  after  chemotherapy  in  both  adults  and  children.  However, 
IgG4  and  IgE  antibodies  to  adult  worm  antigen  (AWA)  and  IgE  antibodies  to  SEA 
increased  in  children  but  remained  unchanged  in  adults  (Grogan  el  aL,  1996).  Similarly, 
in  a  study  of  the  antibody  responses  against  S.  mansoni  AWA  and  SEA  in  Brazilian 
individuals  chronically  infected  with  S.  manson!  before  and  after  treatment  with 
oxamniquine,  there  was  a  decrease  in  the  schistosome-spccific  IgG  level  observed  6 
months  after  treatment.  Although  there  was  significant  decrease  of  anti-SEA  IgG1  and 
IgG3  levels,  the  decrease  of  anti-SEA  IgG4  level  was  much  more  evident  (Vcndramc  et 
al,  2001). 
These  studies  together  indicate  that  treatment  of  schistosomiasis  with  praziquantel 
induces  some  changes  of  the  immune  response  in  the  form  of  an  incrcasc  of  IgE  levels, 
an  antibody  isotype  which  has  been  correlated  with  rcsistancc,  and  decrease  of  IgG4 
levels,  an  antibody  isotype  which  has  been  correlated  with  susceptibility  to  reinfection. 
143 To  further  investigate  the  possibility  that  schistosome  antigen  recognition  is  associated 
with  susceptibility  or  resistance  to  reinfection,  a  unique  serum  bank  containing  samples 
obtained  in  the  reinfection  study  reported  by  (Wilkins  et  al.,  1987)  was  provided 
together  with  access  to  the  parasitological  database.  Using  this  material  it  was  possible 
to  compare  the  isotype  specific  recognition  patterns  of  S  haematobium  soluble  adult 
worm  antigens.  Serum  samples  from  a  resistant  group  (showing  no  or  few  eggs  in  their 
urine  after  exposure  to  re-infection)  and  a  susceptible  group  (showing  high  numbers  of 
eggs  in  their  urine  after  re-infection)  before  treatment,  after  treatment  with  praziquantel 
and  after  re-infection  were  exploited. 
4.2  Materials  and  Methods 
4.2.1  Serum  samples 
Background  information  on  the  serum  samples 
The  serum  samples  were  collected  from  two  villages  (Madina  Samaco  and  Njarinjufa) 
in  Upper  River  Division  of  The  Gambia  (Hagan  et  al.,  1987).  The  communities  were 
mainly  dependent  on  subsistence  agriculture.  The  transmission  of  S  haemalobium  in 
these  villages  was  seasonal.  Pools  forms  in  the  rainy  season  between  June  and 
November.  No  transmission  of  schistosomiasis  occurred  from  December  to  June/July.  A 
cohort  of  40%  of  the  population  of  the  villages  was  included  in  this  study.  In  February 
and  March  1983,  urine  samples  were  collected  for  egg  count  studies  with  intensities  of 
infection  being  assessed.  After  blood  samples  were  collected  (prc-trcatmcnt  sera),  the 
participants  were  treated  with  a  single  dose  of  40mg  kg"  of  praziquantcl.  71rce  months 
after  the  treatment,  further  urine  and  blood  samples  were  collected  (post-trcatmcnt  sera). 
During  the  transmission  season,  careful  observation  of  water  contact  by  trained 
observers  allowed  an  index  of  cumulative  exposure  to  infection  throughout  the 
144 transmission  season  to  be  calculated  for  each  individual.  In  April  1984,5  months  after 
the  end  of  the  transmission  season,  a  third  urine  sample  was  collected  and  the  intensity 
of  re-infection  was  calculated.  Blood  samples  were  also  collected  at  this  time 
(reinfection  sera). 
This  study  showed  that  among  groups  of  subjects  with  an  apparently  similar  intensity  of 
exposure  to  infection,  reinfection  tended  to  be  much  heavier  in  children  under  10  years 
of  age  than  in  10  to  14-year-olds,  while  only  light  infections  were  found  in  the  few 
adults  who  became  reinfected.  This  trend  for  re-infection  to  decrease  with  increasing 
age,  after  an  allowance  for  variation  in  exposure,  was  highly  significant  (P<0.001) 
(Wilkins  et  al.,  1987).  Levels  of  parasite  specific  IgE  were  positively  correlated  with 
resistance  to  reinfection  while  levels  of  JgG4  showed  a  positive  correlation  with 
susceptibility  to  reinfection  (Hagan  et  al.,  199  1). 
Grouping  of  patients'  sera 
Individuals  who  became  re-infected  with  S.  haemalobium  aftcr  treatment  with 
praziquantel  were  considered  to  be  susceptible.  On  the  other  hand,  individuals  with  no 
eggs  detected  in  their  urine  after  exposure  to  reinfection,  were  considered  to  be 
resistant.  Sera  from  five  control  non-infected  individuals  living  in  a  non-endcmic  area 
were  included  in  this  antigen  recognition  study. 
Comparisons  were  carried  out  between  resistant  and  susceptible  groups  at  cach  time 
point  and  between  the  different  time  points  within  the  same  group. 
4.2.2  Antigens 
Freeze-dried  adult  S.  haemalobium  wonns  were  kindly  provided  by  Professor  Frcd 
Lewis  (Biomedical  Research  Institute,  Rockville,  Maryland,  USA).  They  were  rc- 
145 suspended  in  PBS  (pH  7.4)  and  homogenised,  using  a  tissue  homogeniser  immersed  in 
ice  to  prevent  overheating.  Ile  whole  worm  homogenate  was  transferred  into  a 
universal  tube  and  sonicated  on  ice  using  a  sonicator  (Soniprep  150)  for  4  cycles  of  I 
minute  each  with  a  minute  interval  between  pulses  to  prevent  over  heating  of  the 
antigens.  The  supernatant  was  centrifuged  for  20  minutes  at  700OOg  at  4'C.  'me 
supernatant  was  collected  in  a  universal  tube  to  which  a  protease  inhibitor  was  added. 
The  protein  content  of  the  soluble  adult  worm  antigens  preparation  (SWAP)  was  then 
quantified. 
4.23  Determination  of  protein  concentration  of  SWAP 
Five  microlitres  of  PBS  (as  blank),  5pLI  of  each  of  the  standard's  concentrations  (1500, 
1000,500,200,100,50  and  20pg  ml-1)  and  5pl  of  the  sample  were  pipetted  in  each  well 
of  a  microwell  plate.  Standards  and  samples  were  run  in  triplicate.  A  250pl  of 
Coomassie-brilliant  blue  reagent  was  added  to  each  well  and  their  protein 
concentrations  were  measured,  immediately  after  an  initial  shaking  for  30  seconds  at  a 
wavelength  of  595nm  using  a  Dynex  ELISA  plate  reader.  The  protein  concentration  of 
the  homogenate  was  adjusted  to  I  mg  ml"  and  it  was  then  stored  at  -800C. 
4.2.4  Sodium-Dodecyl-Sulphate  Polyacrylamide,  Gel  Electrophoresis 
(SDS-PAGE) 
The  method  used  in  this  study  was  a  modification  of  that  described  by  Lacmmli  (1970). 
The  conditions  of  electrophoresis  and  immunoblotting  were  adjusted  after  several 
preliminary  experiments.  All  reagents  used  for  SDS-PAGE  were  purchased  from 
Invitrogen  (Paisley,  UK).  Schistosoma  haematobium  SWAP  was  treated  with  sample 
buffer  (NuPAGEO  LDS  Sample  Buffer)  4:  1  volume  to  volume,  respectively,  and  then 
boiled  for  5  minutes.  4-12%  gradient  precast  gels  (NuPAGE-0  Novcx  Bis-Tris  Gels) 
146 were  used.  Each  gel  is  Imm  thick  and  has  one  well  for  the  molecular  weight  markers 
(MWM)  and  a  7cm  trough  for  the  sample.  Five  hundred  microlitres  (containing  500pg) 
of  the  SWAP  was  loaded  in  the  trough  on  each  gel  and  run  in  parallel  with  7pl  of  a 
prestained  wide  range  molecular  weight  markers  (SeeBlueo  Pre-Staincd  Standard)  in 
the  single  well.  The  running  buffer  was  prepared  by  diluting  the  running  buffer 
(NuPAGEO  MES  Running  Buffer)  20  times  with  deionised  distilled  water  and  500ml 
was  put  into  the  electrophoresis  cell.  The  gel  was  run  at  80mV  for  the  stacking  gel  and 
then  at  140mV  until  the  bromophenol  blue  dye  was  approximately  0.5  cm  from  the 
bottom  of  the  gel.  The  power  was  then  switched  off,  the  cast  removed  and  the  gel 
carefully  extracted. 
4.2.5  Staining  of  proteins 
After  running  the  proteins  on  SDS-PAGE,  the  proteins  were  stained  to  confirm  that  they 
were  adequately  resolved.  Gels  were  stained  with  Coomassie  blue  stain  for  2h  with 
shaking  at  room  temperature.  The  gels  were  removed  from  the  stain  and  were  dcstained 
with  Coomassie  destain  for  4h  with  shaking  at  room  temperature  (until  the  background 
became  clear).  The  gels  were  then  removed  from  the  destain  solution  and  the  molecular 
weights  of  the  protein  bands  were  measured  using  UV  gel  documentary  systcm  and 
using  a  software  program  (LabworksTm  analysis  software). 
4.2.6  Western  blotting 
After  protein  resolution  onto  the  SDS-PAGE  gel,  a  sheet  of  nitrocellulose  membrane 
was  placed  against  the  surface  of  the  gel  and  a  current  was  allowed  to  pass  across  the 
gel.  This  current  caused  the  proteins  to  move  from  the  gel  onto  the  nitoccliulosc 
membrane.  Once  there,  they  are  bound  firmly  by  non-covalcnt  forces  (Hudson  and  Hay, 
1989).  Three  Whatman  filter  papers,  soaked  in  the  cathode  buffer  (see  appendix),  were 
147 placed  onto  the  flat  surface  of  the  inimunoblot  apparatus.  The  gel  was  placed  over  the 
cathode  papers.  A  piece  of  nitrocellulose  membrane,  0.45um  (Amersham)  was  cut 
slightly  bigger  than  the  size  of  the  gel  and  was  placed  facing  the  gel,  taking  care  to 
exclude  air  bubbles.  One  filter  paper  soaked  in  anode  2  (see  appendix)  was  placed  over 
the  nitrocellulose  membrane.  Two  filter  papers  soaked  in  anode  I  (see  appendix)  were 
then  put  over  the  anode  2  paper.  The  inimunoblot  plate  was  then  covered  and  the 
current  passed.  The  conditions  of  the  protein  transfer  were  adjusted  after  several 
experiments.  A  current  of  200mA  for  35minutes  gave  the  best  results  with  these 
samples.  The  nitrocellulose  membrane  was  then  removed  and  stained  with  Ponceau  S  (a 
red  dye)  to  confirm  that  the  proteins  were  properly  transferred.  The  membrane  was 
washed  with  distilled  water  to  remove  the  dye  and  the  membrane  allowed  to  dry. 
For  proper  alignment  and  comparison  of  the  protein  bands,  a  line  was  drawn  near  the 
bottom  of  the  membrane,  outside  the  protein  migration  area.  Each  membrane  was  cut 
into  18,  numbered,  longitudinal  strips  (enough  for  blotting  the  six  antibody  isotypes 
with  three  serum  samples).  IMe  nitrocellulose  strips  were  blocked  with  0.3%  PBS- 
Tween  solution  for  30minutes  at  room  temperature,  with  shaking.  The  strips  were 
removed  from  the  blocking  buffer  and  washed  with  0.05%  PBS-Tween  wash  buffer  3 
times  of  10  minutes  each.  In  the  mean  time,  serum  samples  were  diluted  1:  100  with 
0.05%  PBS-Tween  solution.  Ile  diluted  serum  samples  were  put  in  universal  tubes  and 
6  strips  (one  strip  for  each  antibody  isotype;  IgG,  IgM,  IgGI,  IgG2,  IgG3  and  IgG4) 
were  incubated  with  the  serum  in  each  universal  tube.  Ile  tubes  containing  the  serum 
samples  and  the  strips  were  then  shaken  over  night  at  4"C.  The  strips  were  rcmovcd 
from  the  sera  and  washed  with  washing  buffer  3  times  for  10  minutes  each.  One  strip 
from  each  serum  sample  was  put  into  a  universal  tube  containing  a  1:  750  dilution  of  the 
secondary  antibodies  [anti-human  IgG,  IgM,  IgGl,  IgG2,  IgG3  or  IgG4  labelled  with 
horse  radish  peroxidase  (HRP)  enzyme].  The  strips  were  incubated  with  the  secondary 
148 antibodies  over  night  at  4'C.  The  strips  were  removed  from  the  secondary  antibodies 
and  washed  with  the  washing  buffer  3  times  for  10  minutes  each.  The  Strips  were 
incubated  with  the  substrate  solution  (see  appendix)  until  the  bands  became  visible.  Tle 
reaction  was  stopped  by  washing  the  strips  with  distilled  water,  3  times,  for  10  minutes 
each.  The  strips  were  then  rearranged  in  their  original  sequence,  the  protein  bands  were 
visualised  using  a  UV  gel  documentary  system  and  the  molecular  weight  of  the  bands 
was  determined.  The  recognition  was  expressed  as  the  percentage  of  senun  samples  of 
each  group  recognising  a  particular  protein  band. 
The  same  procedure  was  employed  for  IgE  with  increasing  the  concentration  of  serum 
samples  to  up  to  1:  10  and  of  the  anti-human  IgE  antibodies  to  1:  50.  Despite  repeated 
attempts,  no  recognition  of  parasite  antigens  by  IgE  was  detected  even  afler  pooling  the 
serum  samples  from  each  group. 
4.2.7  Comparison  between  groups 
After  probing,  identification  of  each  antigen  by  each  serum  sample  of  those  within  the 
susceptible  or  resistant  groups  recognising  a  particular  antigen  was  assessed. 
Recognition  of  each  antigen  was  then  expressed  as  a  percentage  of  those  within  each 
group.  For  comparison  between  resistant  and  susceptible  groups,  the  percentage 
recognition  of  the  susceptible  group  of  each  band  was  subtracted  from  the  value  of  the 
resistant  group.  The  resultant  value  is  the  net  difference  between  both  groups.  The  same 
method  was  employed  when  assessing  the  impact  of  chemotherapy  and  reinfection  on 
the  antibody  isotypes  in  each  group. 
149 4.3  Results 
4.3.1  SDS-PAGE  gel 
A  wide  range  of  glycoproteins/proteins  was  separated  on  the  SDS-PAGF  gel.  In  total 
thirty  distinct  bands  were  recognised  and  their  molecular  masses  ranged  from  5  to 
280kDa.  An  initial  scan  to  identify  which  proteins  were  recognised  by  sera  from 
patients  included  in  this  study  showed  that  sera  reacted  to  manv  of  the  scparatcd 
proteins  (see  figure  4.1  ). 
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150 4.3.2  Antigen  recognition  by  IgM  antibodies 
Most  of  parasite  antigens  were  recognised  by  at  least  some  of  the  sennn  samples  from 
the  resistant  and  susceptible  groups.  Sera  from  control  individuals  did  not  rccognisc  any 
parasite  antigens. 
Differences  in  antigen  recognition  between  resistant  and  susceptible  groups 
Before  treatment,  sera  from  resistant  individuals  showed  more  frequent  recognition  of 
antigens  at  170  (13%),  150  (270/o),  133  (27%),  123  (275/o),  95  (175/6),  84  (27%),  78 
(14%),  74  (18%),  65  (14%),  52-54  (29%),  45-47  (46%),  42  (12%)  and  37kDa  (27%) 
than  the  recognition  by  the  susceptible  group.  Sera  from  susceptible  individuals  showed 
more  frequent  recognition  of  antigens  at  23  (12%)  and  16-18kDa  (39%)  than  the 
resistant  group. 
Three  months  after  treatment  with  PZQ,  sera  from  resistant  individuals  showed  more 
frequent  recognition  of  antigens  at  123  (13%),  95  (25vo),  84  (381/6),  78  (30%),  74 
(26%),  4547  (42%),  42  (IM),  37  (26%)  and  34kDa  (13%)  and  less  frequent 
recognition  of  antigens  at  150  (80/o),  26  (20%),  23  (13%),  16-18  (26%)  and  13kDa 
(18%)  than  the  recognition  by  the  susceptible  group. 
After  exposure  to  re-infection,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  186  (14%),  170  (14%),  95  (17%),  84  (30'/o),  65  (29%),  52-54 
(47%)  and  13kDa  (6%)  and  less  frequent  recognition  of  antigens  at  34  (10%),  28-30 
(29%)  and  23kDa  (12%)  than  the  recognition  by  the  susccptiblc  group. 
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Table  4.1  Percentage  recognition  of  antigen  bands  in  resistant  and  susceptible  groups  at  different 
time  points. 
The  percentage  recognition  of  different  S.  haernatobiurn  antigens  by  sera  from  resistant 
(R)  and  susceptible  individuals  (S)  prior  to  treatment  (Pre-ttt),  three  months  aftcr 
treatment  with  PZQ  (Post-ttt)  and  after  exposure  to  reinfection  (Rcino.  (Note  that  the 
table  is  continued  over  the  next  page). 
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153 Impact  of  treatment  and  re-infection  on  antigen  recognition 
After  treatment  with  PZQ,  sera  from  resistant  individuals  showed  increased  frequency 
in  the  recognition  of  antigens  at  34  (14%)  and  28-3OkDa  (21%)  and  less  frequent 
recognition  of  antigens  at  170  (21%),  150  (36%),  133  (21%),  123  (14%),  84  (14%),  52- 
54  (21%)  and  l3kDa  (14%)  than  the  recognition  patterns  prior  to  treatment.  Sera  from 
susceptible  individuals  showed  more  frequent  recognition  of  antigens  at  65  (17vo),  52- 
54  (17%),  45-47  (17%),  28-3  0  (16%)  and  26kDa  (25%)  and  less  frequent  recognition  of 
antigens  at  84kDa  (25%)  than  the  recognition  patterns  of  the  same  individuals  prior  to 
treatment  (see  figure  4.3). 
After  exposure  to  re-infection,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  186  (14%),  170  (14%)  and  52-54  (41%)  and  less  frequent 
recognition  of  antigens  at  133  (14%),  123  (14Vo),  45-47  (2lVo),  42  (14%),  37  (21%),  34 
(14%)  and  28-3OkDa  (28%)  than  the  recognition  patterns  of  the  same  individuals  three 
months  after  treatment.  Sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  78  (17%),  74  (25%),  45-47  (18%),  34  (8%)  and  34kDa  (8%) 
and  less  frequent  recognition  of  antigens  at  65  (17%),  52-54  (33%),  26  (25%),  16-18 
(24%)  and  l3kDa  (17%)  than  the  recognition  patterns  three  months  after  treatment. 
When  comparing  the  recognition  pattern  after  exposure  to  re-infection  with  the  pre- 
treatment  recognition,  sera,  from  resistant  individuals  showed  more  frequent  recognition 
of  antigens  at  186  (140/o),  65  (14%)  and  52-54kDA  (21%)  and  less  frequent  recognition 
of  antigens  at  170  (70/o),  150  (36%),  133  (36%),  123  (29%),  84  (14%),  45-47  (22%)  and 
37kDa  (14%)  than  the  recognition  patterns  of  the  same  individuals  prior  to  treatment. 
Sera  from  susceptible  individuals  showed  more  frequent  recognition  of  antigens  at  74 
(17%),  4547  (330/o),  37  (17%)  and  28-3OkDa  (17%)  and  less  frequent  recognition  of 
154 antigens  at  186  (80/o),  84  (17%),  52-54  (17%),  16-18  (24%)  and  l3kDa,  (17%)  than  the 
recognition  prior  to  treatment  (see  figure  4.2). 
These  results  showed  that  the  effect  of  treatment  with  PZQ  on  the  pattern  of  recognition 
of  parasite  antigens  in  both  resistant  and  susceptible  individuals  (and  groups)  was 
heterogeneous.  However,  sera  from  resistant  individuals  showed  less  frequent 
recognition  of  antigens  of  high  molecular  weights  (123  to  170kDa)  after  treatment  with 
PZQ.  After  exposure  to  re-infection,  while  sera  from  susceptible  group  showed  more 
frequent  recognition  of  antigens  at  45-47  (33%)  and  37kDa  (17%)  compared  to  the 
recognition  before  treatment,  sera  from  resistant  individuals  showed  less  frequent 
recognition  of  the  same  antigens  (22%  and  14%,  respectively)  as  well  as  of  antigens  at 
molecular  masses  between  123  and  150kDa.  On  the  other  hand,  while  sera  from 
resistant  individuals  showed  more  frequent  recognition  of  antigens  at  186  and  52- 
54kDa,  sera  from  susceptible  individuals  showed  less  frequent  recognition  of  the  same 
antigens  compared  to  the  recognition  before  treatment. 
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Figure  4.2  Differences  in  the  IgM  recognition  pattern  after  exposure  to  reinfection  compared  to  the 
recognition  pattern  prior  to  praziquantel  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  exposure  to  infection  in  both  resistant  and  susceptible  groups  and  the 
differences  plotted. 
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Figure  4.3  Differences  in  the  IgM  recognition  pattern  three  months  after  praziquantel  treatment 
compared  to  the  recognition  pattern  prior  to  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  treatment  in  both  resistant  and  susceptible  groups  and  the  differences 
plotted. 
4.3.3  Antigen  recognition  by  total  IgG  antibodies 
Most  of  parasite  antigens  were  recognised  by  at  least  some  of  the  serum  samples  from 
the  resistant  and  susceptible  groups.  Sera  from  control  individuals  did  not  recognise  any 
parasite  antigens. 
157 Differences  in  antigen  recognition  between  resistant  and  susceptible  groups 
Before  treatment,  there  was  a  general  trend  of  more  frequent  recognition  of  parasite 
antigens  by  sera  from  the  resistant  group  than  from  the  susceptible  group.  The  marked 
differences  were  in  the  recognition  of  antigens  at  95  (101/6),  78  (15%),  74  (19%),  65 
(42Vo),  52-54  (29%),  45-47  (39%),  42  (19%),  37  (271/o),  28-30  (30%)  and  l3kDa  (10%). 
However,  sera  from  susceptible  individuals  showed  more  frequent  recognition  of 
antigens  at  34  (19%)  and  26kDa  (35%)  compared  to  the  recognition  patterns  of  the 
resistant  group. 
After  treatment  with  PZQ,  the  pattern  of  recognition  was  altered.  Sera  from  susceptible 
individuals  showed  more  frequent  recognition  of  antigens  at  186  (17'/o),  150  (10%),  133 
(121/6),  123  (20%),  95  (14%),  84  (11%),  42  (14%),  34  (11%),  28-30  (13%),  26  (20%), 
23  (15%),  20  (15%)  and  16-18kDa  (45%)  than  the  recognition  by  the  resistant  group. 
Sera  from  resistant  individuals  showed  more  frequent  recognition  of  antigens  at  65 
(I  I  O/o)  and  45-47kDa  (17%)  than  the  susceptible  group. 
After  exposure  to  re-infection,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  123  (IOVo),  95  (21%),  84  (33Vo),  78  (26%),  74  (21%),  45-47 
(20%),  34  (10%)  and  26kDa  (26%)  than  the  recognition  patterns  of  the  resistant  group. 
Sera  from  resistant  individuals  showed  more  frequent  recognition  of  antigens  at  65 
(120/6),  52-54  (10%)  23  (11%)  and  20kDa  (14%)  than  the  susceptible  group. 
Impact  of  treatment  and  re-infection  on  antigen  recognition 
After  treatment  with  PZQ,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  78  (14%)  and  26kDa  (14%)  and  less  frequent  recognition  of 
antigens  at  186  (7%),  170  (7%),  95  (7%),  65  (14%),  28-30  (44%),  23  (7%),  20  (21%), 
16-18  (7%)  and  13kDa  (7%)  than  sera  taken  from  the  same  individuals  prior  to 
158 treatment.  Sera  from  susceptible  individuals  showed  an  increased  frequency  in  the 
recognition  of  antigens  after  treatment  compared  with  pre-treatment.  Differences  were 
greatest  for  the  recognition  of  antigens  at  186  (17%),  133  (17%),  123  (17%),  95  (17%), 
78  (33%),  74  (25%),  65  (170/o),  52-54  (30%),  45-47  (17vo),  42  (33%),  37  (25%),  23 
(17%)  and  16-18kDa  (32%)  (see  figure  4.5). 
After  exposure  to  re-infection,  resistant  individuals  showed  a  general  pattern  of 
decreased  recognition  of  parasite  antigens.  They  showed  less  frequent  recognition  of 
antigens  at  133  (141/o),  123  (14%),  84  (140/6),  78  (141/o),  74  (7%),  4547  (24%),  42 
(14%)  and  26kDa  (14%)  and  more  frequent  recognition  of  the  antigen  at  20kDa  (14%) 
compared  to  the  recognition  patterns  of  the  same  individuals  three  months  after 
treatment.  Sera  from  susceptible  individuals,  also,  showed  a  general  pattern  of 
decreased  recognition  of  antigens  than  post-treatment.  They  showed  less  frequent 
recognition  of  antigens  at  186  (17%),  150  (17%),  133  (25%),  123  (25%),  52-54  (17vo), 
42  (25%),  23  (33%),  20  (17%)  and  16-18kDa  (39%)  and  more  frequent  recognition  of 
antigens  at  84  (8%),  78  (80/6),  74  (8%)  and  45-47kDa  (10%)  than  the  recognition 
patterns  of  the  same  individuals  three  months  after  treatment. 
When  comparing  the  recognition  pattern  after  exposure  to  re-infection  with  the  pre- 
treatment  recognition,  sera  from  resistant  individuals  showed  a  decreased  recognition  of 
most  antigens  after  exposure  to  re-infection.  T'hey  showed  less  frequent  recognition  of 
antigens  at  123  (14%),  95  (14%6),  84  (14%),  74  (7%),  65  (21%),  4547  (340/0),  42  (14VO), 
37  (7%),  28-30  (42%)  and  23kDa  (14%)  compared  to  the  recognition  patterns  of  the 
same  individuals  prior  to  treatment.  Sera  from  re-infected  susceptible  individuals 
showed  increased  frequency  in  the  recognition  of  antigens  at  95  (17%),  84  (170/6),  78 
(42%),  74  (33%),  65  (8%),  52-54  (IM),  45-47  (25%)  and  37kDa  (17%)  and  less 
frequent  recognition  of  antigens  at  34  (IM),  23  (17%)  and  20kDa  (17%)  compared  to 
the  recognition  prior  to  treatment  (see  figure  4.4). 
159 These  results  showed  that  after  treatment  with  PZQ,  while  sera  from  resistant 
individuals  showed  a  general  pattern  of  decreased  frequency  of  recognition,  sera  from 
susceptible  individuals  showed  increased  frequency  in  the  recognition  of  most  antigens 
after  treatment  compared  to  the  recognition  prior  to  treatment.  Furthermore,  while  sera 
from  re-infected  susceptible  individuals  showed  increased  frequency  in  the  recognition 
of  antigens  at  molecular  masses  between  37  and  95kDa  (especially  the  78,74  and  45- 
47kDa)  sera  from  resistant  individuals  exposed  to  re-infection  during  the  same  period 
showed  less  frequent  recognition  of  the  same  antigens  compared  to  the  recognition  prior 
to  treatment. 
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Figure  4.4  Differences  in  the  IgG  recognition  pattern  after  exposure  to  reinfection  compared  to  the 
recognition  pattern  prior  to  praziquantel  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  perccntage 
recognition  after  exposure  to  infection  in  both  resistant  and  susceptible  groups  and  the 
differences  plotted. 
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Figure  4.5  Differences  in  the  IgG  recognition  pattern  three  months  after  praziquantel  treatment 
compared  to  the  recognition  pattern  prior  to  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  treatment  in  both  resistant  and  susceptible  groups  and  the  differences 
plotted. 
4.3.4  Antigen  recognition  by  IgGl  antibodies 
Most  of  parasite  antigens  were  recognised  by  at  least  some  of  the  serum  samples  from 
the  resistant  and  susceptible  groups.  Sera  from  control  individuals  did  not  recognise  any 
parasite  antigen. 
Differences  in  antigen  recognition  between  resistant  and  susceptible  groups 
Before  treatment,  sera  from  resistant  individuals  showed  more  frequent  recognition  of 
antigens  at  95  (17%),  78  (10%),  74  (37%),  65  (21%),  52-54  (21%),  45-47  (23%)  and 
161 
-40  -20  0  20 37kDa  (13%)  and  less  frequent  recognition  of  antigens  at  42  (12%),  34  (25%),  28-30 
37Vo),  26  (26%)  and  23kDa,  (14%)  compared  to  the  susceptible  group. 
After  treatment  with  PZQ,  sera  from  susceptible  individuals  showed  a  generally 
increased  frequency  in  the  recognition  of  most  antigens  compared  to  the  resistant  group. 
The  main  differences  were  in  the  recognition  of  antigens  at  78  (15%),  74  (200/6),  52-54 
(17%),  45-47  (45%),  42  (56%),  37  (1  Mo),  34  (25%),  26  (36%),  23  (24%),  16-18  (15%) 
and  l3kDa  (20%). 
After  exposure  to  reinfection,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  150  (17%),  133  (17%),  123  (181/6),  74  (11%),  45-47  (20%), 
42  (320/o),  34  (17%),  26  (26)  and  16-18kDa  (14%)  compared  to  the  resistant  group. 
However,  sera  from  resistant  individuals  showed  more  frequent  recognition  of  antigens 
at  186  (14%),  170  (14%)  and  95  (25%). 
Impact  of  treatment  and  reinfection  on  antigen  recognition 
After  treatment  with  PZQ,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  150  (14%),  133  (14%),  123  (14%)  and  28-3OkDa  (21%)  and 
less  frequent  recognition  of  antigens  at  52-54  (21%),  4547  (42%)  and  42kDa  (36%) 
compared  to  the  recognition  patterns  of  the  same  individuals  prior  to  treatment.  Sera 
from  susceptible  individuals  showed  increased  recognition  particularly  of  antigens  at 
133  (250/6),  123  (25%),  78  (25%),  74(50%),  52-54  (170/6),  45-47  (25%),  37  (17%),  26 
(17%),  23  (17%),  20  (17Vo),  16-18  (25%)  and  l3kDa  (25%)  after  treatment  than  prior  to 
treatment  (see  figure  4.7). 
After  exposure  to  re-infection,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  186  (14%),  170  (14%),  78  (14%)  and  42kDa  (7%)  and  less 
frequent  recognition  of  antigens  at  150  (14%),  133  (21%),  123  (14%),  65  (14%),  37 
162 (14%),  28-30  (36%)  and  16-18kDa  (14%)  compared  to  the  recognition  patterns  of  the 
same  individuals  after  treatment.  Sera  from  susceptible  individuals  showed  decreased 
recognition  after  treatment  especially  of  antigens  at  133  (17%),  74  (17%),  52-54  (17%), 
45-47  (25%),  42  (17%),  37  (250/o),  28-30  (250/o),  26  (17%),  23  (17%),  20  (17%),  16-18 
(I  6Vo)  and  13kDa  (25%). 
When  comparing  the  recognition  pattern  after  exposure  to  reinfection  with  the  pre- 
treatment  recognition,  sera  from  resistant  individuals  showed  more  frequent  recognition 
of  antigens  at  78kDa  (14%)  and  less  frequent  recognition  of  antigens  at  74  (14%),  65 
(14%),  52-54  (22%),  4547  (24%),  42  (290/6),  37  (2  1  %)  and  28-3  OkDa  (14%)  compared 
to  samples  taken  from  the  same  individuals  prior  to  treatment.  On  the  other  hand,  sera 
from  susceptible  individuals  showed  more  frequent  recognition  of  antigens  at  123 
(I  7Vo),  78  (17%)  and  74kDa  (33%)  and  less  frequent  recognition  of  antigens  at  42  (8%), 
37  (8%),  34  (8%)  and  28-3OkDa  (45%)  compared  to  the  recognition  patterns  prior  to 
treatment  (see  figure  4-6). 
These  results  showed  that  while  the  effect  of  treatment  with  PZQ  on  the  recognition 
pattern  of  the  resistant  individuals  was  heterogeneous,  sera  from  susceptible  individuals 
showed  a  general  pattern  of  increased  recognition  of  most  antigens  especially  antigens 
of  molecular  masses  between  34  and  74kDa  as  a  direct  result  of  treatment  with 
praziquantel.  After  exposure  to  re-infection,  scra  from  susceptible  individuals  showed 
more  frequent  recognition  of  antigens  at  74  (33%),  65  (8%)  and  4547kDa  (81yo) 
compared  to  the  recognition  patterns  prior  to  treatment.  Sera  from  resistant  individuals 
showed  less  frequent  recognition  of  the  same  antigens  (14,14  and  24%,  respectively) 
than  the  recognition  prior  to  treatment. 
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Figure  4.6  Differences  in  the  IgGI  recognition  pattern  after  exposure  to  reinfection  compared  to 
the  recognition  pattern  prior  to  praziquantel  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  exposure  to  infection  in  both  resistant  and  susceptible  groups  and  the 
differences  plotted. 
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Figure  4.7  Differences  in  the  IgGI  recognition  pattern  three  months  after  praziquantel  treatment 
compared  to  the  recognition  pattern  prior  to  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  treatment  in  both  resistant  and  susceptible  groups  and  the  differences 
plotted. 
4.3.5  Antigen  recognition  by  IgG2  antibodies 
Few  proteins  from  the  parasite  were  recognised  by  IgG2  in  the  serum  samples  from  the 
resistant  and  susceptible  groups.  IgG2  antibodies  in  sera  from  control  indIvIduals  did 
not  recognise  any  parasite  antigen. 
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Before  treatment  with  PZQ,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  a  133  (7Vo),  123  (7%),  74  (14%),  45-47kDa  (7%)  compared  to 
the  recognition  pattern  in  the  susceptible  individuals. 
After  treatment  with  PZQ,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  150  (8%),  133  (8%),  123  (8/o),  45-47  (17?  /o),  42  (17%o),  28-30 
(17%)  and  23  (8%)  and  less  frequent  recognition  of  antigens  at  52-54  (7%)  compared  to 
the  recognition  pattern  in  the  resistant  individuals. 
After  exposure  to  reinfection,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  84  (11%),  28-30  (8%)  and  26  (8%)  compared  to  the 
recognition  pattern  in  the  resistant  individuals. 
Impact  of  treatment  and  reinfection  on  antigen  recognition 
After  treatment  with  PZQ,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  most  antigens  particularly  of  antigens  at  78  (17%),  74  (17%),  45-47 
(17%),  42  (17%)  and  28-3OkDa  (17%)  compared  to  the  recognition  patterns  of  the  same 
individuals  prior  to  treatment.  Sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  78  (14%)  and  52-54kDa  (7%)  and  less  frequent  recognition  of 
antigens  at  133  (71/o)  and  123  (7%)  compared  to  the  recognition  patterns  of  the  same 
individuals  prior  to  treatment  (see  figure  4.9). 
After  exposure  to  reinfection,  sera  from  resistant  individuals  showed  less  frequent 
recognition  of  antigens  at  78  (70/o),  74  (7%),  52-54  (7%),  and  4547kDa  (7%)  and  more 
frequent  recognition  of  the  antigen  at  42kDa  (7%)  compared  to  the  recognition  pattern 
of  the  same  individuals  after  treatment.  Sem  from  susceptible  individuals  showed  less 
166 frequent  recognition  of  most  antigens  especially  of  antigen  at  45-47  (17%)  and  more 
frequent  recognition  of  antigens  at  84  (8%)  and  26kDa  (8%)  compared  to  the 
recognition  pattern  after  treatment. 
When  comparing  the  recognition  pattern  after  exposure  to  reinfection  with  the  pre- 
treatment  recognition,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  84  (8%),  78  (8*/o),  74  (8%),  42  (M),  28-30  (8%)  and  26kDa 
(8%)  compared  to  samples  taken  from  the  same  individuals  prior  to  treatment.  Sera 
from  resistant  individuals  showed  more  frequent  recognition  of  antigens  at  78  (8%)  and 
42kDa  (8%)  and  less  frequent  recognition  of  antigens  at  133  (8%),  123  (8%),  74  (M) 
and  45-47kDa  (8%)  compared  to  the  recognition  patterns  prior  to  treatment  (see  figure 
4.8). 
These  results  showed  that  while  the  effect  of  treatment  with  PZQ  on  the  recognition 
pattern  of  the  resistant  individuals  was  heterogeneous,  there  was  a  general  pattern  of 
increased  IgG2  recognition  of  parasite  antigens  in  the  susceptible  individuals  as  a  direct 
result  of  treatment  with  praziquantel.  After  exposure  to  re-infection,  sera  from 
susceptible  individuals  showed  more  fi-equent  recognition  of  antigens  at  74kDa 
compared  to  the  recognition  patterns  prior  to  treatment.  Sera  from  resistant  individuals 
showed  less  frequent  recognition  of  the  same  antigen. 
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Figure  4.8  Differences  in  the  IgG2  recognition  pattern  after  exposure  to  reinfection  compared  to 
the  recognition  pattern  prior  to  praziquantel  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  exposure  to  infection  in  both  resistant  and  susceptible  groups  and  the 
differences  plotted. 
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Figure  4.9  Differences  in  the  IgG2  recognition  pattern  three  months  after  praziquantel  treatment 
compared  to  the  recognition  pattern  prior  to  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  treatment  in  both  resistant  and  susceptible  groups  and  the  differences 
plotted. 
4.3.6  Antigen  recognition  by  IgG3  antibodies 
Most  of  the  proteins  from  the  parasite  were  recognised  by  IgG3  in  at  least  some  of  the 
serum  samples  from  the  resistant  and  susceptible  groups.  IgG3  antibodies  in  sera  from 
control  individuals  did  not  recognise  any  parasite  antigen. 
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Before  treatment  with  PZQ,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  proteins  at  123  (5%),  78  (6%),  65  (20%),  52-54  (28%),  45-47  (30%),  42 
(12%)  and  37kDa  (18%)  compared  to  sera  from  the  susceptible  individuals.  The 
susceptible  individuals,  on  the  other  hand,  showed  more  frequent  recognition  of 
antigens  at  186  (17%),  150  (12%),  95  (7%),  84  (27%),  74  (5%),  28-30  (43%),  26  (12%), 
23  (18%),  16-18  (29%)  and  II  kDa  (8%)  compared  to  the  resistant  group. 
Three  months  after  treatment  with  PZQ,  sera  from  resistant  individuals  showed  more 
frequent  recognition  of  antigens  at  170  (21%)  and  65kDa.  (27%)  compared  to  the 
susceptible  group.  Sera  from  susceptible  individuals  showed  more  frequent  recognition 
of  antigens  at  74  (180/6),  52-54  (14%),  45-47  (11%),  42  (19%),  26  (13%),  23  (20%),  16- 
18  (17%)  and  l3kDa  (20%)  compared  to  the  resistant  group. 
After  exposure  to  infection,  sera  from  susceptible  individuals  showed  more  frequent 
recognition  of  antigens  at  95  (20%)  and  74kDa  (20%)  compared  to  the  resistant  group. 
Sera  from  resistant  individuals  showed  more  frequent  recognition  of  antigens  at  186 
(7%),  170  (70/o),  84  (13%),  78  (14%),  65  (14%),  52-54  (3  1  O/o),  45-47  (11  O/o)  and  23kDa 
(19%)  compared  to  the  susceptible  group. 
Impact  of  treatment  and  reinfection  on  antigen  recognition 
IgG3  recognition  of  S  haematobium  adult  wonn  antigens  was  altered  in  both  resistant 
and  susceptible  groups  after  treatment  with  praziquantel.  Three  months  after  the 
treatment,  sera  from  resistant  individuals  showed  more  frequent  recognition  of  antigens 
at  186  (14%),  170  (14%),  28-30  (43%)  and  23kDa  (14%)  and  less  frequent  recognition 
of  antigens  at  95  (14%),  78  (14%),  74  (21%),  52-54  (42%),  45-47  (27%),  42  (14%)  and 
37kDa  (14%)  compared  to  the  frequency  of  recognition  patterns  of  the  same  individuals 
170 prior  to  treatment.  Sera  from  susceptible  individuals  showed  more  frequent  recognition 
of  antigens  at  45-47  (8/o),  42  (17%),  23  (17%)  and  l3kDa  (17%)  and  less  frequent 
recognition  of  antigens  at  186  (80/o),  150  (170/6),  95  (17%),  84  (33%)  and  28-3OkDa 
(M)  compared  to  the  recognition  patterns  observed  with  sera  taken  before  treatment 
(see  figure  4.11). 
After  exposure  to  re-infection,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  antigens  at  78  (14%),  74  (14%),  52-54  (28%),  4547  (21%),  37  (14%),  23 
(14%)  and  16-18kDa  (14%)  and  less  frequent  recognition  of  antigens  at  170  (14%),  150 
(14%),  133  (21%),  123  (21%)  and  65kDa  (21%)  compared  to  the  recognition  patterns  of 
the  same  individuals  after  treatment.  Sera  from  susceptible  individuals  showed  more 
frequent  recognition  of  antigens  at  74  (17%)  and  37kDa  (17%)  and  less  frequent 
recognition  of  antigens  at  133  (17Vo),  123  (17%),  52-54  (16%),  42  (17%),  26  (17%),  23 
(25%)  and  l3kDa  (17%)  compared  to  the  recognition  observed  after  treatment. 
When  comparing  the  recognition  after  exposure  to  re-infection  with  the  pre-treatment 
values,  sera  taken  from  resistant  individuals  after  exposure  to  re-infection  showed  more 
frequent  recognition  of  antigens  at  186  (70/o),  84  (7%),  28-30  (35%)  and  23kDa  (29%) 
and  less  frequent  recognition  of  antigens  at  150  (141yo),  133  (14%),  123  (140/o),  95 
(2  10/6),  74  (7%),  65  (14%)  and  4547kDa  (14%)  compared  to  the  recognition  patterns  of 
the  same  individuals  prior  to  treatment.  Sera  taken  from  susceptible  re-infected 
individuals  showed  more  frequent  recognition  of  antigens  at  74  (8%)  and  37kDa  (17%) 
and  less  frequent  recognition  of  antigens  at  186  (17%),  150  (25%),  133  (17%),  84 
(33%),  52-54  (17%),  28-30  (M),  23  (8%)  and  16-18kDa  (17%)  compared  to  the 
recognition  patterns  prior  to  treatment  (see  figure  4.10). 
These  results  illustrate  that  the  effect  of  praziquantel  treatment  on  the  humoral  immune 
response  to  schistosome  antigens  is  heterogeneous  with  much  variation  among 
171 individuals.  However,  sera  from  resistant  individuals  showed  a  trend  of  decreased 
recognition  against  antigens  of  medium  molecular  masses  (37  to  123kDa)  while  sera 
from  susceptible  individuals  showed  a  trend  of  decreased  recognition  against  antigens 
of  higher  molecular  masses  (74  to  186kDa).  After  12  months  of  exposure  to  re- 
infection,  sera  from  resistant  individuals  showed  increased  recognition  of  antigens  at 
28-30  (35%)  and  23kDa  (29%)  compared  to  the  recognition  prior  to  treatment.  Sera 
from  susceptible  individuals  showed  less  frequent  recognition  of  the  same  antigens  after 
the  same  period  of  exposure. 
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Figure  4.10  Differences  in  the  IgG3  recognition  pattern  after  exposure  to  reinfection  compared  to 
the  recognition  pattern  prior  to  praziquantel  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  exposure  to  infection  in  both  resistant  and  susceptible  groups  and  the 
differences  plotted. 
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Figure  4.11  Differences  in  the  IgG3  recognition  pattern  three  months  after  praziquantel  treatment 
compared  to  the  recognition  pattern  prior  to  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  treatment  in  both  resistant  and  susceptible  groups  and  the  differences 
plotted. 
4.3.7  Antigen  recognition  by  IgG4  antibodies 
After  western  blotting  and  probing,  the  percentage  of  serum  samples  of  each  group 
recognising  each  antigen  band  was  calculated.  Sera  from  control  individuals  did  not 
recognise  any  parasite  antigen. 
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Most  of  the  proteins  from  the  parasite  were  recognised  by  at  least  some  of  the  serum 
samples  from  the  resistant  and  susceptible  groups.  Before  treatment,  the  percentages  of 
recognition  of  different  antigens  were  generally  higher  in  the  susceptible  group  than  in 
the  resistance  group  with  antigens  of  molecular  masses  of  52-54  (31%),  4547  (52%), 
34  (35%),  28-30  (30%),  26  (27%)  and  16-18kDa  (33%)  being  the  most  frequently 
recognised.  Only  antigens  of  170  (6%)  and  65kDa  (14%)  were  recognised  more 
frequently  by  resistant  group  than  by  the  susceptible  group. 
Three  months  after  treatment  with  PZQ,  sera  from  susceptible  individuals  showed  a 
general  pattern  of  more  frequent  recognition  of  most  antigens  than  the  resistant  group 
particularly  of  antigens  at  74  (18'Yo),  45-47  (20'/o),  37  (26%),  34  (331yo),  26  (37%),  20 
(19%),  13  (38%)  and  IlkDa  (26%).  Sera  from  resistant  individuals  showed  more 
frequent  recognition  of  antigens  at  170  (21%)  and  150kDa  (19%)  compared  to  the 
susceptible  group. 
After  exposure  to  reinfection,  sera  from  the  susceptible  group  still  showed  more 
frequent  IgG4  antibody  recognition  of  a  wide  range  of  antigens  than  the  resistant  group. 
However  the  greatest  differences  were  in  the  recognition  of  antigens  at  74  (33%),  4547 
(40%)  and  42  (33'Yo),  28-30  (25Vo),  16-18  (30%),  13  (54%)  and  II  kDa  (33%). 
Impact  of  treatment  and  reinfection  on  antigen  recognition 
After  treatment  with  PZQ,  sera  from  resistant  individuals  showed  an  increased 
frequency  of  recognition  of  antigens  at  170  (71/o),  150  (21%),  133  (14%),  123  (7vo),  95 
(14%),  45-47  (70/o),  42  (14%),  26  (7%)  and  16-18kDa  (22%)  and  a  decreased  frequency 
of  recognition  of  antigens  at  84  (7%),  74  (14%),  34  (7%)  and  13kDa  (14%)  compared  to 
the  frequency  of  recognition  of  antigens  by  sera  from  the  same  patients  prior  to 
174 treatment.  Sem  from  susceptible  patients  showed  more  frequent  recognition  of  antigens 
at  133  (17),  123  (80/6),  65  (8),  42  (17Vo),  37  (259/6),  26  (170/6),  23  (80/6),  20  (80/o),  13 
(8%)  and  II  kDa  (17%)  compared  to  the  recognition  pattern  of  the  resistant  group  (see 
figure  4.13). 
After  exposure  to  infection  after  PZQ  treatment,  sera  from  resistant  individuals  showed 
a  decreased  frequency  of  recognition  of  most  antigens  except  antigens  at  84  (7'Yo)  and 
26kDa  (7%)  which  were  recognised  more  frequently  after  exposure  to  infection 
compared  to  the  recognition  pattern  after  treatment.  The  greatest  reductions  were  in  the 
recognition  of  antigens  at  150  (36%),  133  (29%),  123  (21%),  45-47  (37%),  42  (21%), 
28-30  (29%)  and  16-18kDa  (37%).  Sera  from  susceptible  patients  showed  decreased 
frequency  in  the  recognition  of  antigens  at  133  (25%),  123  (17%),  37  (25vo),  34  (17%), 
26  (33%)  and  23kDa  (25%)  and  increased  recognition  of  antigens  at  170  (8%),  84 
(17%),  74  (8%),  42  (8%)  and  l3kDa  (80/6). 
When  comparing  the  recognition  of  antigens  by  sera  of  infected  individuals  before 
treatment  and  after  exposure  to  re-infection,  sera  from  resistant  individuals  maintained  a 
reduced  frequency  of  recognition  of  most  antigens  after  exposure  to  re-infection  except 
the  antigens  at  95  (7%)  and  26kDa  (141/o)  which  showed  an  increase  in  the  percentage 
recognition.  On  the  other  hand,  sera  from  susceptible  individuals  showed  reduction  in 
the  percentage  recognition  of  all  protein  bands  except  those  of  84  (8%),  42  (25'Yo),  13 
(17%)  and  II  kDa  (17%)  (see  figure  4.12). 
These  results  showed  that  after  treatment  of  S  haemalobium  infection  with  praziquantcl 
there  was  heterogeneity  in  the  effect  of  treatment  on  IgG4  isotypc  reactivity.  AfIcr 
treatment,  some  antigen  bands  were  rccognised  more  frequently  and  others  less 
frequently  than  by  sera  taken  prior  to  treatment.  After  exposure  to  rc-infcction, 
individuals  who  were  not  re-infected  were  considered  resistant  and  their  serum  samples 
175 showed  a  decreased  percentage  recognition  of  antigens  at  42,13  and  II  kDa  and 
increased  percentage  recognition  of  the  26kDa  (14%)  antigens  compared  to  sera  from 
susceptible  individuals  who  were  reinfected  during  the  same  transmission  period. 
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Figure  4.12  Differences  in  the  IgG4  recognition  pattern  after  exposure  to  reinfection  compared  to 
the  recognition  pattern  prior  to  praziquantel  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  exposure  to  infection  in  both  resistant  and  susceptible  groups  and  the 
differences  plotted. 
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Figure  4.13  Differences  in  the  IgG4  recognition  pattern  three  months  after  praziquantel  treatment 
compared  to  the  recognition  pattern  prior  to  treatment. 
The  percentage  recognition  prior  to  treatment  was  extracted  from  the  percentage 
recognition  after  treatment  in  both  resistant  and  susceptible  groups  and  the  differences 
plotted. 
4.4  Discussion: 
While  several  control  measures  have  been  exploited  to  control  schistosome  infection 
chemotherapy  now  underpins  virtually  all  major  control  programmes.  Concern  for  the 
relatively  limited  use  of  anthelminthics  in  areas  that  are  endemic  for  the  major  parasitic 
worrns  has  led  the  World  Health  Assembly  to  adopt  resolution  54.19  to  encourage 
WHO  member  states  to  seek  to  achieve  75%  deworining  of  schoolchildren  by  2010.  In 
177 response  to  the  resolution,  a  number  of  countries  in  sub-Saharan  Africa  have 
implemented  chemotherapy-based  control  activities.  However,  the  occurrence,  though 
limited,  of  schistosome  strains  with  lower  susceptibility  to  chemotherapy  and  the 
occurrence  of  reinfection  after  chemotherapy  are  major  concerns  for  the  long-term 
sustainability  of  chemotherapy  as  the  sole  tool  for  control  (Hagan  and  Sharaf,  2003). 
Although  the  most  important  impact  of  chemotherapy  is  the  removal  of  worms,  eggs  or 
larval  stages  that  are  responsible  for  the  induction  of  pathology,  recent  studies  have 
indicated  that  anti-schistosomal  drugs  particularly  praziquantel,  may  alter  the  immune 
responses  to  infection.  For  example  children,  considered  to  be  potentially  susceptible  to 
reinfection  had  their  immune  responses  profiles  modified  after  treatment  with 
praziquantel  in  such  a  way  that  they  were  similar  to  those  of  adults  considered  to  be 
resistant  to  reinfection  (Mutapi  et  al.,  1998;  Mduluza  et  al.,  2001).  In  addition  there  is 
strong  evidence  supporting  the  view  that  in  communities  treated  with  PZQ  there  was  a 
decrease  in  the  prevalence  and  intensity  of  infection  which  has  obvious  benefits  for  the 
population  (Gryseels  and  Nkulikyinka,  1989;  Talaat  and  Miller,  1998;  Abu-Elyazeed  el 
al.,  1998;  Campagne  et  al.,  200  1). 
It  is  generally  accepted  that  in  order  to  achieve  satisfactory,  long-term  and  sustainable 
control  of  schistosome  infection,  several  control  measures  will  have  to  be  employed. 
Vaccination  has  been  used  as  a  very  powerful  tool  for  the  control  of  many  bacterial  and 
viral  diseases.  Over  the  last  two  decades,  several  attempts  have  been  made  to  develop 
and  test  an  efficacious  anti-schistosome  vaccine.  The  complex  life  cycle  and  the 
antigenic  complexity  of  each  life  stage  as  well  as  the  complex  network  of  immune 
responses  elicited  by  schistosome  infection  are  major  obstacles  to  the  development  of 
such  a  vaccine.  Nevertheless,  a  number  of  promising  vaccine  antigens  have  been 
identified.  Some  have  been  tested  in  animal  models,  and  at  least  one  has  reached  phase 
Il  clinical  trials  for  safety  and  immunogcnicity  in  humans.  Vaccine  candidate  antigens 
178 have  been  identified  in  a  number  of  ways,  by  screening  DNA  libraries  with  serum  from 
infected  animals  or  animals  that  had  been  immunised  against  infection  with  irradiated 
parasites.  Serum  from  such  animals,  or  from  humans  naturally  exposed  to  infection  (and 
considered  to  be  resistant  to  infection),  has  also  been  used  to  screen  for  parasite  antigen 
recognition  by  immunoprecipitation  using  protein  A  or  protein  0  Sepharose  or  that  have 
been  separated  by  SDS-PAGE,  in  one  or  two  dimensions  and  blotted  to  nitrocellulose. 
The  identification  of  vaccine  candidate  antigens  using  human  serum  has  been  facilitated 
by  attempts  to  determine  immunological  correlates  of  resistance  to  reinfection  in 
immunoepidemiological  studies  in  humans  (Butterworth  et  al.,  1996).  Serum  samples 
from  studies  that  have  demonstrated  a  degree  of  resistance  to  infection  in  naturally 
exposed  individuals  has  obvious  value  for  screening  schistosome  antigens. 
The  serum  samples  exploited  in  the  present  study  were  obtained  from  an 
immunoepidemiological  study  by  Hagan  and  his  colleagues  (1991)  that  gave  the  first 
clear  immune  correlation  between  the  parasite  specific  IgE  and  IgG4  and  the  resistance 
or  susceptibility  to  reinfection  with  S.  haematobium.  They  reported  that  parasite  specific 
IgE  correlated  with  resistance  to  reinfection  while  IgG4  correlated  with  susceptibility  to 
reinfection  (Hagan  et  al.,  1991).  The  present  study  was  designed  to  investigate  the 
differences  in  antigen  recognition  between  potentially  resistant  individuals  and 
potentially  susceptible  individuals  after  exposure  to  reinfection  with  S.  haemaloblum. 
The  effect  of  treatment  with  praziquantel  on  the  immune  responses  of  resistant  and 
susceptible  individuals  was  also  investigated. 
Before  discussing  the  results  of  the  present  study,  it  is  important  to  note  that  the 
molecular  weights  of  the  proteins  reported  herein  may  vary  slightly  from  the  reported 
molecular  weights  obtained  in  other  studies.  17his  is  due  to  the  limitations  of  the  SDS- 
PAGE  technique  in  making  precise  determinations  of  molccular  weights  of  proteins. 
Even  with  the  two  dimensional  SDS-PAGE  and  mass  spectrometry,  which  is  a  far 
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error  factor  of  up  to  2%  of  the  molecular  weight  of  the  identified  protein  (Berg  et  al., 
2002b).  It  is  worth  mentioning  that  schistosomes  share  most  of  their  antigens  as 
evidenced  by  their  cross  reactivity.  Several  studies  confirmed  the  reactivity  of  sera  or 
lymphocytes  obtained  from  hosts  infected  with  one  schistosome  species  with  antigenic 
preparations  from  the  other  schistosome  species  (Abdel-Hafez  et  aL,  1983;  Barral-Netto 
et  al.,  1983;  Amanor  et  al.,  1996).  Using  immunoprecipitation  techniques,  it  was 
reported  that  the  immune  responses  of  patients  infected  with  S.  mansoni  or  S. 
haematobium  were  so  similar  that  differentiation  could  not  be  established  easily 
(Norden  and  Strand,  1984).  However,  some  species-specific  antigens  were  identified  for 
each  schistosome  species  (Kelly  et  al.,  1987;  Amanor  et  al.,  1996). 
The  effect  of  treatment  with  PZQ  on  the  recognition  pattern  of  &  haemajobium  SWAP 
by  IgM  antibodies  was  heterogeneous  in  both  resistant  and  susceptible  individuals  with 
some  antigens  being  recogriised  more  frequently  and  others  less  frequently,  three 
months  after  treatment,  compared  to  the  recognition  pattern  prior  to  treatment.  However 
when  the  same  individuals  were  exposed  to  reinfection,  sera  from  infected  individuals 
maintained  more  frequent  recognition  of  antigens  at  4547,42,37,34  and  28-3OkDa. 
Sera  from  resistant  individuals  recognised  these  antigens  less  frequently  compared  to 
the  recognition  three  months  after  treatment  or  prior  to  treatment.  One  possible 
interpretation  of  these  data  is  that  the  reduction  in  IgM  recognition  may  be  a 
contributory  factor  in  rendering  these  individuals  resistant  to  reinfection.  In  the 
susceptible  individuals,  the  enhanced  recognition  of  these  antigens  by  IgM  may 
compete  with  potentially-protective  antibodies  rendering  these  individuals  susceptible 
to  reinfection.  These  results  and  this  interpretation  arc  consistent  with  the  reported  role 
of  IgM  as  a  blocking  antibody  (Butterworth  et  al.,  1987;  Ndhlovu  el  al.,  1996). 
180 Three  months  after  treatment  with  PZQ,  sera  from  susceptible  individuals  showed  more 
recognition  of  almost  all  antigens  except  the  28-3OkDa  antigen  by  IgGI  antibody 
isotype  compared  to  the  recognition  prior  to  treatment.  When  the  same  individuals  were 
reinfected.  they  failed  to  maintain  the  higher  levels  of  recognition  and  showed  a  further 
reduction  in  the  recognition  of  the  antigen  of  28-3OkDa.  The  effect  of  treatment  on  the 
recognition  pattern  of  sera  from  resistant  individuals  was  heterogeneous.  The  greatest 
increase  in  the  recognition  was  the  recognition  of  the  antigen  at  28-3OkDa.  However, 
the  resistant  individuals  failed  to  maintain  this  increased  recognition  after  exposure  to 
reinfection.  The  boost  in  recognition  of  the  28-3OkDa  antigens  after  treatment  may  have 
contributed  to  the  observed  protection.  While  the  treatment  boosted  the  responses  it 
seems  that  it  was  insufficient  to  stimulate  a  long-term  increase  in  antibodies  against  this 
antigen.  Others  have  speculated  that  in  order  to  acquire  sufficient  levels  of  protective 
antibody  isotypes,  several  episodes  of  schistosome  infection  (Li  el  al.,  2002)  or  repeated 
chemotherapy  (Mduluza  et  al.,  2001)  may  be  required. 
After  treatment  with  PZQ,  the  recognition  of  S.  haematobium  SWAP  by  IgG3  in  sera 
from  resistant  and  susceptible  individuals  showed  heterogeneous  changes.  The  most 
striking  effects  of  treatment  on  the  recognition  pattern  were  increased  frequency  of 
recognition  of  antigens  of  23  and  28-3OkDa  of  both  resistant  and  susceptible 
individuals.  However,  while  sera  from  resistant  individuals  maintain  the  increased 
recognition  after  exposure  to  reinfection,  sera  from  susceptible  individuals  failed  to 
maintain  such  response.  These  observations  favour  the  possibility  that  PZQ  may  have, 
albeit  temporarily,  an  immunising  effect  (Mutapi  et  al.,  1998;  Woolhousc  and  I  lagan, 
1999;  Mutapi  et  al.,  2003).  However,  although  the  present  study  provided  an  evidence 
for  this  hypothesis,  other  factors  may  be  involved  in  the  difference  in  the  immune 
responses  between  resistant  and  susceptible  individuals.  The  resistant  individuals  (mean 
age  35±13.5  years)  of  the  present  study  are  significantly  older  than  the  susceptible 
181 individuals  (mean  age  8.2±3  years).  Ile  protective  response  of  the  resistant  individuals 
observed  in  the  present  study  may  result  from  prolonged  experience  of  the  immune 
system  of  those  individuals  with  parasite  antigens  released  from  naturally  dying 
parasites  and  repeated  infection  rather  than  the  release  of  these  antigens  in  response  to 
enhanced  parasite  death  by  the  chemotherapy  (Hagan  et  al.,  1985;  Butterworth  et  al., 
1985;  Woolhouse  et  al.,  199  1;  Fulford  et  al.,  1992)  or  it  may  be  attributed  to  age  per  se 
(van  dam  et  al.,  1996;  Ouma  et  al.,  1998). 
In  the  present  study,  the  majority  of  antigens  were  less  frequently  recognised  at  all  time 
points  by  IgG4  antibody  isotype  of  sera  from  resistant  individuals  compared  to  sera 
from  susceptible  individuals.  Although  sera  from  both  resistant  and  susceptible 
individuals  showed  heterogeneous  changes  in  the  recognition  pattern  in  response  to 
treatment  with  PZQ,  the  recognition  of  most  antigens  became  less  frequent  after 
exposure  to  reinfection  in  sera  from  resistant  individuals  compared  to  susceptible 
individuals.  These  results  agree  with  the  proposed  role  of  IgG4  as  a  blocking  antibody 
during  schistosome  infections  (Hagan  et  al.,  1991;  Demeure  el  al.,  1993;  Ndh1ovu  et  al., 
1996).  Similar  effects  of  treatment  with  PZQ  on  the  recognition  of  S.  mansoni  SWAP 
by  IgG4  antibody  isotye  were  reported  by  Satti  and  colleagues.  They  reported  that  the 
resistant  group  maintained  the  same  level  of  IgG4  to  SWAP  after  treatment  compared  to 
a  significant  increase  in  the  susceptible  group  (Satti  el  al.,  1996).  Furthermore,  Mduluza 
and  colleagues  treated  children  aged  under  six  years  of  age  and  living  in  a  S. 
haematobium  endemic  area  with  praziquantel  every  eight  weeks  for  two  years. 
Chemotherapy  reduced  infection  prevalence  and  mean  intensity  of  infection.  no 
immunoglobulin  levels  changed  during  the  course  of  treatment  with  a  shift  towards 
'protective'  mechanisms.  The  significant  changes  noted  in  some  individuals  were  the 
drop  in  'blocking'  IgG2  and  IgG4  whereas  the  'protecting!  IgA  and  IgGl  levels 
182 increased.  However,  the  antibody  profiles  in  the  rest  of  the  children  remained  generally 
unchanged  throughout  the  study  (Mduluza  et  aL,  2001). 
The  recognition  of  the  majority  of  antigens  by  total  IgG  antibodies  were  more  frequent, 
prior  to  treatment  with  PZQ,  in  sera  from  resistant  individuals  compared  to  sera  from 
susceptible  individuals.  Three  months  after  treatment,  the  recognition  pattern  changed 
with  most  antigens  being  more  frequently  recognised  by  sera  from  susceptible 
individuals  than  resistant  individuals.  Because  of  the  preponderance  of  IgG4  antibodies 
in  the  serum  of  infected  individuals,  the  pattern  of  recognition  obtained  from  the  blots 
when  assessing  the  total  IgG  antibody  responses  will  be  dominated  by  the  antigens  that 
are  recognised  by  IgG4.  In  practice  therefore  the  patterns  of  antigen  recognition 
obtained  for  total  IgG  and  IgG4  were  virtually  similar. 
Interestingly,  some  of  the  known  vaccine  candidates  were  highly  immunogenic  and 
frequently  recognised  by  different  antibody  isotypes  from  the  serum  samples  employed 
in  the  present  study.  The  recognition  of  these  vaccine  candidates  was  different  between 
resistant  and  susceptible  individuals  with  some  antigen  specific  antibody  isotypcs  being 
associated  with  resistance  and  others  associated  with  susceptibility  to  reinfection.  After 
exposure  to  reinfection,  sera  from  resistant  individuals  showed  a  higher  frequency  of 
recognition  of  the  antigen  of  28-3OkDa  by  IgG3  antibody  isotype  compared  to  the 
susceptible  individuals.  The  28-3OkDa  antigen  band  recognised  in  this  study  may 
correspond  to  glutathione-S-transferase  (GSI)  which  has  been  idcntificd  in  all 
schistosome  species  as  a  major  enzyme  acting  as  an  antioxidant  and  involved  in 
detoxification  of  xenobiotics.  GST  is  one  of  the  leading  vaccine  candidate  antigens. 
GST  was  tested  in  independent  trials  in  animals  that  were  coordinated  by  WHO.  Like 
the  other  vaccine  candidate  antigens  it  failed  to  give  greater  than  the  40%  level  of 
protection  that  had  been  set  as  the  cut-off  for  success.  Nonetheless  in  infected  human 
populations,  schistosome  anti-fecundity  immunity  has  been  associated  with  JgA  and 
183 IgG3  responses  (Riveau  et  al.,  1998;  Remoue  et  al.,  2000)  directed  against  GST.  In 
phase  I  clinical  trials  it  was  found  that  following  3  injections  of  Mpg  of  S. 
haematobium  GST  in  alum  hydroxide  as  adjuvant  (Bilhvax),  a  strong  IgG  inunune 
response  was  elicited  in  immunised  individuals.  Analysis  of  isotypic  profile  revealed 
high  levels  of  IgGl,  IgG3  and  low  levels  of  IgG2  and  IgA  (Capron  et  aL,  2002). 
On  the  other  hand,  after  exposure  to  reinfection,  sera  from  susceptible  individuals 
showed  higher  recognition  of  the  28-3OkDa  antigen  by  the  IgM,  IgG2  and  IgG4 
antibody  isotypes  compared  to  the  resistant  individuals.  These  results  are  in  agreement 
of  those  of  Al-Shcrbiny  and  colleagues  (2003).  They  investigated  the  cellular  and 
humoral  immune  responses  of  peripheral  blood  lymphocytes  from  individuals  resistant 
or  susceptible  to  reinfection  with  S.  manson!  in  response  to  in  vitro  stimulation  with 
SM28-GST.  They  reported  that  increased  levels  of  antigen  specific  IgA  and  IgE  were 
associated  with  resistance  while  IgG2  and  IgM  antibodies  were  associated  with 
susceptibility  to  infection  (Al  Sherbiny  el  aL,  2003).  The  increased  IgG4  recognition  in 
the  susceptible  group  may  interfere  with  the  neutralising  effects  of  the  protective 
isotypes  rendering  them  more  susceptible  to  reinfection.  It  has  been  demonstrated  that 
IgG4  antibodies  may  compete  with  the  protective  antibodies  for  the  recognition  of  the 
same  antigens  and  thus  act  as  blocking  antibodies  (Butterworth  el  al.,  1987;  1  lagan  el 
al.,  1991;  Demeure  et  aL,  1993). 
In  the  present  study,  sera  from  resistant  individuals  exposed  to  reinfection  showed  more 
frequent  recognition  of  antigens  at  23kDa  by  IgG3  antibody  compared  to  scra  from 
susceptible  individuals.  These  results  appear  to  parallel  those  of  Webster  and  collcagucs 
(1996).  They  reported  that  the  recognition  of  the  rSm22  (rSm22.6)  by  human  IgG3, 
IgG4,  IgE  and  IgA  was  increased  in  a  group  of  naturally  exposed  individuals  considercd 
to  be  resistant  to  reinfection.  However,  only  the  IgE  antibody  response  against  this 
antigen  was  significantly  correlated  with  resistance  to  reinfection  aftcr  treatment 
184 (Webster  et  al.,  1996).  In  vitro  stimulation  of  lymphocytes  from  the  peripheral  blood  of 
individuals  resistant  to  infection  with  S.  mansoni  showed  preferential  production  of 
IgG3  in  response  to  stimulation  with  multiple  antigenic  pepticles  (MAP3)  from  the 
integral  membrane  antigen  Sm23  (Al  Sherbiny  et  aL,  2003). 
in  the  present  study,  IgM,  IgG3  and  IgGI  antibodies  of  scra  from  resistant  individuals 
showed  more  frequent  recognition  of  the  antigen  of  84kDa  compared  to  the  susceptible 
individuals.  The  84kDa  antigen  could  be  the  S.  haematobium  equivalent  of  the  calcium 
binding  protein  (Calpain  Sm-p80)  which  was  reported  by  Hota-Michell  and  colleagues 
(1997).  They  reported  that  recombinant  Sm-p80  provided  a  29-39%  reduction  in  worm 
burden  when  they  immunised  mice  and  challenged  them  with  S  mansoni.  The 
recombinant  Sm-p80  was  recognised  by  IgA,  19M,  IgGl,  and  IgG3  isotype  antibodies 
found  in  S.  mansoni-infected  humans  (Hota-Mitchell  et  al,  1997).  DNA  immunisation 
using  Sm-p80  with  or  without  plasmids  encoding  granulocyte-macrophage  colony- 
stimulating  factor  (GM-CSF)  and  interleukin-4  (IL-4)  were  tried  in  mice.  'Fhe  protection 
achieved  with  administration  of  GM-CSF  DNA  with  Sm-p80  DNA  was  associated  with 
distinct  increases  in  total  IgG  and  IgGI  titers,  whereas  the  coadministration  of  IL-4 
DNA  with  Sm-p80  DNA  resulted  in  a  slight  elevation  of  IgG  I  and  IgG3  titers  (Siddiqui 
et  al.,  2003). 
After  exposure  to  reinfection,  sera  from  resistant  individuals  showed  more  frequent 
recognition  of  the  antigen  of  65kDa  by  IgM  and  IgG3  compared  to  sera  from 
susceptible  individuals.  It  is  possible  to  speculate  that  this  antigen  band  may  correspond 
to  the  68kDa  antigen  from  S.  mansoni  (SmW68)  reported  by  King  and  colleagues.  Tlicy 
found  a  negative  correlation  between  intensity  of  infection  and  the  recognition  of  tile 
SmW68  antigen  by  IgM  antibodies  in  chronically  infected  individuals  (King  et  al., 
1989). 
185 One  of  the  most  frequently  recognised  antigen  bands  in  the  present  study  was  that  of 
95kDa  which  is  most  likely  the  S.  haematobium  equivalent  of  paramyosin  (97kDa). 
Paramyosin  is  a  myofibrillar  protein  found  exclusively  in  invertebrates  and  has  been 
identified  in  all  schistosome  species  (McManus,  1999).  The  95kDa  antigen  was  highly 
recognised  by  all  antibody  isotypes  of  sera  from  both  susceptible  and  resistant 
individuals.  However,  sera  form  resistant  individuals  showed  more  frequent  recognition 
of  the  95kDa  band  by  IgG1  and  IgM  and  less  frequent  recognition  by  total  IgG  and 
IgG3  compared  to  the  susceptible  individuals,  after  exposure  to  reinfection.  In  a  small 
community  infected  with  S.  japonicum  there  was  a  higher  recognition  of  paramyosin  by 
IgA  antibodies  in  older  putatively  resistant  individuals  (Hernandez  et  aL,  1999). 
Futhermore,  oral  immunisation  of  mice  with  recombinant  S.  japonicum  paramyosin 
elicited  significantly  increased  levels  of  antigen  specific  IgGI,  IgG2a,  IgG2b  and  IgM 
(Kalinna  and  McManus,  1997).  In  vitro  stimulation  of  peripheral  blood  lymphocytes 
from  infected  individuals  with  Sm97-paramyosin  revealed  association  bctwccn  antigen 
specific  IgE  and  resistance  and  between  total  IgG,  IgG  I,  IgG2,  IgG3,  IgG4  and  IgA  and 
susceptibility  to  reinfection  (Al  Sherbiny  et  al.,  2003). 
Ile  antigen  band  of  52-54kDa  was  represented  as  a  strong  band  on  the  SDS-PAGE. 
After  exposure  to  reinfection,  sera  from  resistant  individuals  showed  more  frcqucnt 
recognition  of  the  52-54kDa  band  by  IgG3  and  IgM  antibodics  compared  to  the 
susceptible  individuals.  This  antigen  band  may  correspond  to  the  PR52-filamin.  In  mice 
vaccinated  with  DNA  of  the  partial  coding  sequence  of  the  structural  protein,  filamin 
lead  to  50%  protection.  The  protection  offered  was  associated  with  clcvatcd  IcvcIs  of 
total  IgG  and  IgG2a  antibodies  (Cook  et  al.,  2004). 
The  37kDa  band  in  the  present  study  which  May  correspond  to  glyccraldchydc-3- 
phosphate  dehydrogenase  (G3PDH)  was  more  frequently  recogniscd  by  IgM  and  JgG4 
antibody  isotypes  of  sera  from  susceptible  individuals  than  resistant  individuals.  After 
186 exposure  to  reinfection,  while  sera  from  the  susceptible  individuals  showed  more 
frequent  recognition  of  the  37kDa  antigen  by  total  IgG,  IgGl  and  IgG3  isotypes 
compared  to  the  recognition  prior  to  treatment,  sera  from  the  resistant  individuals 
showed  less  recognition.  However  when  the  percentage  recognition  of  both  resistant 
and  susceptible  individuals  was  directly  compared,  there  was  a  tendency  of  more 
frequent  recognition  of  this  antigen  by  IgGl  and  IgG3  isotypes  for  sera  taken  from  the 
resistant  individuals.  I'liese  results  are  correspondent  to  those  of  EI-Ridi  and  colleagues. 
They  investigated  the  recognition  patterns  of  the  recombinant  G3PDII  as  well  as 
different  peptides  from  this  molecule.  They  used  sera  from  adolescent  individuals 
resistant  or  susceptible  to  reinfection  with  schistosome  infection.  The  antigen  was 
recognised  more  frequently  by  IgG4  and  IgM  antibody  isotypes  of  sera  from  susceptible 
individuals  while  there  was  more  recognition  by  IgG,  IgGl  and  IgG3  isotypes  of  sera 
from  resistant  individuals  (El  Ridi  et  aL,  2001a;  El  Ridi  el  al.,  2001b).  Similarly,  IgGl 
antibodies  from  sera  of  resistant  individuals  recogniscd  one  of  the  B  cell  dcten-ninants 
of  S.  mansoni  G3PDH  (Sm  37-5)  more  than  sera  from  susceptible  individuals  (Argiro  et 
al.,  2000). 
There  were  some  other  antigens  that  were  recogniscd  with  patterns  that  might  be 
expected  of  antigens  that  were  contributing  to  protection.  For  instance,  the  antigen  of 
16-18kDa  was  more  frequently  recogniscd  by  the  IgG3  isotypc  of  scra  from  resistant 
individuals  after  exposure  to  reinfection  compared  to  the  susceptible  group.  Scra  from 
the  susceptible  group  showed  more  frequent  recognition  of  the  same  antigen  by  JgG4 
and  IgM  antibodies  after  exposure  to  reinfection.  Ibis  antigen  may  correspond  to  PN  18- 
cyclophillin.  Al  Sherbiny  and  others  investigated  the  in  vitro  response  of  peripheral 
blood  lymphocytes  from  resistant  and  susceptible  individuals  after  stimulation  with 
pNI8-cyclophillin.  Resistance  to  reinfection  was  correlated  with  increased  levels  of 
antigen  specific  IgGlantibody  isotye  (Al  Sherbiny  et  al.,  2003). 
187 Furthermore,  sera  from  susceptible  individuals  showed  more  recognition  of  antigen  of 
45-47kDa  by  total  IgG,  IgGl,  IgG3  and  IgM  antibodies  after  exposure  to  reinfection 
compared  to  sera  from  resistant  individuals.  This  antigen  may  correspond  to  PIAS- 
phosphoglycerate  kinase.  After  in  vitro  stimulation  of  peripheral  blood  lymphocytes 
from  resistant  and  susceptible  individuals  by  PL45-phosphoglyccrate  kinase  revealed 
correlation  of  IgE  with  resistance  and  IgGI  with  susceptibility  to  reinfection  (Al 
Sherbiny  et  al.,  2003). 
It  should  also  be  mentioned  that  there  is  a  consensus  that  IgE  antibody  is  one  of  the 
most  important  antibody  involved  in  the  resistant  to  schistosome  infection  in  humans 
and  it  has  been  correlated  with  resistance  to  human  reinfection  with  schistosome 
infection  in  many  immunoepiderniological  studies  including  the  study  from  which  the 
sera  of  the  present  study  were  obtained  (Hagan  et  aL,  1991).  The  procedure  applied  for 
investigating  the  recognition  patterns  of  S.  haemalobium  SWAP  by  IgM  and  different 
IgG  isotypes  were  used  for  the  IgE  antibody.  Despite  the  use  of  higher  concentrations  of 
serum  samples  and  secondary  antibodies,  no  recognition  by  IgE  antibody  was  achieved 
in  the  present  study.  The  recognition  patterns  by  IgA  antibody  were  not  investigated  in 
the  present  study  essentially  because  of  the  limited  quantities  of  the  serum  samples. 
In  conclusion  the  work  presented  in  this  chapter  has  demonstrated  that: 
1.  The  treatment  with  PZQ  can  cause  alteration  of  the  immune  rcsponscs  from 
responses  characteristic  of  susceptible  individuals  to  protective  responses. 
2.  Most  of  the  identified  vaccine  candidates  were  recognised  by  sera  from  putativcly 
resistant  individuals  by  inunune  responses  characteristic  of  protcction. 
3.  The  28-3OkDa  antigen  (ShGST)  was  rccognised  more  frequently  by  IgG3  of  sera 
from  resistant  individuals  and  by  IgM,  IgG2  and  IgG4  in  susceptible  individuals. 
188 4.  The  23kDa.  antigen  was  recognised  more  frequently  by  IgG3  of  scra  from  resistant 
individuals. 
5.  The  95kDa  (paramyosin)  was  recognised  more  frequently  by  IgM  and  IgG  I  of  scra 
from  resistant  individuals. 
6.  The  84kDa  (Calpain)  was  recognised  more  frequently  by  IgM,  IgG  I  and  IgG3  of  sera 
from  resistant  individuals. 
189 Chapter  Five 
General  Discussion Human  schistosomiasis  is  one  of  the  most  important  parasitic  diseases  and  it  constitutes 
a  major  health  problem  in  many  areas  in  the  world  especially  in  sub-Saharan  Aftica. 
Although  several  measures  have  been  used  to  control  the  infection,  chemotherapy  is  still 
the  cornerstone  for  the  most  successfid  control  programs  around  the  world.  Praziquantel 
is  now  the  drug  of  choice  for  treatment  of  all  schistosome  species  infecting  humans  and 
has  been  used  in  mass  chemotherapy  scale  in  control  programmes  in  many  areas 
(Magnussen,  2003;  Hagan  et  aL,  2004).  Ile  exact  mode  of  action  of  PZQ  is  not  fully 
understood.  However,  the  most  important  effects  of  PZQ,  the  tegumental  damage  and 
muscular  contraction,  have  been  attributed  to  its  effects  on  calcium  influx  and 
redistribution.  Other  effects  including  its  effects  on  the  metabolic  pathways  of  the 
parasite  have  been  proposed  (Cioli  et  aL,  1995). 
However,  because  of  the  limited  efficacy  of  praziquantel  on  the  immature  stages  of 
schistosomes  (Sabah  et  al.,  1986)  there  is  a  high  probability  of  missing  some  of  the 
infected  population  thus  ensuring  the  continued  transmission  of  the  disease.  Although 
repeated  doses  of  praziquantel  and  combination  chemotherapy  regimens  can  help 
reduce  this  Problem,  this  appears  to  be  impractical  for  control  programs  in  the  endemic 
areas.  Furthermore,  the  appearance  of  schistosome  strains  with  decreased  susceptibility 
to  the  effects  of  praziquantel  (Ismail  et  al.,  1996)  has  cmphasised  the  necessity  for 
investigation  and  discovery  of  new  drugs  for  treatment  of  schistosomiasis  (Cioli,  2000). 
In  the  last  few  years,  Mirazie,  an  extract  of  myrrh,  has  been  devclopcd  and  liccnsed  for 
use  for  the  treatment  of  human  schistosomiasis.  Since  then,  thcrc  has  bccn  a  lot  of 
debate  in  the  scientific  communities  about  the  real  potential  for  its  cfficacy  against 
schistosome  infections.  In  the  present  study,  the  effects  of  MZD  against  S.  mansoni 
were  investigated  both  in  vitro  and  in  vivo,  comparcd  to  the  standard  drug  PZQ.  I'lic 
effects  of  both  drugs  on  the  hosts'  immune  responses  to  schistOsOme  infection  wcre  also 
191 investigated.  Finally,  the  effects  of  in  vitro  exposure  to  both  drugs  on  the  protein 
expression  of  the  parasite  were  investigated. 
The  in  vitro  effects  of  both  drugs  on  the  viability  of  schistosomula  of  S  manson!  were 
investigated  using  the  toluidine  blue  dye  exclusion  test  and  the  Hoechst  test.  The 
principle  of  these  tests  is  that  intact  parasite  membrane  is  impermeable  to  these  dyes 
and  hence  only  damaged  or  dead  parasites  will  be  stained  (Modha  et  al.,  1997).  The 
effects  on  the  fluidity  of  the  outer  membrane  of  the  parasite,  which  is  important  for 
many  biochemical  processes,  were  also  investigated  using  the  fluorescent  recovery  after 
photobleaching  technique.  The  effects  of  both  drugs  were  confirmed  by  virtue  of 
scanning  electron  microscopy.  As  shown  in  chapter  2,  the  in  vitro  studies  revealed  that 
MZD,  albeit  at  high  doses,  is  more  effective  against  the  schistosomula  of  S.  mansoni 
than  PZQ.  These  results  are  not  unique  since  other  drugs  such  as  artcmisinin  derivatives 
were  reported  to  have  more  effects  against  immature  stages  of  schistosome  than  PZQ 
(Xiao  and  Catto,  1989).  The  possibility  of  treating  schistosomiasis  with  drugs  that  affect 
different  life-cycle  stages  of  the  parasite  has  renewed  the  focus  of  attention  on  the 
potential  benefits  of  combination  chemotherapy.  This  combination  of  PZQ,  against 
adult  worms,  and  artemether,  against  immature  stages,  was  tried  in  mice  and  hamsters 
infected  with  either  S  japonicum  or  S.  mansoni  and  having  different  developmental 
stages  present  in  the  animals  at  the  time  treatment  was  administered.  The  worm 
reductions  obtained  with  the  combination  therapy  were  greater  than  those  obtained  with 
pZQ  alone  (Utzinger  et  al.,  2001a).  If  these  effects  can  be  repeated  in  vivo  one  would 
expect  that  NED  might  be  used  effectively  in  combination  with  PZQ.  One  important 
aspect  that  was  not  investigated  in  the  present  study  and  needs  further  investigation  is 
the  effect  of  MZD  on  the  immature  stages.  However  that  is  because  the  present  study 
was  designed  essentially  to  answer  a  simple  question,  that  is  "Is  Mirazid'o  cffcctivc 
against  S  mansoni?  " 
192 The  in  vitro  studies  revealed  that  PZQ  was  more  effective  than  MZD  against  the  adult 
worms  of  S.  mansoni.  A  prolonged  exposure  to  high  concentrations  of  MZD  was 
necessary  to  cause  damage  to  the  surface  of  the  parasite.  The  most  striking  and  earliest 
cffect  of  MZD  was  the  separation  of  worm  pairs.  The  unpairing  CffCct  started  within 
15min  after  exposure.  The  exact  mechanism  of  worm  separation  is  not  clear,  however, 
SEM  revealed  surface  damage  and  blebs  on  the  interior  surface  of  the  gynaecophoric 
canal  of  male  parasite  that  extraordinarily  occurred  after  relatively  short  pcriods  of 
exposure  to  lower  concentrations  of  MZD.  This  preferential  surface  damage  might  give 
a  clue  to  the  cause  of  the  observed  worm  separation.  In  murine  schistosomiasis  it  was 
reported  that  MZD  caused  unpairing  of  worm  pairs  and  shifting  of  separated  worms  to 
the  livers  (Badria  et  al.,  2001).  However,  the  hepatic  shift  per  se  is  not  a  criterion  for 
drug  efficacy  since  some  drugs  and  even  anaesthetics  can  cause  a  temporary  hepatic 
shift  of  schistosomcs.  Once  the  effect  of  the  drug  is  lost  they  resume  their  position  in 
their  normal  habitat  (Aboul-Atta  et  al.,  1989).  Another  interesting  observation  after 
exposure  of  adult  worms  to  MZD  was  a  temporary  increase  in  worm  motility.  With 
time,  the  motility  returned  to  normal  and  then  diminished.  Several  antischistosome 
drugs  have  been  shown  to  increase  worm  motility  including  oxamniquine  and  PZQ  at 
sub-lethal  doses  (Chavassc  et  al.,  1979).  In  the  case  of  hycanthone  and  oxamniquine, 
the  increased  worm  motility  was  attributed  to  the  blockage  of  the  acetylcholine 
receptors,  thus  removing  the  inhibitory  effects  of  acetylcholine  (Hillman  and  Senft, 
1975). 
As  one  would  expect,  PZQ  caused  very  early  contractions  of  the  parasite  musculature 
followed  later  by  surface  damage  with  the  characteristic  surface  blcbbings.  TEM 
revealed  that  while  PZQ  caused  disruption  of  the  parasite  tegument,  musculature  and 
parenchyma,  MZD  apparently  caused  physical  damage  only  to  the  surface  of  the 
193 parasite.  Both  drugs  caused  a  significant  reduction  in  the  fluidity  of  the  parasites' 
surface  membrane. 
The  present  study  attempted  to  shed  light  on  the  mode(s)  of  action  of  MZD.  Its  effect  on 
calcium  distribution  was  investigated  using  the  NO  dye.  Both  MZD  and  PZQ  caused  a 
significant  increase  in  the  levels  of  intra-parasite  calcium.  Taking  these  results  together 
with  the  parasite  surface  damage  caused  by  both  drugs,  it  is  possible  to  speculate  that 
both  MZD  and  PZQ  share  some  of  their  modes  of  action.  However,  the  extent  of 
damage  caused  by  MZD  might  point  to  a  possibility  of  a  more  localised  action  of  this 
drug.  In  this  context,  Triton  X-100  was  shown  to  cause  surface  damage  of  adult 
schistosome  and  to  increase  calcium  accumulation  inside  the  parasites  (Dcpcnbusch  et 
al.,  1983). 
The  in  vivo  effects  of  MZD  and  PZQ  were  investigated  using  the  murine  model. 
Although  PZQ  was  very  effective  in  causing  worm  reductions,  and  reductions  of  liver 
and  tissue  egg  burden,  MZD  did  not  show  any  of  these  effects.  11c  apparent 
discrepancy  between  the  in  vitro  and  the  in  vivo  results  of  the  present  experiments  are 
not  fully  understood.  The  pharmacokinetics  of  MZD  may  be  one  explanation  for  this 
discrepancy.  It  is  possible  that  MZD  is  poorly  absorbed,  rapidly  mctaboliscd  or  cleared 
from  the  circulation.  In  any  case,  the  level  of  MZD  in  the  blood  may  not  be  enough  to 
exert  the  actions  that  were  obtained  in  vitro.  In  order  to  get  these  effects  one  would 
predict  that  very  large  doses  are  needed,  doses  that  proved  to  be  toxic  to  mice  (Botros  et 
al.,  2004).  However,  earlier  studies  in  mice  reported  the  efficacy  of  MZD  in  reducing 
worm  and  egg  burdens  (Badria  et  al.,  2001).  Another  possibility  is  that  one  or  more  of 
the  many  compounds  that  are  constituents  of  MZD  might  be  responsible  for  the  anti- 
schistosome  effects  while  others  might  have  no  effects  and  may  even  have  deleterious 
effects  on  the  hosts.  If  these  active  components  could  be  idcntiried  one  would  predict 
that  efficacy  of  NED  can  be  greatly  increased.  Preliminary  attempts  to  fractionate  MZD 
194 by  column  chromatography  and  using  different  concentrations  of  dichloromcthanc  in 
hexanc,  revealed  10  fractions.  The  potential  anti-schistosome  effects  of  these  fractions 
was  assessed  and  revealed  that  only  two  of  these  fractions  had  anti-schistosomal  effects 
(data  not  shown).  Further  fractionation  experiments  are  in  progress. 
The  results  of  the  in  vivo  studies  do  not  agree  with  the  reported  efficacy  of  MZD  in 
human  studies.  In  human  studies,  MZD  was  used  to  treat  both  S.  haemalobium  and  S. 
mansoni  infected  Egyptians  with  cure  rates  of  more  than  90%  being  reported  (Sheir  el 
al.,  2001;  El  Baz  et  aL,  2003).  'Ibis  might  be  attributed  to  differences  in  the  drug 
metabolic  pathways  in  humans  and  mice.  However,  other  human  studies  failed  to 
demonstrate  any  significant  anti-schistosomal  effects  of  MZD  (Fenwick  el  aL,  2003). 
Sheir  and  colleagues  and  El  Baz  and  colleagues  reported  that  MZD  caused  an  apparent 
improvement  of  the  symptoms  of  infected  individuals.  The  possibility  that  MZD  instead 
of  affecting  the  worm  burden  might  have  anti-pathology  effects  was  investigated  in  the 
present  study.  Although  there  are  some  differences  between  the  immunopathology  of 
schistosome  in  humans  and  mice,  there  is  enough  similarity  to  allow  murine  infections 
to  be  used  to  investigate  the  likely  effects  on  pathology  in  humans  (Chcever  el  aL, 
2002).  There  was  no  significant  difference  in  the  diameter  of  liver  granulomas  or  their 
eosinophil  contents  in  MZD-treated,  PZQ-treated  and  un-treated  mice.  However,  in 
MZD  treated  mice,  the  slight  decrease  in  the  diameter  of  liver  granulomas  and  fibrosis 
was  accompanied  with  a  preferential  decrease  of  Th2  type  immune  response  cytokincs. 
Spleen  cells  and  LNs  from  mice  treated  with  MZD  produced  lower  amounts  of  IL-10, 
IL-4  and  IL-13  in  response  to  stimulation  with  either  SEA  or  SWAP  compared  to  the 
un-treated  mice.  This  might  indicate  an  anti-inflammatory  cffect  of  MZD  or  one  or 
more  of  its  components  (Kimura  et  al.,  200  1). 
195 The  in  vitro  effects  of  both  MZD  and  PZQ  on  the  soluble  proteome  of  adult  worrns  of  S. 
mansoni  were  investigated.  The  use  of  the  powerful  DIGE  technique  allowed  the 
comparison  between  two  samples  in  one  gel  with  the  advantage  of  them  being  run  under 
identical  conditions.  Although  several  protein  spots  were  expressed  differently  in  both 
drug  treated  and  control  parasites,  only  three  proteins  were  identified  using  the  MALDI 
ToF  and  electrospray  tandem  mass  spectrometry.  This  is  partly  because  the  genome 
sequence  of  S.  mansoni  has  yet  to  be  completed  (LoVerde  et  aL,  2004).  Some  proteins 
such  as  actin  had  reduced  expression  in  MZD-treated  worms.  Interestingly  other 
proteins  were  more  highly  expressed  in  drug  treated  parasites.  For  instance,  paramyosin, 
which  is  a  leading  vaccine  candidate,  showed  a  4-fold  increased  expression  in  worms 
exposed  to  MZD  compared  to  control  parasites.  In  worms  exposed  to  PZQ,  there  was  a 
2-fold  increase  in  the  expression  of  fructose  1,6  bisphosphate  a1dolase  compared  to 
control  parasites.  Whatever  the  mechanism  of  this  differential  expression  of  such 
proteins  in  drug-exposed  worms,  the  increased  expression  of  some  proteins  might  shcd 
some  light  on  the  changes  of  the  immune  responses  that  occur  after  the  use  of  some 
anti-schistosome  drugs. 
in  addition  to  its  chemotherapeutic  effects  against  schistosomcs,  PZQ  has  been 
proposed  to  have  the  capacity  to  enhance  immune  protection  against  reinfection.  As 
reported  by  others,  treatment  of  infected  children  can  change  their  immune  responses 
from  'putatively  susceptible  to  reinfection'  to  immune  responses  similar  to  adults  that  is 
'putatively  resistant  to  reinfection'  (Mutapi  et  al.,  1998;  Mduluza  et  al.,  2001).  Thc 
hypothesis  behind  the  immune  priming  effect  of  PZQ  is  that,  by  damaging  or  killing 
worms,  PZQ  might  expose  previously  concealed  parasite  antigens  or  simply  initiate  the 
release  of  a  considerable  amount  of  parasite  antigens  that  normally  would  have  been 
released  only  after  a  long  duration  of  infection  in  conditions  of  normal  exposure 
(Hamett  and  Kusel,  1986;  Woolhouse  and  Hagan,  1999). 
196 In  the  present  study,  the  differences  in  the  recognition  patterns  of  SWAP  S. 
haematobium  prior  to  PZQ  treatment,  after  treatment  and  after  exposure  to  reinfection 
were  addressed  with  an  emphasis  on  the  differences  between  resistant  and  susceptible 
individuals  and  the  impact  of  chemotherapy  on  the  humoral  immune  responses  against 
different  parasite  antigens.  Not  surprisingly,  most  of  the  identified  vaccine  candidates 
were  highly  recognised  by  sera  from  both  resistant  and  susceptible  individuals. 
However,  resistant  individuals  more  frequently  recognised  some  of  these  antigens  by 
antibody  isotypes  that  have  been  characterised  as  those  that  might  be  associated  with 
protective  immune  responses.  For  instance,  an  antigen  band  of  28-3OkDa  (Sh28GST) 
was  recognised  more  frequently  by  the  IgG3  antibody  isotype  and  less  frequently  by 
IgM,  IgG2  and  IgG4  antibody  isotypes  of  sera  from  resistant  compared  to  susceptible 
individuals. 
ARer  treatment  with  PZQ,  many  antigens  including  some  of  the  potential  vaccine 
candidate  antigens  were  recognised  by  antibody  isotypes  that  favoured  protective 
immune  responses  compared  to  their  recognition  prior  to  treatment.  However, 
sometimes  such  immune  responses  were  not  maintained  when  the  individuals  wcrc 
exposed  to  reinfection  and  thus  rendered  susceptible  to  reinfection.  It  seems  reasonable 
that  repeated  treatments  might  be  necessary  to  maintain  such  protective  immune 
responses  (Mduluza  et  aL,  200  1). 
Conclusion 
Although  MZD  was  effective  against  the  schistosomula  and  adult  stages  of  S.  mansoni, 
in  vitro,  the  results  of  the  in  vivo  experiments  in  the  murine  model  do  not  support  the 
use  of  MZD  for  the  treatment  of  schistosomiasis.  Further  independent  investigations  of 
its  efficacy  in  human  studies  may  need  to  be  done.  Until  this  happens,  all  measures  must 
be  taken  to  ensure  that  MZD  is  withheld  in  order  that  it  is  not  substituted  for  the  more 
197 effective  drug,  PZQ,  in  communities  where  both  drugs  are  available.  Otherwise,  there 
will  be  a  risk  of  an  increase  in  the  prevalence  of  human  schistosomiasis  which  is  now 
partly  under  control,  in  many  parts  of  the  world  by  virtue  of  the  efficacy  of  PZQ. 
Another  major  factor  against  the  use  of  MZD  on  a  community  basis  is  its  cost  (double 
that  of  PZQ)  and  the  inconvenience  of  the  way  of  its  administration. 
The  present  study  supports  the  efficacy  of  PZQ  for  treatment  of  schistosome  infections. 
it  also  supports  the  hypothesis  that  PZQ,  albeit  after  repeated  cycles  of  treatment,  can 
help  the  development  of  protective  immune  responses  by  infected  individuals.  Ibis  is 
perhaps  a  consequence  of  an  increase  in  antigen  production  and  expression  by  the 
parasites. 
In  conclusion  the  work  presented  in  the  present  thesis  has  demonstrated  that 
1.  Both  MZD  and  PZQ  showed  in  vitro  anti-schistosome  activities  against  S. 
mansoni. 
2.  MZD  was  more  effective  against  schistosomula  than  PZQ  in  vitro  but  its  cfflcacy 
was  less  against  adult  wonns. 
3.  Lengthy  exposures  to  high  concentrations  were  necessary  for  the  Cffects  of  MZD 
to  be  evident. 
4.  Although  there  were  similarities  in  the  effects  of  MZD  and  PZQ  after  in  vitro 
exposure,  the  extent  of  the  damage  was  distinct  for  each  drug. 
5.  Both  MZD  and  PZQ  caused  an  increase  in  the  intra-parasite  calcium  lcvcls. 
6.  MZD  had  no  anti-schistosome  activity  in  infected  mice.  On  the  other  hand  PZQ 
caused  a  significant  reduction  in  wonn  burden  and  liver  and  gut  egg  loads. 
198 7.  There  were  no  significant  differences  in  the  diameter  or  cell  content  of  liver 
granulomas  from  treated  mice. 
8.  The  treatment  with  PZQ  can  cause  alteration  of  the  immune  responses  from 
responses  characteristic  of  susceptible  individuals  to  protective  responses. 
9.  Most  of  the  identified  vaccine  candidates  were  recognised  by  sera  from  putatively 
resistant  individuals  by  immune  responses  characteristic  of  protection. 
10.  The  28-3OkDa  antigen  (ShGST)  was  recognised  more  frequently  by  IgG3  of  sera 
from  resistant  individuals  and  by  IgM,  IgG2  and  IgG4  in  susceptible  individuals. 
11.  The  23kDa  antigen  was  recognised  more  frequently  by  IgG3  of  sera  from 
resistant  individuals. 
12.  The  95kDa  (paramyosin)  was  recognised  more  frequently  by  IgM  and  IgG  I  of 
sera  from  resistant  individuals. 
13.  The  84kDa  (Calpain)  was  recognised  more  frequently  by  IgM,  IgG  I  and  IgG3  of 
sera  from  resistant  individuals. 
14.  In  vitro  exposure  of  adult  wonns  to  PZQ  caused  increased  expression  of  fructose 
1,6  bisphosphate  aldolase  supporting  the  immunising  hypothesis  of  some  anti- 
schistosome  drugs. 
15.  In  vitro  exposure  of  adult  worms  to  MZD  caused  increased  expression  of 
paramyosin  and  decreased  expression  of  actin. 
199 Suggestions  for  future  work 
The  efficacy  of  MZD  against  early  schistosome,  infection  should  be  investigated. 
From  the  results  of  the  present  in  vitro  experiments,  one  would  expect  that  if 
MZD  has  any  anti-schistosome  effects  it  is  more  likely  to  be  against  the 
immature  stages  of  the  parasite. 
2.  The  true  potential  of  MZD  in  treatment  of  human  schistosomiasis  should  be 
independently  investigated. 
3.  Based  on  the  results  of  the  preliminary  studies  on  the  effects  of  MZD  on  the 
immunopathology  of  schistosome  infection,  the  possibility  that  MZD  can  affect 
the  immunopathology  of  human  disease  needs  further  investigation. 
4.  Fractionation  of  MZD  and  identification  of  the  potential  anti-schistosome 
components  is  strongly  recommended.  One  would  expect  if  there  is  a  potential 
anti-schistosome  effect  of  this  mixture  of  compounds,  identification  of  the  active 
ingredient  would  greatly  improve  this  efficacy. 
S.  Further  studies  on  the  effects  of  PZQ  and  other  drugs  on  the  soluble  schistosomc 
proteome,  would  greatly  increase  our  understanding  of  the  mode  of  actions  of 
these  drugs.  This  is  possible  with  the  use  of  the  rapidly  developing  2-D  PAGE 
and  mass  spectrometry  techniques.  It  is  expected  that  these  techniques  would  be 
applicable  with  more  efficiency  in  the  near  future  especially  when  the  gcnome 
of  schistosome  is  completed. 
Making  use  of  the  2-D  PAGE  and  mass  spectrometry  techniques  it  is  now 
possible  to  study  the  differences  in  the  recognition  patterns  of  parasite  antigcns 
in  resistant  and  susceptible  individuals.  The  impact  of  chcmothcrapy  on  the 
200 recognition  patterns  of  such  parasite  antigens  can  be  also  investigated.  The 
antigens  associated  with  protective  responses  in  resistant  individuals  can  then  be 
identified  and  investigated  as  potential  vaccine  candidates. 
201 Appendix 
Reagents  used  in  western  blotting 
Phospate  buffered  saline  (pH  7.2) 
Amount 
Na2HP04-121120  60.  Og 
Na2HP04.2H20  13.6g 
NaCl  8.5g 
De-ionised  and  distilled  water  Completed  to  I  litre 
Coomassie  Blue  Stain 
Amount 
Methanol  250.  Oml 
Acetic  acid  100.0mi 
Glycerol  10.0ml 
Coomassie  Blue  Log 
De-ionised  and  distilled  water  Completed  to  I  litre 
Coomassie  Blue  Destain 
Amount 
Methanol  250.0m], 
Acetic  acid  100.0ml 
Glycerol  10.0mi 
De-ionised  and  distilled  water  Completed  to  I  litre 
Tris  Buffered  Saline  (TBS) 
Amount 
NaCl  9g 
Tris  HCI  1.6g 
pH  Adjusted  to  pil  7.6  with  I  ICI 
De-ionised  and  distilled  water  leted  to  I  litre 
202 Anode  1  solution 
Amount  Final  concentration 
Tris-  base  36.3g  300mM 
Methanol  200ml  20% 
DdH20  800ml 
The  Tris-  base  was  dissolved  in  800ml  of  water  and  then  the  methanol  was  added  to 
make  a  litre. 
Anode  2  solution 
Amount  Final  concentration 
Tris-  base  3.  Og  25mM 
Medmol  200ml  20% 
DdH20  800ml 
Cathode  solution 
A  40mM  of  6-amino-caproic  acid  was  dissolved  in  I  litre  of  anode  2  solution  to  obtain 
the  cathode  solution. 
Substrate  solution  for  development  of  the  western  blotting  reaction 
Amount 
4-chloro-I  -naphthol  90mg 
Medmol  20ml 
TBS  I  00ml 
H202  (immediately  before  development)  200pl 
203 Reagents  used  in  ELISA 
Phosphate  buffered  saline 
Amount 
NaCI  8g 
KCI  0.2g 
Na2HP04  1.15g 
KH2PO4  0.21g 
DdH20  Complete  to  I  litre 
HCI  Adjust  the  pH  to  7.2-7.4 
Wash  buffer 
To  1  litre  of  PBS,  0.5ml  Tween  X20  was  added  to  reach  a  concentration  of  0.05% 
Tween.  PH  must  be  7.2-7.4. 
Block  buffer 
Amount 
PBS  I  litre 
BSA  I  Og 
Sucrose  sog 
I  NaN3  I  0.5g 
Reagent  diluent 
Ten  grams  of  BSA  were  dissolved  in  I  litre  of  PBS  to  reach  a  final  concentration  of  I% 
BSA.  The  solution  was  sterilised  through  a  0.2pm  filter. 
204 Reagents  used  in  the  2D  gel  electrophoresis 
DIGE  lysis  buffer 
Final  concentration 
Urea  7M 
Thiourea  2M 
CHAPS 
ý 
4% 
Tns  base 
1  [- 
25mM 
Sample  rehydration  stock  buffer 
Amount  Final  concentration 
Urea  (FW  60.06)  12g  8M 
CHAPS  0.5g  2%  (w/v) 
IPG  Buffer  125pl  0.5%  (V/V) 
Bromophenol  blue  50pl  1%  solution  0.002% 
Double  distilled  H20  Complete  to  25ml 
I 
The  stock  was  aliquoted  in  2.5ml  aliquots  and  stored  at  -200C.  7mg  of  DTT  was  added 
for  each  aliquot  just  prior  to  use. 
Sample  equilibration  buffer 
Amount  Final  concentration 
Tris-HCI,  pH  8.8  lO.  OmI  50m.  M 
Urea  (FW  60.06)  72.07g  6M 
Glycerol  (87%  V/V)  69ml  30%  (v/v) 
SDS  (FW  288.38)  4.0  g  2%  (w/v) 
Bromophenol  blue  400pl  of  1%  solution  0.002%  (w/v) 
Double  distilled  H20  Complete  to  200ml 
The  stock  solution  was  aliquoted  in  10ml  aliquots  and  stored  at  -200C.  Just  prior  to  usc 
100mg  of  DTT  was  added  to  l0ml  of  the  stock  to  prepare  the  first  equilibration  bufficr. 
To  prepare  the  second  equilibration  buffer,  250mg  of  iodacetamide  was  added  to  10ml 
of  the  stock  solution. 
I 
205 SDS  gel  electrophoresis  buffer 
Amount  Final  concentration 
Tris-base  (FW  12  1.1)  30.3  g  2M 
Glycine  (FW  75.07)  144.0  g  192  mM 
SDS  (FW  288.38)  10.0  g  0.1%  (W/V)  I 
Double  distilled  H20  I  Complete  to  10  litre 
Store  at  room  temperature 
Preparation  of  the  12.5%  PAGE 
Amount 
Acrylamide/Bis  40%  (w/v)  281.25ml 
Tris  (1.5M,  pH  8-8)  225ml 
10%  (w/v)  SDS  9.0mi 
10%  (w/v)  Ammonium  Persulfate  (APS)  9.  OmI 
10%  (w/v)  TEMED  (immediately  before  use)  1.24ml 
Double  distilled  H20  Complete  to  900ml 
Agarose  sealing  solution 
Amount  Final  concentration 
SDS  Electrophoresis  buffer 
-- 
100  mi 
arose  Xg  0.5  g  0.5% 
Bromophenol  blue  200  til  0.002%  (w/v) 
Add  all  ingredients  into  a  500  ml  Erlenmeyer  flask.  Swirl  to  disperse.  Ifeat  in  a 
microwave  oven  on  low  or  a  heating  stirrer  until  the  agarose  is  completely  dissolvcd. 
Do  not  allow  the  solution  to  boil  over.  Dispense  2  ml  aliquots  into  screw-cap  tubes  and 
store  at  room  temperature. 
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